Please join us for a scientific symposium

Non-Infectious Uveitis

A Short Look Back and a Long Look Forward

Friday, 20 September
18:15–19:15

Hermes Auditorium, Level 2
Acropolis Convention Centre

AGENDA

Welcome

Session 1
Epidemiology, immunopathology, and the role of cytokines in non-infectious uveitis

Session 2
Classifying and stratifying patients to manage non-infectious uveitis and its complications

Session 3
Where are we for treatment guidelines?

Session 4
Scientific exchange

This meeting is organised and funded by AbbVie
Dear EVER members,

As EVER president it is my pleasure and a privilege to invite you to the 2013 EVER meeting in Nice, France. Our 2012 meeting inaugurated this Congress venue, and judging from the broad attendance, one can only conclude that many EVER members consider this location to be a very convenient one.

During the last decade ophthalmology has witnessed many important changes: the pathogenesis of wet AMD is better understood and we start to have effective treatment; pharmacological interventions for vitreoretinal interface pathology are now a fact; thanks to innovative therapies we will be able to postpone or to avoid surgery in a substantial number of patients with keratoconus; cataract surgery will probably move from manual surgery to laser surgery in the near future; and last but not least, the first results of gene therapy for retinal dystrophies in humans have been published in the last years. These are just a few examples to illustrate how the constant progress in basic science and the results of translational and clinical research have a major impact on the way we tackle blindness and vision loss in our patients. The great thing about the EVER meeting is that it provides a platform for discussion to all those who participate in this complex process that leads to progress in Visual Science and Ophthalmology: from the basic scientist to the highly subspecialized clinician, from the young PhD student to the internationally renowned expert. The informal atmosphere at EVER and the ample opportunity for discussion during the conference create a favourable climate for dialogue and cross-fertilization.

It is our hope that future European collaborations and projects may be initiated at the EVER meetings.

This year’s programme brings the usual combination of forty-five Special Interest Symposia from the eleven EVER sections; six Commercial Interest Symposia, eighteen Courses; Key Note lectures, some delivered by world class scientists; joint meetings with twelve other Groups, Clubs or Societies; and of course traditional poster sessions with opportunity for face-to-face discussion. It is not always easy to strike the right balance between basic science and clinical research, but the Board members are aware of this issue and will monitor it in the future.

While it is clear that the quality of the scientific programme is our prime concern, I am equally convinced that most EVER members will greatly appreciate the charms, the climate and the surroundings of Nice, an ideal setting for the social activities of the EVER meeting. The social programme in 2013 will include as a novelty a Farewell party on Saturday evening. I hope that this party will unite happy attendants, ready to go home with good memories of a memorable meeting. I look forward to share these moments with you!

Philippe Kestelyn
President EVER 2013
Targeting the mediators of inflammation

GURDEX® (Dexamethasone 700 micrograms intravitreal implant in applicator)

Abbreviated Prescribing Information

Presentation: Intravitreal implant in applicator. One implant contains 700 micrograms of dexamethasone. Dispersible injection device containing a red-chip implant which is not visible. The implant is approximately 5 mm in diameter and 6 mm in length.

Indications: Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). Treatment of adult patients with inflammation of the posterior segment of the eye preventing or non-infectious uveitis.

Dosage and Administration: Please refer to Summary of Product Characteristics before prescribing. GURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injection. The recommended dose is one GURDEX implant to the affected eye. Administration to both eyes concurrently is not recommended. Repeat doses should be considered when a patient experiences a response to treatment followed by disease progression or a relapse in activity. The physician’s opinion may benefit from retreatment without being exposed to x-ray damage risk. Patients with haemoglobinopathies or immunodeficiencies should be assessed by the implantation. Patients requiring a dermatology in tissue, which is not detected by GURDEX, should not be treated. There is only very limited information on repeat dosage intervals less than 1 month. There is currently no evidence of repeat administration in posterior segment non-infectious uveitis. Beyond 1 implant in human retina, patients should be monitored following the injection to permit early treatment if an infection or increased intravitreal pressure occurs. No dose adjustments required for elderly population (≥ 65 years). No special considerations required for renal or hepatic impairment. No relevant side effects in the postmarketing population in macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). The safety and efficacy of GURDEX in patients with intraocular hypertension in the paediatric population have not been established. No data are available. Single-agent intravitreal implant is contraindicated for intravitreal use only. The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and sterile eyedrops (epinephrine). A broad spectrum topical antimicrobial should be given prior to and the day of the injection procedure. Before the injection, the preservative free eyedrops and sterile solution should be dispersed using the example drops of peridate sodium 5% solution on the conjunctiva as it was done in the clinical trials for the approval of GURDEX® and adequate local anaesthesia should be administered. Review the injection from the cornea and superior for damage. In sterile field, open the glass pack and gently place the implant in the retrolubricum. Carefully remove the cap from the applicator. The base of the applicator should be used immediately. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. With the bevel of the needle up away from the scissors, advance the needle about 1 mm into the scissors then redirect toward the centre of the eye into the intrascleral cavity until the scissors olea come against the conjunctival. Slowly push the actuator button until a audible click is noticed. Before withdrawing the applicator from the eye, make sure that the actuator button is fully pressed and has locked flush with the applicator surface. Remove the needle in the same direction as you entered the eye. Immediately after injecting, GURDEX must be indolent ophthalmoscopy in the quadrant of the injection site and conjunctival examination. If injection is not performed within 30 seconds of opening the foil for the injection, the implant may not be visualised. In cases in which the implant cannot be visualised, take a sterile cotton bud and lightly gentle on the skin allowing the implant to be visualised. Following the intravitreal injection patients should continue to be treated with a broad spectrum antimicrobial.
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Word from the President</td>
<td>1</td>
</tr>
<tr>
<td>About EVER</td>
<td>5</td>
</tr>
<tr>
<td>Board 2013</td>
<td>6</td>
</tr>
<tr>
<td>General Information</td>
<td>8</td>
</tr>
<tr>
<td>Grants</td>
<td>11</td>
</tr>
<tr>
<td>Partnership</td>
<td>12</td>
</tr>
<tr>
<td>About the Programme Book</td>
<td>14</td>
</tr>
<tr>
<td>Programme Committee 2013</td>
<td>15</td>
</tr>
<tr>
<td>Floor plan</td>
<td>16</td>
</tr>
<tr>
<td>Exhibition</td>
<td>17</td>
</tr>
<tr>
<td>Industry Sponsored Symposia overview</td>
<td>18</td>
</tr>
<tr>
<td>Courses overview</td>
<td>19</td>
</tr>
<tr>
<td><strong>Wednesday, September 18</strong></td>
<td>21</td>
</tr>
<tr>
<td>Morning session</td>
<td>22</td>
</tr>
<tr>
<td>Lunchtime session: Industry-sponsored symposium 1</td>
<td>25</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>26</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>30</td>
</tr>
<tr>
<td>Opening Ceremony</td>
<td>33</td>
</tr>
<tr>
<td><strong>Thursday, September 19</strong></td>
<td>35</td>
</tr>
<tr>
<td>First morning session</td>
<td>36</td>
</tr>
<tr>
<td>Keynote Lecture: Balwantray CHAUHAN</td>
<td>39</td>
</tr>
<tr>
<td>Second morning session</td>
<td>40</td>
</tr>
<tr>
<td>Lunchtime session: Industry-sponsored symposium 2</td>
<td>43</td>
</tr>
<tr>
<td>Ophthalmic Research Lecture: Neville OSBORNE</td>
<td>44</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>45</td>
</tr>
<tr>
<td>Poster session 1</td>
<td>48</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>52</td>
</tr>
<tr>
<td><strong>Friday, September 20</strong></td>
<td>57</td>
</tr>
<tr>
<td>First morning session</td>
<td>58</td>
</tr>
<tr>
<td>Keynote Lecture: Alfredo SADUN</td>
<td>60</td>
</tr>
<tr>
<td>Second morning session</td>
<td>61</td>
</tr>
<tr>
<td>Lunchtime session: Industry-sponsored symposium 3</td>
<td>64</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>65</td>
</tr>
<tr>
<td>Poster session 2</td>
<td>69</td>
</tr>
<tr>
<td>Business Meetings of the Scientific Sections</td>
<td>73</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>74</td>
</tr>
<tr>
<td>Evening session: Industry-sponsored symposium 4</td>
<td>77</td>
</tr>
<tr>
<td><strong>Saturday, September 21</strong></td>
<td>79</td>
</tr>
<tr>
<td>First morning session</td>
<td>80</td>
</tr>
<tr>
<td>Keynote Lecture: Nicholas BAZAN</td>
<td>83</td>
</tr>
<tr>
<td>Second morning session</td>
<td>84</td>
</tr>
<tr>
<td>Lunchtime session: Industry-sponsored symposium 5</td>
<td>87</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>88</td>
</tr>
<tr>
<td>Poster session 3</td>
<td>92</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>97</td>
</tr>
<tr>
<td>Evening session: EVER General Assembly and Prize Giving</td>
<td>101</td>
</tr>
<tr>
<td>Presenting first authors</td>
<td>105</td>
</tr>
<tr>
<td>Presenting authors by country</td>
<td>111</td>
</tr>
<tr>
<td>Congress Time Schedule</td>
<td>112</td>
</tr>
<tr>
<td>Sponsors</td>
<td>back cover</td>
</tr>
</tbody>
</table>
L’innovation en Ophtalmologie va bien au-delà des médicaments

Chez Novartis, compléter l’innovation scientifique par le service, c’est notre philosophie de partenariat. Découvrez ViaOpta, un ensemble de services que Novartis a conçu pour vous, ainsi que pour vos patients.

Rétina Base, une grande médiathèque numérique de la rétine mise à disposition des ophtalmologistes

Espace documentation et outils pour vos patients

Informations professionnelles innovantes et entretiens d’experts

Agenda des congrès nationaux et internationaux

Pour plus d’informations, retrouvez cette offre de services sur le site www.viaopta.fr
The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

Membership
Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

The benefits of EVER membership are:
• submission of abstracts to EVER annual meeting
• reduced registration fee for EVER annual meeting
• organizing Special Interest Symposia (SIS) and courses during the EVER annual meeting
• participating in the EBO review courses
• EACCME granted 21 European CME credits (ECMEC) recognized by the American Medical Association-for the EVER annual meetings
• voting rights for the election of the Board Members (except members-in-training and emeritus members)
• 12 travel grants for best abstracts to attend the EVER annual meeting
• free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.3)
• quarterly E-Newsletter

Elections
This year new representatives of the scientific sections
• Lens / Cataract
• Retina / Vitreous
will be elected through electronic voting. Voting 2013 will close on September 20, midnight. The result of the elections will be announced at the General Assembly on Saturday September 21, 2013. The scientific sections will hold their Business Meetings on Friday, September 20, 2013 from 16:00 - 16:40. The agenda is available on page 73. The following 3 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2014:
• Anatomy / Cell Biology
• Electrophysiology/ Physiological Optics/ Vision Sciences
• Molecular Biology / Genetics / Epidemiology
The statutes and by-laws are available on the website: www.ever.be » about » statutes.

MEMBERS ACCORDING TO SCIENTIFIC SECTIONS

Participants:

Clinical with or without research: 73 %
Research only: 27 %

27% 73%

Participants:

Clinical with or without research: 73 %
Research only: 27 %
EXECUTIVE COMMITTEE

Philippe KESTELYN
• President

Catherine CREUZOT
• Secretary General

Jean-Jacques GICQUEL
• Treasurer

Marcela VOTRUBA
• Programme Secretary

Constantin POURNARAS
• President Elect

Thierry ZEYEN
• Vice President

Alfred WEGENER
• Vice-President Elect

Leopold SCHMETTERER
• Past President

Marlene VERLAECKT
• Executive Officer

Lies VAN EYCKEN
• Executive Assistant

Brecht SPILEERS
• Junior Executive Officer

Paul MOERS
• Webmaster

Kapucijnenvoer 33, 3000 Leuven, Belgium - tel +32 16 233 849, fax +32 16 234 097 - ever@ever.be
Nadja KNOP
• Anatomy / Cell Biology

Thomas FUCHSLUGER
• Cornea / Ocular Surface

Werner SPILEERS
• Electrophysiology, Physiological Optics, Vision Sciences

Alain BRON
• Glaucoma

Andrew DICK
• Immunology / Microbiology

Alfred WEGENER
• Lens and Cataract

Bart LEROY
• Molecular Biology / Genetics / Epidemiology

Aki KAWASAKI
• Neuro-ophthalmology / Strabismology / Paediatric / History

Laurence DESJARDINS
• Pathology / Oncology

Gerhard GARHOFER
• Physiology / Biochemistry / Pharmacology

Constantin POURNARAS
• Retina / Vitreous

Bozena ROMANOWSKA-DIXON
• East Europe

Jean-Pierre CAUJOLLE
• Nice, France
Venue
EVER 2013 will be held at the Acropolis Convention Center in Nice, France
→ visit the website on www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, September 18 at 11:00 and concludes on Saturday, September 21 at 19:30 with a Farewell Cocktail.

Registration
Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

On-site registration starts on Wednesday, Sept 18, 09:00.

Please note that:
• being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
• if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
• if you register as an Eye-care, Technician or Nurse, you need to prove your status with a document signed by the Head of your Department

Registration fees on-site

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVER member / SIS &amp; Course-invited speaker</td>
<td>455</td>
<td>390  *</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>250</td>
<td>200  *</td>
</tr>
<tr>
<td>Non-member</td>
<td>800</td>
<td>645  *</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>400</td>
<td>310  *</td>
</tr>
<tr>
<td>Eye-Care / Technician / Nurse</td>
<td>200</td>
<td>180  *</td>
</tr>
<tr>
<td>Congress Dinner (member / non-member)</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Congress Dinner (in training)</td>
<td>60</td>
<td>60</td>
</tr>
</tbody>
</table>

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunisia, Ukraine

Website
The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can
• obtain up-to-date information about the scientific programme and the EVER 2013 meeting and view the status (session, hour, place) of your presentation
• pay on-line and obtain an overview of past payments
• look for other EVER members
• access general information about EVER
• access Acta Ophthalmologica, the EVER journal
• cast your vote for officers
• print CME certificate after each congress you attended

Housing / Travel

AdvancedFair has negotiated special rates for accommodation in several categories of hotels.

The Nice Côte d’Azur Airport is located 15 minutes from the Acropolis, at 7 km from the city centre.

The tramway line connects most of the hotels with the Acropolis Convention Center.

Weather
Nice enjoys an exceptional microclimate. A Mediterranean city opening onto the sea, it is protected from the main winds by its mountains. It is renowned for its mild climate in winter and its sunshine.

Tourist information

The city of Nice is located on the French Riviera in Provence-Alpes-Côte d’Azur. Blessed by a sunny, temperate climate, Nice attracts visitors from around the world. Among its many attractions are its beautiful beaches, lovely seaside promenade, interesting museums, famous city landmarks and other tourist attractions.

Day excursions are available from Nice to Antibes, Juan-les-Pins, Monte Carlo, Cannes and to other towns.
Welcome Reception
The Welcome Reception is open for all participants
• Wednesday 19:00 - 21:00
  in Exhibition area, Acropolis Convention Center

Congress Dinner
Registration for the Congress Dinner is required.
Members/non-members: 90 EUR
Members in training: 60 EUR
Space is limited.
• Friday 20:30 in Hotel NEGRESCO
  37, promenade des Anglais, 06000 Nice

Coffee
Included in the registration fee are the coffee/tea and soft drinks offered throughout the whole meeting.

Internet access
Wi-Fi internet access is available in the Convention Center.

Photographs
It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.

Publication of the abstracts
The abstracts of the EVER 2013 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Business Meetings
EVER Business Meetings of the scientific sections
Friday, 16:00 - 16:40
• ACB ..................................................... Gallieni 1 & 2
• COS ......................................................... Rhodes 1
• EOVS ........................................................... Hermes
• G ............................................................... Hermes
• IM ............................................................. Rhodes 1
• LC ............................................................. Rhodes 4
• MBGE ...................................................... Gallieni 5
• NSHP ........................................................... Rhodes 3
• PO ............................................................. Rhodes 2
• PBP .......................................................... Athena
• RV ............................................................. Athena
Agenda see page 73

EVER General Assembly and Prize Giving
Saturday, 18:00 - 19:30 in room Hermes
Agenda see page 101

Withdrawals
First authors unable to attend EVER for reasons beyond their control, may request the permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 1, 2013.

No-shows
Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits
The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2013 congress on Sept 18-21 in Nice, France.

CME credit certificates can be printed from the EVER website after the congress.

Liability
The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

Poster Prizes
A poster prize of 200 EUR will be awarded for the best poster in each section. One additional EOVS poster prize will be generously sponsored by the Alta Eficacia Tecnologia, SL, Spain.

The winners will be chosen by the poster moderators and will be announced in the General Assembly and followed by the prize giving ceremony on Saturday September 21. Please make sure to attend.

No prize will be given after the congress.

EVER 2013 congress App
Travel grants for best abstract

We are pleased to announce that the following 11 members have received a travel grant of 500 EUR each, from the 11 EVER sections:

- **ACB - Marialaura AMADIO - Italy**
  4662 - ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human ARPE-19 cells

- **COS - Amy LYNCH - Ireland**
  3436 - Influence of growth factors on keratocyte phenotype in serum free media

- **EOVS - Markus WIRTH - Germany**
  T028 - Keep an eye on the Pi – Using the Raspberry Pi as inexpensive, yet powerful platform for vision research

- **G - Yuka AOYAMA - Japan**
  T032 - The prediction error of the visual field sensitivity is large at the steep ‘border’ of glaucomatous scotoma

- **IM - Benjamin PENAUD - France**
  3454 - Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis: A retrospective monocentric study

- **LC - Gah-Jone WON - Canada**
  S077 - The effects of actomyosin inhibitors on cytoskeletal distributions in the lens

- **MBGE - Audrey GIOCANTI-AUREGAN - France**
  T071 - Profiling miRNAs in a hyperglycemic and hypoinsulinemic Ins2Akita mouse model

- **NSPH - Gonzague FACON - France**
  F068 - Definition of a normative basis for peripapillary nerve fibers thickness in childhood with sd-oct

- **PBP - Houda TAHIRI - Canada**
  4774 - Retinal pigment epithelium cell-derived microparticles mediate oxidative stress-induced retinal cell dysfunction

- **PO - Zita STEIBER - Hungary**
  S092 - Expression of stem cell markers in human uveal melanoma

- **RV - Guillaume DEBELLEMANIÈRE - France**
  3464 - Evaluation of cone photoreceptor density using adaptive optics retinal imaging in patients under treatment with hydroxychloroquine

---

Alta Eficacia Tecnologia SL, Spain, travel grant

Alta Eficacia Tecnologia is pleased to announce a travel grant of 500 EUR for the best paper in the EOVS section

- **Dorota POJDA-WILCZEK - Poland**
  1666 - Possibility of visual prognosis based on flash visual evoked potential in cases of early brain damage

The prize will be presented by Professor Celia SANCHEZ RAMOS at the General Assembly.

---

Quartett

3 grants of 500 EUR each supported by Quartett for best paper in COS
- Translation Medicare
- Basic Research
- Clinical Research

The papers will be chosen during the congress. The grants will be handed over during the General Assembly.
EVER - European Association for Vision and Eye Research

We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In CONCORDIA pro VISU

The following societies collaborate with EVER to unify European ophthalmology by promoting quality education in ophthalmology and its scientific foundations (the societies are listed in alphabetical order):

EB0 - European Board of Ophthalmology

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 23, 27.

From this year on and in order to evaluate the level of knowledge, a pre-test will be proposed online. Each speaker will extensively review the answers during his presentation.

EUPO - European University Professors of Ophthalmology

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe.

In 2014 the EUPO course on RETINA will be organized prior the EVER congress in Nice, France on Sept 30 - Oct 1.

SOE - Societas Ophthalmologica Europea

SOE aims to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and between their National Societies. Today, its mission is to become a central point in European ophthalmology through education and by fostering collaboration with subspecialty societies and supranational organisations both within Europe and beyond.

The 2015 SOE Congress will take place from 6-9 June, 2015 in Vienna Austria.
ACTA OPHTHALMOLOGICA - EVER’s journal

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.3)

ARVO - Association for Research in Vision and Ophthalmology

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 75.

EEBA - European Eye Bank Association

The EEBA is a technical-scientific organization comprising individual members from 83 eye banks from 25 European countries. Founded with the simple objective of sharing information regarding eye-banking, the Association is today the leading pan-national association in Europe dedicated to the advancement of eye-banking and an authoritative reference point for eye banks wishing to work according to quality standards. The EEBA is collaborating with EVER since 2012. See page 47.

FAN - European Fluorescein Angiography Club

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 88.

FRO - Belgian Fund for Research in Ophthalmology

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 24 and 29.

GOA - Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 59.

KPro Study Group

The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, synthetic corneas and artificial corneal implants. This International Group aims to foster the development and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro Study Group is collaborating with EVER since 2004. See pages 88 and 97.

OOG - The Ophthalmic Oncology Group

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 85, 89 and 98.

SOIE - Society for Ophthalmo-Immunoinfectiology in Europe

The aims are to form an association of ophthalmologists and other doctors or scientists having an interest in the field of ophthalmico-Immu-Infectiology and to share mutual experiences in order to contribute to the progress of each member in this field, to promote education by organising or sponsoring symposia or courses or by contributing to publications in this field and to promote contacts between clinical centres in order to realise collaborative studies. SOIE is collaborating with EVER since 2008. See pages 37 and 86.
This programme book is organised chronologically.

Four digit numbers refer to oral presentations:

\[ X \times X \times X \]

Day | Timeslot | Hall | Order in session

One letter and three digit numbers refer to posters:

\[ X \times X \times X \]

Day | Order in the postersession

The sessions are colour-coded:

<table>
<thead>
<tr>
<th>Special Interest Symposium (SIS)</th>
<th>Keynote Lecture</th>
<th>Poster Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free Papers (FP)</td>
<td>General Assembly &amp; Business Meeting</td>
<td>Social</td>
</tr>
<tr>
<td>Joint Meeting (Joint M)</td>
<td>Course</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Commercial Interest Symposium (CIS)</td>
<td></td>
</tr>
</tbody>
</table>

FP = Free Paper session
SIS = Special Interest Symposium
CIS = Commercial Interest Symposium
⊙ = EVER travel grant recipient
⊙ = Alta Eficacia Tecnologia SL, Spain, travel grant recipient
\( \text{rf} \) = Rapid Fire presentation
* = Conflict of interest disclosed

Scientific sections:

<table>
<thead>
<tr>
<th>ACB</th>
<th>COS</th>
<th>COS</th>
<th>EOVS</th>
<th>G</th>
<th>IM</th>
<th>LC</th>
<th>MBGE</th>
<th>NSPH</th>
<th>PBP</th>
<th>PO</th>
<th>RV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anatomy/Cell Biology</td>
<td>Cornea/Ocular Surface</td>
<td>Cornea/Ocular Surface</td>
<td>Electrophysiology, Physiological Optics, Vision Sciences</td>
<td>Glaucoma</td>
<td>Immunology/Microbiology</td>
<td>Lens and Cataract</td>
<td>Molecular Biology/Genetics/ Epidemiology</td>
<td>Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology</td>
<td>Physiology/Biochemistry/Pharmacology</td>
<td>Pathology/Oncology</td>
<td>Retina/Vitreous</td>
</tr>
</tbody>
</table>
**Programme Committee meeting, June 2013**

**Programme secretary, Marcela VOTRUBA**

**Section programme secretaries**

<table>
<thead>
<tr>
<th>Section</th>
<th>Programme area</th>
<th>Programme secretary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACB</td>
<td>Anatomy/Cell Biology</td>
<td>Ulla AAPOLA</td>
</tr>
<tr>
<td>COS</td>
<td>Cornea/Ocular Surface</td>
<td>Jean-Jacques GICQUEL</td>
</tr>
<tr>
<td>EOVS</td>
<td>Electrophysiology, Physiological Optics, Vision Sciences</td>
<td>Miguel CASTELO-BRANCOO</td>
</tr>
<tr>
<td>G</td>
<td>Glaucoma</td>
<td>Sayeh POURJAVAN</td>
</tr>
<tr>
<td>IM</td>
<td>Immunology/Microbiology</td>
<td>Piergiorgio NERI</td>
</tr>
<tr>
<td>LC</td>
<td>Lens and Cataract</td>
<td>Ralph MICHAEL</td>
</tr>
<tr>
<td>MBGE</td>
<td>Molecular Biology/Genetics/Epidemiology</td>
<td>Marzena GAJECKA</td>
</tr>
<tr>
<td>NSPH</td>
<td>Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/History of Ophthalmology</td>
<td>Dominique BREMOND-GIGNAC</td>
</tr>
<tr>
<td>PBP</td>
<td>Physiology/Biochemistry/Pharmacology</td>
<td>Neville OSBORNE</td>
</tr>
<tr>
<td>PO</td>
<td>Pathology/Oncology</td>
<td>Karin LÖFFLER</td>
</tr>
<tr>
<td>RV</td>
<td>Retina/Vitreous</td>
<td>Anita LEYS</td>
</tr>
</tbody>
</table>
Acropolis Convention Center, Nice, France
INDUSTRY-SPONSORED SYMPOSIA OVERVIEW

The Commercial Interest Symposia throughout the EVER 2013 congress:

**Wednesday, September 18**

**ALLERGAN**

Industry-sponsored symposium 1:

**Glaucoma and the Ocular Surface**

12:30 - 13:30 in room Rhodes 2 ................................................................. 25

**Thursday, September 19**

**Théa**

Industry-sponsored symposium 2:

**Micronutrition: Part of the retinal specialists’ armamentarium?**

12:35 - 13:35 in room Rhodes 2 ................................................................. 43

**Friday, September 20**

**CROMA**

Industry-sponsored symposium 3:

**Enhanced Oxidative Stress and ocular surface**

12:35 - 13:35 in room Hermes ................................................................. 64

**abbvie**

Industry-sponsored symposium 4:

**Non-infectious uveitis. A short look back and a long look forward**

18:15 - 19:15 in room Hermes ................................................................. 77

**Saturday, September 21**

**BAYER**

Industry-sponsored symposium 5:

**Aflibercept: an innovation in health care for a chronic condition**

12:35 - 13:35 in room Rhodes 2 ................................................................. 87
The 18 courses throughout the EVER 2013 congress:

**Wednesday, September 18**

<table>
<thead>
<tr>
<th>Course</th>
<th>Time</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course 1</td>
<td>11:00 - 12:30</td>
<td>RV: Macular hole</td>
<td>22</td>
</tr>
<tr>
<td>Course 2</td>
<td>11:00 - 12:30</td>
<td>G: Glaucoma? Yes I can!</td>
<td>23</td>
</tr>
<tr>
<td>Course 3</td>
<td>11:00 - 12:30</td>
<td>IM: EBO review course: Intraocular Inflammation and Infection - Part I</td>
<td>23</td>
</tr>
<tr>
<td>Course 4</td>
<td>13:30 - 15:00</td>
<td>COS: The amniotic membrane: new regenerative therapies and their potential impact on the clinical management of ocular surface diseases</td>
<td>26</td>
</tr>
<tr>
<td>Course 5</td>
<td>13:30 - 15:00</td>
<td>IM: EBO review course: Intraocular Inflammation and Infection - Part II</td>
<td>27</td>
</tr>
<tr>
<td>Course 6</td>
<td>15:05 - 16:35</td>
<td>RV: Retinal detachment</td>
<td>30</td>
</tr>
<tr>
<td>Course 7</td>
<td>15:05 - 16:35</td>
<td>COS: An update on corneal infectious diseases</td>
<td>30</td>
</tr>
<tr>
<td>Course 8</td>
<td>15:05 - 16:35</td>
<td>EOVS: Visual electrophysiology</td>
<td>32</td>
</tr>
</tbody>
</table>

**Thursday, September 19**

| Course 9 | 11:05 - 12:35 | PO: The management of pigmented fundus lesions                        | 41   |
| Course 10 | 14:15 - 15:45 | COS: An update on corneal procedures                                   | 45   |
| Course 11 | 16:30 - 18:00 | PO: Practical ophthalmic pathology - basics, updates and new insights | 53   |

**Friday, September 20**

| Course 12 | 08:30 - 10:00 | ACB: Cell biological techniques for eye research                      | 59   |
| Course 13 | 11:00 - 12:30 | PO: Don’t panic: Hitchhiker’s guide to statistics                     | 62   |
| Course 14 | 11:00 - 12:30 | NSPH: Visual Fields: Back to Basics                                    | 63   |
| Course 15 | 13:40 - 15:10 | COS: Corneal Dystrophies – from molecular basis to therapeutic approach | 65   |
| Course 16 | 16:45 - 18:15 | COS/ACB: Stem cells for treatment of eye diseases                     | 75   |

**Saturday, September 21**

| Course 17 | 08:30 - 10:00 | RV: Pseudophakic retinal detachment                                    | 80   |
| Course 18 | 16:15 - 17:45 | LC: Femtosecond laser cataract surgery                                 | 98   |
## Course 1  Macular hole

**RV**

Georgios PAPPAS

Macular Hole Surgery is almost 25% of macular surgery. The pathophysiology of this condition is getting clearer using new diagnostic tools. There are many controversies though regarding best treatment and the tools used for the treatment of this condition. This course aims to give answers and directions for the optimal treatment of the condition.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1411</td>
<td>Pathophysiology of macular hole and diagnostic tools</td>
<td>STAPPLER T–Liverpool</td>
</tr>
<tr>
<td>11:12</td>
<td>1412</td>
<td>ILM peeling or not - The best dye</td>
<td>POURNARAS JA–Lausanne</td>
</tr>
<tr>
<td>11:24</td>
<td>1413</td>
<td>Posture face-down or not? The best tamponade</td>
<td>FRIMPONG-ANSAH K–Plymouth</td>
</tr>
<tr>
<td>11:36</td>
<td>1414</td>
<td>20g, 23g, 25g or 27g - The best forceps</td>
<td>GOTZARIDIS S–Athens</td>
</tr>
<tr>
<td>11:48</td>
<td>1415</td>
<td>Partial thickness macular holes and pharmacological treatment</td>
<td>GEORGALAS I–Athens</td>
</tr>
<tr>
<td>12:00</td>
<td>1416</td>
<td>What are we doing in difficult cases (Not closed, Myopic, Large)?</td>
<td>PAPPAS G–Heraklion</td>
</tr>
<tr>
<td>12:12</td>
<td>1417</td>
<td>Mechanism of macular hole closure</td>
<td>REPPUCILV–New York</td>
</tr>
</tbody>
</table>

---

## SIS Update on limbus disorders in children

**COS/NSPH**

Dominique BREMOND-GIGNAC, Jean-Jacques GICQUEL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1421</td>
<td>Update on ocular surface disorders in aniridia</td>
<td>BREMOND-GIGNAC D–Amiens</td>
</tr>
<tr>
<td>11:22</td>
<td>1422</td>
<td>Update on corneal dystrophies in children</td>
<td>CHIAMBARETTA F–Clermont Ferrand</td>
</tr>
<tr>
<td>11:44</td>
<td>1423</td>
<td>LSCD - What clues does the infant limbus hold?</td>
<td>YEUNG A–Nottingham</td>
</tr>
<tr>
<td>12:06</td>
<td>1424</td>
<td>Update on ocular surface burn in children</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
</tbody>
</table>
### Course 2  Glaucoma? Yes I can!  
**G**  
Alain BRON  

This course is designed for beginners in glaucoma who are mostly interested in daily clinical practice. It is really possible to improve your own glaucoma management with basic examinations. After this course you probably will better use your slit lamp to find useful clinical signs for glaucomas. Gonioscopy is a key step in the diagnosis and the management of the glaucomas as well. Clinical examination of the optic disc is determinant for the diagnosis and the evaluation of progression. A better understanding of functional and structural tests is mandatory when you have to order those tests. Five teachers, all glaucoma experts will lead you during this course with very simple and clear recommendations. They would like to provide you with a ready-to-use clinical tool kit for glaucomas.

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Instructor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1431</td>
<td>My basic slit-lamp? Yes I can!</td>
<td>BRON A--Dijon</td>
</tr>
<tr>
<td>11:18</td>
<td>1432</td>
<td>Gonioscopy? Yes I can!</td>
<td>HOMMER A--Vienna</td>
</tr>
<tr>
<td>11:36</td>
<td>1433</td>
<td>Clinical examination of the optic disc? Yes I can!</td>
<td>JONAS J--Mannheim</td>
</tr>
<tr>
<td>11:54</td>
<td>1434</td>
<td>Function in glaucoma? Yes I can!</td>
<td>ZEYEN T--Leuven</td>
</tr>
<tr>
<td>12:12</td>
<td>1435</td>
<td>Structure in glaucoma? Yes I can!</td>
<td>SUNARIC MEDEVAND G--Geneva</td>
</tr>
</tbody>
</table>

### SIS PBP  
**Ocular imaging**  
Gerhard GARHOFER, Leopold SCHMETTERER  

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Instructor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1441</td>
<td>Doppler optical coherence tomography</td>
<td>SCHMETTERER L--Vienna</td>
</tr>
<tr>
<td>11:22</td>
<td>1442</td>
<td>Retinal oximetry methodology</td>
<td>HARDARSON S--Reykjavik</td>
</tr>
<tr>
<td>11:44</td>
<td>1443</td>
<td>Determination of macular pigment</td>
<td>BERENDSCHOT T--Maastricht</td>
</tr>
<tr>
<td>12:06</td>
<td>1444</td>
<td>In vivo cell-scale imaging of the human retina by adaptive optics</td>
<td>PAQUES M--Paris</td>
</tr>
</tbody>
</table>

### Course 3  EBO review course: Intraocular Inflammation and Infection - Part I  
**IM**  
Bahram BODAGHI, Carl P HERBORT  

The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Instructor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1451</td>
<td>Pathophysiology of uveitis</td>
<td>DICK A--Bristol</td>
</tr>
<tr>
<td>11:15</td>
<td>1452</td>
<td>Classification of uveitis</td>
<td>ANDROUDI S--Thessaloniki</td>
</tr>
<tr>
<td>11:30</td>
<td>1453</td>
<td>Signs and symptoms of uveitis</td>
<td>NERI P, CAPUANO V, PIRANI V, ARAPI I, MARIOTTI C, GIOVANNINI A--Ancona</td>
</tr>
<tr>
<td>11:45</td>
<td>1454</td>
<td>Laboratory work-up and specialized investigations</td>
<td>PLEYER U--Berlin</td>
</tr>
<tr>
<td>12:00</td>
<td>1455</td>
<td>Imaging in uveitis: techniques and indications</td>
<td>HERBORT C--Lausanne</td>
</tr>
<tr>
<td>12:15</td>
<td>1456</td>
<td>Therapeutic management of uveitis</td>
<td>DICK A--Bristol</td>
</tr>
</tbody>
</table>
**WEDNESDAY**

### MORNING SESSION

**SIS EOVS**  
**Doctor, the eyes won’t keep still**  
**Graham HOLDER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session ID</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1461</td>
<td>The initial consult</td>
<td>SPIEERS W–Leuven</td>
</tr>
<tr>
<td>11:20</td>
<td>1462</td>
<td>Genetically determined causes of eye movement disorders</td>
<td>LEROY B–Ghent</td>
</tr>
<tr>
<td>11:40</td>
<td>1463</td>
<td>The neurological approach</td>
<td>KAWASAKI A–Lausanne</td>
</tr>
<tr>
<td>12:00</td>
<td>1464</td>
<td>The role of electrophysiology</td>
<td>HOLDER G–London</td>
</tr>
</tbody>
</table>

**Joint M. FRO - Belgian Fund for Research in Ophthalmology - part 1**  
**Marie José TASSIGNON, Laure CASPERS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session ID</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>1471</td>
<td>The effect of local rock-inhibition on uveitis</td>
<td>HOLLANDERS K–Leuven</td>
</tr>
<tr>
<td>11:12</td>
<td>1472</td>
<td>Identification of the gene signature of retinal endothelial cells during classical experimental autoimmune uveitis, Th1- and Th17-dependent uveitis</td>
<td>LIPSKI D</td>
</tr>
<tr>
<td>11:24</td>
<td>1473</td>
<td>Evaluating hyaluronic acid as a coating strategy for intravitreally injected nanomedicines for retinal gene therapy</td>
<td>MARTENS T–Ghent</td>
</tr>
<tr>
<td>11:36</td>
<td>1474</td>
<td>Examining the optical qualities of explanted IOLs</td>
<td>NI DHUBHGHAIL S</td>
</tr>
<tr>
<td>11:48</td>
<td>1475</td>
<td>Development of a classification system for normal and keratoconic human corneas to assist in the detection of early keratoconus through a machine learning algorithm</td>
<td>RUIZ HIDALGO I</td>
</tr>
<tr>
<td>12:00</td>
<td>1476</td>
<td>Potential implications of epigenetic changes in human retinal pigmented epithelium during diabetic retinopathy</td>
<td>SALIK D–Bruxelles</td>
</tr>
<tr>
<td>12:12</td>
<td>1477</td>
<td>Complementary effects of mitomycin-c and anti-fibrotic agents on surgical outcome after glaucoma filtration surgery</td>
<td>VAN BERGEN T–Leuven</td>
</tr>
<tr>
<td>12:24</td>
<td>1478</td>
<td>Endothelial recovery by novel rock-inhibitors in the cornea</td>
<td>SUNAVE D–Leuven</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Welcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:35</td>
<td>Glaucoma and the ocular surface</td>
<td>BRON A–Dijon</td>
<td></td>
</tr>
<tr>
<td>12:47</td>
<td>How to recognize and decide if a patient suitable for PF therapy</td>
<td>GONI F–Barcelona</td>
<td></td>
</tr>
<tr>
<td>12:59</td>
<td>PF Monotherapy</td>
<td>ROSSETTI L–Milano</td>
<td></td>
</tr>
<tr>
<td>13:11</td>
<td>PF Combo therapy</td>
<td>SUNARIC MEGEVAND G–Geneva</td>
<td></td>
</tr>
<tr>
<td>13:23</td>
<td>Q &amp; As</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FIRST AFTERNOON SESSION

WEDNESDAY

SIS  Dietary fatty acids: from mechanisms to epidemiology and clinical application in the prevention of Age-related Macular Degeneration (AMD)  Athena

RV  Lionel BRETILLON

<table>
<thead>
<tr>
<th>Time</th>
<th>No.</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>1611</td>
<td>Dietary fat consumption and AMD: Epidemiological facts</td>
<td>DELCOURT C–Bordeaux</td>
</tr>
<tr>
<td>13:48</td>
<td>1612</td>
<td>Omega-3 fatty acids and prevention of cardiovascular events</td>
<td>DALLONGEVILLE J–Lille</td>
</tr>
<tr>
<td>14:06</td>
<td>1613</td>
<td>The mechanisms of the action of omega-3s in the retina</td>
<td>ACAR N–Dijon</td>
</tr>
<tr>
<td>14:24</td>
<td>1614</td>
<td>Prospects: Dietary -3 polyunsaturated fatty acids, CCR2+ monocyte recruitment, and AMD?</td>
<td>SENNLAUB F–Paris</td>
</tr>
<tr>
<td>14:42</td>
<td>1615</td>
<td>How to handle the dietary requirements in clinical practice in ophthalmology</td>
<td>CREUZOT C–Dijon</td>
</tr>
</tbody>
</table>

Course 4  The amniotic membrane: new regenerative therapies and their potential impact on the clinical management of ocular surface diseases  Hermes

COS  Jean-Jacques GICQUEL, Andrew HOPKINSON

The Amniotic Membrane (AM) story is pretty much at a conclusion. Over the last 10 years, AM transplantation has dramatically changed our approach of the treatment of ocular surface diseases. Nowadays, new AM based regenerative therapies have been developed and they may once again have a significant impact on how we manage our patients. We propose to an intermediate audience, an update on the many new technologies being developed, including corneal mimetic constructs, decellularised corneas and innovative stem cells technologies.

<table>
<thead>
<tr>
<th>Time</th>
<th>No.</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>1621</td>
<td>Amniotic membrane transplantation: Implications for corneal wound healing</td>
<td>GICQUEL JJ, DUA HS–Nottingham</td>
</tr>
<tr>
<td>13:48</td>
<td>1622</td>
<td>Intra and inter donor variations of amniotic membrane</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>14:06</td>
<td>1623</td>
<td>The new clinical applications of dried amniotic membrane</td>
<td>HOPKINSON A, ALLEN C, DUA HS–Nottingham</td>
</tr>
<tr>
<td>14:24</td>
<td>1624</td>
<td>Challenges in manufacturing an amniotic membrane alternative for corneal regeneration</td>
<td>WILSON S, HOPKINSON A–Nottingham</td>
</tr>
<tr>
<td>14:42</td>
<td>1625</td>
<td>Amniotic membrane as a tissue engineering substrate</td>
<td>BRANCH M–Nottingham</td>
</tr>
</tbody>
</table>
# FIRST AFTERNOON SESSION 13:30 - 15:00

## FP COS

### Free papers COS 1/5: Corneal inflammation and wound healing

**Rhodes 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:42</td>
<td>1632</td>
<td>New matrix therapy in chronic corneal ulcers resistant to conventional therapies</td>
<td>HUGNY LARROQUE C, DERRIEN S, COCHENER B–Brest</td>
</tr>
<tr>
<td>14:06</td>
<td>1634</td>
<td>Diagnostic traps based on nomenclature of inflammatory changes in corneal confocal microscopy in vivo</td>
<td>SMEDOWSKI A, WYLEGALA E, WOJCIK L–Katowice</td>
</tr>
<tr>
<td>14:18</td>
<td>1635</td>
<td>Short-time reproducibility of tearfilm osmolarity measurement assessed with electrical impedance</td>
<td>SCHMIDL D, KAYA S, NEPP J, SCHMETTERER L, GARHOFER G–Vienna</td>
</tr>
<tr>
<td>14:30</td>
<td>1636</td>
<td>Corneal Langerhans cell and dry eye examinations in ankylosing spondylitis</td>
<td>MARSOVSZKY L, NEMETH J, RESCH MD, TOLDI G, LEGANY N, KOVACS L, BALOG A–Budapest, Szeged</td>
</tr>
<tr>
<td>14:42</td>
<td>1637</td>
<td>Experimental evidence of fluid secretion of rabbit lacrimal gland ductal epithelia</td>
<td>TOTH-MOLNAR E, KATONA M, FACSKO A, VENGLOVICZ V, NEMETH L, HEGYI P–Szeged</td>
</tr>
</tbody>
</table>

### SIS Neuroprotection: past and future strategies

**Rhodes 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>1641</td>
<td>Pharmacological strategies related to ocular neuroprotection</td>
<td>GARHOFER G–Vienna</td>
</tr>
<tr>
<td>13:50</td>
<td>1642</td>
<td>Importance of taurine in maintaining retinal function</td>
<td>PICAUD S, FROGER N–Paris</td>
</tr>
<tr>
<td>14:10</td>
<td>1643</td>
<td>Clinical neuroprotection in relation to ophthalmology</td>
<td>ROSSETTI L–Milano</td>
</tr>
<tr>
<td>14:30</td>
<td>1644</td>
<td>Possible reasons for a miss match between animal neuroprotection studies and clinical findings</td>
<td>OSBORNE N–Oviedo</td>
</tr>
</tbody>
</table>

### Course 5 EBO review course: Intraocular Inflammation and Infection - Part II

**Rhodes 3**

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>1651</td>
<td>B27-associated uveitis, Fuchs uveitis</td>
<td>WILLERMAIN F–Bruxelles</td>
</tr>
<tr>
<td>13:45</td>
<td>1652</td>
<td>Infectious uveitis</td>
<td>PLEYER U–Berlin</td>
</tr>
<tr>
<td>14:00</td>
<td>1653</td>
<td>Behçet disease, VKH, sarcoidosis</td>
<td>KHAIRALLAH M, KHALDOUN R–Monastir</td>
</tr>
<tr>
<td>14:15</td>
<td>1654</td>
<td>White dot syndromes</td>
<td>HERBORT C–Lausanne</td>
</tr>
<tr>
<td>14:30</td>
<td>1655</td>
<td>Pediatric uveitis</td>
<td>BODAGHI B–Paris</td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td>Conclusions</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Presenters</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>13:30</td>
<td>FP</td>
<td>Motion-onset visual evoked potentials - Important tool in vision and eye research</td>
<td>Kubova Z, Kuba M, Kremlacek J, Langrova J, Szanyi J, Vit F, Chutna M–Hradec Králové</td>
</tr>
<tr>
<td>13:42</td>
<td>FP</td>
<td>Pure neuroretinal dysfunction in diabetic retinopathy occurring prior to endothelial and vascular damage</td>
<td>Reis A, Mateus C, MeIo P, Figueira J, Cunha-Vaz J, Castelo-Branco M–Coimbra</td>
</tr>
<tr>
<td>13:54</td>
<td>FP</td>
<td>Ophthalmic care – Reaching out to the ageing population. Experiences in Sweden</td>
<td>Martin L–Eskilstuna</td>
</tr>
<tr>
<td>14:06</td>
<td>FP</td>
<td>Characterization of human corneal grafts’ transparency by optical coherence tomography and scattering measurements</td>
<td>Hoffart L–Marseille</td>
</tr>
<tr>
<td>14:18</td>
<td>FP</td>
<td>Optic disc hamartomas in a family with heterozygous mutation in the VMD2 gene: Clinical, diagnostic and molecular genetic findings</td>
<td>Todorova M, Schordert DF, Valmaggia C–Basel, Sion, St. Gallen</td>
</tr>
<tr>
<td>14:30</td>
<td>FP</td>
<td>Possibility of visual prognosis based on flash visual evoked potential in cases of early brain damage</td>
<td>Pojda-Wilczek D–Katowice</td>
</tr>
<tr>
<td>13:30</td>
<td>Joint M.</td>
<td>Identification of a novel gene for autosomal dominant retinitis pigmentosa by combined linkage analysis and whole</td>
<td>Van Cauwenbergh C–Ghent</td>
</tr>
<tr>
<td>14:06</td>
<td>Joint M.</td>
<td>Unraveling molecular and cellular mechanisms underlying inflammation- and aging-induced blood-retinal barrier disruption</td>
<td>Van Hoove J–Leuven</td>
</tr>
<tr>
<td>14:18</td>
<td>Joint M.</td>
<td>Histology and immunohistochemistry of the vitreolenticular interface in developmental cataracts</td>
<td>Van Loveren J–Edegem</td>
</tr>
<tr>
<td>14:30</td>
<td>Joint M.</td>
<td>Functional characterization of ECSIT, a candidate disease gene for primary congenital glaucoma (PCG) on chromosome 19p13.2</td>
<td>Verdin H–Ghent</td>
</tr>
<tr>
<td>14:42</td>
<td>Joint M.</td>
<td>Self aligning recombinant human collagen scaffolds for corneal tissue engineering</td>
<td>Zakkaria N–Edegem</td>
</tr>
</tbody>
</table>
Course 6  Retinal detachment
RV  Catherine CREUZOT, Jean-Paul BERROD

The aim of this course is to present the signs and the treatment of different clinical cases of retinal detachment. The indication of vitrectomy or scleral buckling will be considered. Cases of retinal detachment occurring in myopic patients or exudative retinal detachment will be presented. Finally, the problem of tractional retinal detachment will be considered.

<table>
<thead>
<tr>
<th>Time</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>Retinal detachment without PVR CREUZOT C–Dijon</td>
</tr>
<tr>
<td>15:23</td>
<td>Retinal detachment with PVR BERROD JP–Nancy</td>
</tr>
<tr>
<td>15:41</td>
<td>DR in myopic patients TADAYONI R–Paris</td>
</tr>
<tr>
<td>15:59</td>
<td>Exudative retinal detachment DE SMET MD–Lausanne</td>
</tr>
<tr>
<td>16:17</td>
<td>Tractional retinal detachment MASSIN P–Paris</td>
</tr>
</tbody>
</table>

Course 7  An update on corneal infectious diseases
COS  Jean-Jacques GICQUEL, Dominique BREMOND-GIGNAC

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we’ll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amnion Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

<table>
<thead>
<tr>
<th>Time</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>Corneal bacterial infections: A practical approach GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>15:27</td>
<td>Herpes and Zoster infections update LABETOULLE M, ROUSSEAU A–Le Kremlin Bicêtre</td>
</tr>
<tr>
<td>15:49</td>
<td>The particularities of corneal infectious diseases in children BREMOND-GIGNAC D–Amiens</td>
</tr>
<tr>
<td>16:11</td>
<td>New emerging treatments in severe corneal infectious diseases GICQUEL J, DUA HS–Poitiers, Nothingham</td>
</tr>
</tbody>
</table>
### New frontier in glaucoma surgery: Trans-trabecular meshwork

- **Rhodes 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>SIS G/ACB</td>
<td>iStent implant</td>
<td>LIM K, POURJAVAN S</td>
</tr>
<tr>
<td>15:27</td>
<td></td>
<td>Trabectome surgery</td>
<td>LONGSTAFF S, SHEFFIELD N</td>
</tr>
<tr>
<td>15:49</td>
<td></td>
<td>Other trans-trabecular meshwork implants</td>
<td>LIM K, LONDON E</td>
</tr>
<tr>
<td>16:11</td>
<td></td>
<td>Basic science behind trabecular meshwork surgeries</td>
<td>OVERBY D, LONDON E</td>
</tr>
</tbody>
</table>

### Free papers PBP 1/2: Neuroprotection and ocular blood flow

- **Rhodes 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>FP PBP</td>
<td>Rod microglia is absent from microglial changes in mice retina contralateral to experimental glaucoma</td>
<td>GALLEGO B, DE HOZ R, RAMIREZ AJ, SALAZAR JJ, ROJAS B, TRIVINO A, RAMIREZ JM, MADRID J</td>
</tr>
<tr>
<td>15:17</td>
<td></td>
<td>Neuropeptide Y Y1 receptor is neuroprotective and modulates microglia reactivity in the rat retina</td>
<td>AMBROSIO AF, ELVAS F, MADEIRA M, BRUDZEWSKY D, MARTINS J, MARTINS T, CAVADAS C, SANTIAGO AR, COIMBRA</td>
</tr>
<tr>
<td>15:41</td>
<td></td>
<td>Modified connexin43 mimetic peptide shows higher efficacy in reducing retinal ganglion cell loss and vessel leak after retinal ischemia</td>
<td>RUPENTHAL I, CHEN Y, TEAGUE R, PERRETT J, DANESH-MEYER H, TOTH J, GREEN C, AUCKLAND, BRISBANE</td>
</tr>
<tr>
<td>16:05</td>
<td></td>
<td>Optic nerve head autoregulation during changes in arterial blood pressure</td>
<td>BOLTZ A, TOLD R, PALKOVITS S, SCHMIDL D, NAPORA K, GARHOFER G, SCHMETTERER L, VIENNA</td>
</tr>
</tbody>
</table>

### How biologic agents are changing the story of uveitis: anti-TNF-α agents and more

- **Rhodes 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>SIS IM</td>
<td>The evolution of monoclonal antibodies</td>
<td>DICK A</td>
</tr>
<tr>
<td>15:23</td>
<td></td>
<td>What I should do before considering biologic agents</td>
<td>WILLERMAIN F, BRUSSELS</td>
</tr>
<tr>
<td>15:41</td>
<td></td>
<td>Long-term clinical outcomes in patients with refractory uveitis associated with Behçet’s disease treated with infliximab</td>
<td>ABU EL ASRAR A, RIYADH</td>
</tr>
<tr>
<td>16:17</td>
<td></td>
<td>The “strange story” of Interferon-α: A very peculiar biologic agent</td>
<td>BODAGHI B, PARIS</td>
</tr>
</tbody>
</table>
Course 8 Visual electrophysiology  
EOVS  
Graham HOLDER, Bart LEROY

To discuss the clinical applications of visual electrophysiology.

15:05 1761 A general introduction to the tests and abnormality localisation  
LEROY B–Ghent

15:27 1762 Electrophysiology in acquired disease  
HOLDER G–London

15:49 1763 Electrophysiology in inherited disease  
LEROY B–Ghent

16:11 1764 Electrophysiology and imaging  
HOLDER G–London

FP Free papers PO 1/2: New insights into uveal melanoma  
Gallieni 1 & 2

Martine J JAGER, Nathalie CASSOUX

15:05 1771 Effect of hypoxic stress on induction and plasticity of tumour-induced immune cells in uveal melanoma  
BRONKHORST IHG, JEHS TML, DIJKGRAAF EM, LUYTEN GPM, VAN DER VELDEN PA, VAN DER BURG SH, JAGER MJ–Leiden

15:17 1772 Targeting the hypoxia pathway in uveal melanoma cells  
ASNAGHI L, LIN MH, LIM KS, LIM KJ, BAR EE, EBERHART CG–Baltimore, Cleveland

15:29 1773 Epigenetic regulation of the epithelial phenotype in uveal melanoma  
VERSLOUIS M, DE LANGE MJ, VAN PELT S, LUYTEN GPM, JAGER MJ, VAN DER VELDEN PA–Leiden

15:41 1774 Gain of chromosome 6 status does not influence HLA-expression in uveal melanoma  
VAN PELT S, VAN ESSEN TH, BRONKHORST IHG, VERSLOUIS M, LUYTEN GPM, VAN HALL T, VAN DEN ELSEN PJ, VAN VELDEN PA, JAGER MJ–Leiden

15:53 1775 A new and standardized method to sample and analyse vitreous biopsies by the Cellient® automated cell block system  
VAN GINDERDEUREN R, VAN CALSTER J–Leuven

16:05 1776 Ophthalmic histopathology samples – are we sending enough?  
DEV BORMAN A, HASSANI M, KESHARAJU R, NADERI K, GHANZI-NOURI S–Chelmsford, Plymouth, Colchester

16:17 1777 Orbital melanocytosis and OTA naevus  
DE KEIZER RJW, LAUWERS N, DE GROOT V–Antwerp
16:45  Welcome by the President EVER 2013  
Philippe KESTELYN - President 2013  

WELCOME

17:15  EVER 2013 Lecture: Advances in OCT imaging  
Leopold SCHMETTERER - Past-President  
Introduction by Philippe KESTELYN

EVER Lecture

17:50  Major Central European contributions to international ophthalmology  
Andrzej GRZYBOWSKI  
Introduction by Marcela VOTRUBA

European Ophthalmic Heritage Lecture

18:25  Telomere maintenance and retinal vascularisation  
Tero KIVELÄ  
Introduction by Einar STEFANSSON  
Award presentation

EVER/ACTA Lecture

19:00 - 21:00  EVER Welcome Reception  
Reception opened by Philippe Kestelyn  
EVER 2013 President

WELCOME RECEPTION
### Thursday 08:30 - 10:00

**First Morning Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>SIS RV</td>
<td>Macular edema</td>
<td>Catherine CREUZOT, Pascale MASSIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pathophysiology of macular edema</td>
<td>JONAS J–Mannheim</td>
</tr>
<tr>
<td>08:48</td>
<td></td>
<td>Can we quantify macular edema outcome?</td>
<td>MASSIN P–Paris</td>
</tr>
<tr>
<td>09:06</td>
<td></td>
<td>Functional assessment of macular edema</td>
<td>MIDENA E–Padova</td>
</tr>
<tr>
<td>09:24</td>
<td></td>
<td>How to select our treatments?</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>09:42</td>
<td></td>
<td>How to organise the follow-up of patients with macular edema?</td>
<td>POURNARAS CJ–Genève</td>
</tr>
<tr>
<td>08:30</td>
<td>SIS G</td>
<td>Dealing with advanced glaucoma</td>
<td>Ejaz ANSARI</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td>Definition and diagnosis of advanced glaucoma</td>
<td>ZEYEN T–Leuven</td>
</tr>
<tr>
<td>08:52</td>
<td></td>
<td>Treatment of advanced glaucoma</td>
<td>BRON A–Dijon</td>
</tr>
<tr>
<td>09:14</td>
<td></td>
<td>Differential diagnosis</td>
<td>ANSARI E–Maidstone</td>
</tr>
<tr>
<td>09:36</td>
<td></td>
<td>Counselling in advanced glaucoma</td>
<td>ANSARI E–Maidstone</td>
</tr>
<tr>
<td>08:30</td>
<td>SIS ME and retinal disease</td>
<td>ME and retinal disease</td>
<td>Susan LIGHTMAN, Anat LOEWENSTEIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ME and Retinal Disease</td>
<td>AMBATI J–Lexington</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ME and Visual Acuity</td>
<td>TADAYONI R–Paris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ME and RVO</td>
<td>LOEWENSTEIN A–Tel Aviv</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ME and Uveitis</td>
<td>LIGHTMAN S–London</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussions and Close</td>
<td></td>
</tr>
</tbody>
</table>
### SIS PO
**Non-Graves’ orbital Inflammation**

**Rhodes 2**

**First Morning Session 08:30 - 10:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2241</td>
<td>Rationale for a diagnostic approach</td>
<td>GAVARD-PERRET A, ROBERT PY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nice, Limoges</td>
</tr>
<tr>
<td>08:52</td>
<td>2242</td>
<td>Clinics, biopsy and pathology</td>
<td>ROBERT P</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limoges</td>
</tr>
<tr>
<td>09:14</td>
<td>2243</td>
<td>Inflammatory orbital lesions (IOI)</td>
<td>DE KEIZER RJW, BJLSMA WR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Edegem, Utrecht</td>
</tr>
<tr>
<td>09:36</td>
<td>2244</td>
<td>Orbital biopsies - the pathologist’s perspective</td>
<td>COUPLAND S</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Liverpool</td>
</tr>
</tbody>
</table>

### Joint M.
**Improved monitoring and treatment of endogenous uveitis is modifying disease management/outcomes I: VKH disease**

**Rhodes 3**

**IM**

**Piergiorgio NERI, Carl P HERBORT**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2251</td>
<td>Pathophysiology of the development of intraocular inflammation in VKH</td>
<td>HERBORT C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lausanne</td>
</tr>
<tr>
<td>08:45</td>
<td>2252</td>
<td>ICGA features in VKH</td>
<td>BOUCHENAKI N, HERBORT CP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Geneva, Lausanne</td>
</tr>
<tr>
<td>09:00</td>
<td>2253</td>
<td>OCT for VKH</td>
<td>NAKAI K</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Suita</td>
</tr>
<tr>
<td>09:15</td>
<td>2254</td>
<td>Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids</td>
<td>ABU EL ASRAR A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Riyadh</td>
</tr>
<tr>
<td>09:30</td>
<td>2255</td>
<td>Vogt-Koyanagi-Harada disease: Sunset-glow fundus is not a fatality any more</td>
<td>HERBORT C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lausanne</td>
</tr>
<tr>
<td>09:45</td>
<td>2256</td>
<td>The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease</td>
<td>ABU EL ASRAR A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Riyadh</td>
</tr>
</tbody>
</table>
### SIS
#### Mitochondria and the eye: mitochondrial dysfunction and disease
**Rhodes 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 08:30  | Oxidative-induced RGC-5 cell death culture involves mitochondrial dysfunction and can be attenuated by hydrogen sulphide.  
          | **OSBORNE N**—Oviedo                                                        |
| 08:48  | Advancing age and mitochondrial dysfunction impair optic nerve recovery after IOP challenge  
          | **CROWSTON JG**—Melbourne                                                  |
| 09:06  | The expanding clinical spectrum of dominant optic atrophy  
          | **YU-WAI-MAN P**—Newcastle upon Tyne                                        |
| 09:24  | Sensorineural hearing loss in OPA1-linked disorders  
          | **BONNEAU D, MILEA D, LERUEZ S, DEFOORT-DHELLEMMES S, CROCHET M, LAMBLIN J, LENAERS G, PROCACCIO V, REYNIER P, BONNEAU-AMATI P**—Angers, Lille, Montpellier |
| 09:42  | The unsolved genetics of LHON: Beyond mtDNA primary mutations what else?  
          | **CARELLI V**—Bologna                                                      |

### SIS
#### Clearance systems in the RPE cells-implications to AMD
**Gallieni 1 & 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 08:30  | The endolysosomal system and AMD: Insights from a novel genetically engineered mouse model  
          | **SINHA D, VALAPALA M, ZIGLER JS, HOSE S**—Baltimore                           |
| 09:00  | Crosstalk of proteasomes and autophagy in RPE cells  
          | **KAARNIRANTA K**—Kuopio                                                    |
| 09:30  | A novel role for the immunoproteasome in retinal function  
          | **FERRINGTON D**—Minneapolis                                                 |
THURSDAY

10:15 - 11:00

**KEYNOTE LECTURE**

Hermes

Balwantray CHAUHAN

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Introduction by Alain Bron</td>
</tr>
<tr>
<td>10:25</td>
<td>Why what you have been taught about the optic disc may not be entirely true CHAUHAN B–Halifax</td>
</tr>
<tr>
<td>10:55</td>
<td>Award of the EVER certificate of honour</td>
</tr>
</tbody>
</table>
### SECOND MORNING SESSION

**THURSDAY**

<table>
<thead>
<tr>
<th>FP</th>
<th>RV</th>
<th>Free papers RV 1/4: Surgical retina</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2411</td>
<td>Postoperative quality of life in macula-off rhegmatogenous retinal detachment patients and its relation to visual function</td>
<td>Groningen</td>
</tr>
<tr>
<td>11:17</td>
<td>2412</td>
<td>Posterior vitreous detachment in highly myopic eyes undergoing vitrectomy</td>
<td>Paris, Strasbourg</td>
</tr>
<tr>
<td>11:29</td>
<td>2413</td>
<td>Epiretinal membrane surgery in highly myopic eyes a case control study</td>
<td>Nancy</td>
</tr>
<tr>
<td>11:41</td>
<td>2414</td>
<td>Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction associated with macular hole from the MIVI-TRUST clinical program</td>
<td>Ayr, Toulouse, Ghent, Leuven</td>
</tr>
<tr>
<td>11:53</td>
<td>2415</td>
<td>Baseline characteristics predictive of pharmacologic vitreomacular adhesion resolution in the ocriplasmin MIVI-TRUST program</td>
<td>Munich</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIS</th>
<th>G</th>
<th>Myths and misconceptions in glaucoma</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2421</td>
<td>Myths and misconceptions about glaucoma blindness</td>
<td>Antwerp</td>
</tr>
<tr>
<td>11:27</td>
<td>2422</td>
<td>Misconception about the intraocular pressure</td>
<td>Brussels</td>
</tr>
<tr>
<td>11:49</td>
<td>2423</td>
<td>Generics are the same or similar?</td>
<td>Gent</td>
</tr>
<tr>
<td>12:11</td>
<td>2424</td>
<td>Myths and misconceptions in treatment adherence</td>
<td>London</td>
</tr>
</tbody>
</table>
### SECOND MORNING SESSION  
11:05 - 12:35  
THURSDAY

#### SIS  
Developments in corneal regeneration – NEXCR (Network of Excellence in Corneal Regeneration)  
Herbert VAN ESSEN, Marie - José TASSIGNON

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2431</td>
<td>Novel strategies for angioregression at the ocular surface</td>
<td>BOCK F, CURSIEFEN C–Cologne</td>
</tr>
<tr>
<td>11:23</td>
<td>2432</td>
<td>Mesenchymal stem cells and corneal regeneration</td>
<td>HOPKINSON A, BRANCH M–Nottingham</td>
</tr>
<tr>
<td>11:41</td>
<td>2433</td>
<td>Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation</td>
<td>ZAKARIA N, KOPPEN C, TASSIGNON MJ–Antwerp</td>
</tr>
<tr>
<td>12:17</td>
<td>2435</td>
<td>Suitability of a fish scale-derived collagen matrix (FSCM) as artificial cornea</td>
<td>VAN ESSEN TH, VAN ZIJL L, SPARKS SJ, CHEN G, LIN CC, LAI HI, LUYTEN GPM, GHALBZOURI AEL, JAGER MJ–Leiden</td>
</tr>
</tbody>
</table>

#### Course 9  
The management of pigmented fundus lesions  
Laurence DESJARDINS, Bertil DAMATO

The course will cover benign and malignant, congenital and acquired pigmented lesions of the fundus. Congenital pigmented lesions of the fundus are rare and can sometimes be confused with naevus or melanoma. The clinical aspects and pathology of all these lesions will be described. The differential diagnosis between benign naevi and suspicious naevi and the description and follow up of such lesions will allow the audience to get precise guidelines for the management of choroidal naevi. Focus will then be made on malignant uveal melanoma, including clinical aspects with the prognostic factors and treatment options. Radiotherapy techniques and surgical techniques will be developed in details.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2441</td>
<td>Congenital and other pigmented fundus lesions</td>
<td>CAUJOLLE JP–Nice</td>
</tr>
<tr>
<td>11:23</td>
<td>2442</td>
<td>Suspicious choroidal naevi</td>
<td>KIVELÄ T–Helsinki</td>
</tr>
<tr>
<td>11:41</td>
<td>2443</td>
<td>Malignant melanoma of the uvea: Diagnosis, characterization and prognosis</td>
<td>MIDENA E–Padova</td>
</tr>
<tr>
<td>11:59</td>
<td>2444</td>
<td>Malignant melanoma of the uvea: Radiotherapy techniques</td>
<td>DESJARDINS L–Paris</td>
</tr>
<tr>
<td>12:17</td>
<td>2445</td>
<td>Malignant melanoma of the uvea: Surgical techniques</td>
<td>DAMATO B–Liverpool</td>
</tr>
</tbody>
</table>
### THURSDAY

#### SIS

**IM/G**

**Inflammation and glaucoma: good or bad?**

*Rhodes 3*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2451</td>
<td>Uveitis and glaucoma: A practical approach</td>
<td>BODAGHI B–Paris</td>
</tr>
<tr>
<td>11:27</td>
<td>2452</td>
<td>Autoimmune mechanisms in primary open angle glaucoma</td>
<td>GRUS F–Mainz</td>
</tr>
<tr>
<td>12:11</td>
<td>2454</td>
<td>How inflammatory reactions affect POAG topical and surgical treatment?</td>
<td>LABBE A, BAUDOUIN C–Paris</td>
</tr>
</tbody>
</table>

---

**Grand rounds in ophthalmic genetics**

*Rhodes 4*

*MBGE* Bart LEROY, Christian HAMEL

This SIS will provide a forum for researchers and clinicians alike to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. Both SIS organisers will be present, together with other leaders in the field of ophthalmic genetics. Because of the format of the SIS, there will be no formal speakers set in stone from the outset, as all EVER participants will be free to submit cases during the meeting prior to this session. As such, the format will be similar to the FAN Club meeting.

---

#### FP

**Free papers ACB 1/2: Modelling corneal epithelium and cell biology of retina**

*Gallieni 1 & 2*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05</td>
<td>2471</td>
<td>Restoration of keratocyte cell phenotype through epithelial-stromal cell interactions in a 3D hydrogel model</td>
<td>WILSON SL–Nottingham</td>
</tr>
<tr>
<td>11:17</td>
<td>2472</td>
<td>Culture optimisation of CD34-positive corneal stromal stem cells and transdifferentiation into corneal epithelial cells</td>
<td>SIDNEY LE, BRANCH MJ, HASHMANI K, DUAS HS, HOPKINSON A–Nottingham</td>
</tr>
<tr>
<td>11:29</td>
<td>2473</td>
<td>Small molecule induction promotes corneal epithelial cell differentiation from human pluripotent stem cells</td>
<td>SKOTTMAN H, MIKHAILOVA A, UUSITALO H, ILMARINEN T–Tampere</td>
</tr>
<tr>
<td>12:05</td>
<td>2476</td>
<td>Glucocorticoid modulation of agonist induced microvascular endothelial permeability</td>
<td>SHAMS F, HUDSON N, OCKRIM Z, TUROWSKI P–London</td>
</tr>
<tr>
<td>12:11</td>
<td>2477</td>
<td>Comparative gene expression analysis of corneal stroma mesenchymal stem cell-like cells, limbal epithelial stem cells and bone marrow-derived mesenchymal stem cells</td>
<td>VEREB Z, POLISKA SZ, ALBERT R, OLSTAD OK, MOE MC, FESUS L, PETROVSKI G–Debrecen, Oslo</td>
</tr>
</tbody>
</table>
LUNCHTIME SESSION

INDUSTRY-SPONSORED SYMPOSIUM  Rhodes 2

Micronutrition: Part of the retinal specialists’ armamentarium?

Moderator: Catherine CREUZOT

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35</td>
<td>2541</td>
<td>Micronutrition; Opinion and use among European Ophthalmologists</td>
<td>ASLAM T–Manchester</td>
</tr>
<tr>
<td>12:55</td>
<td>2542</td>
<td>New evidence on nutritional supplements</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>13:15</td>
<td>2543</td>
<td>How to go further? From fundamental research to clinical practice</td>
<td>DELMAS D, LAYANA A–Dijon</td>
</tr>
</tbody>
</table>
### 13:40 - 14:15

**THURSDAY**

**OPHTHALMIC RESEARCH LECTURE**

Hermes

*Neville OSBORNE*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>Introduction by Uwe Pleyer</td>
</tr>
<tr>
<td>13:45</td>
<td>The neuroscience of glaucoma in relation to the possibility for neuroprotection</td>
</tr>
</tbody>
</table>

OSBORNE N–Oviedo
### FIRST AFTERNOON SESSION

#### SIS Vitreoretinal interface disorders

**Athena**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>2611</td>
<td>POURNARAS CJ–Genève</td>
<td>Normal and abnormal vitreoretinal interface conditions</td>
</tr>
<tr>
<td>14:30</td>
<td>2612</td>
<td>TADAYONI R–Paris</td>
<td>Assessment and classification of vitreoretinal interface disorders</td>
</tr>
<tr>
<td>14:45</td>
<td>2613</td>
<td>POURNARAS JA–Lausanne</td>
<td>Natural history of vitreoretinal interface disorders</td>
</tr>
<tr>
<td>15:00</td>
<td>2614</td>
<td>LE MER Y–Paris</td>
<td>Medical management of vitreoretinal interface disorders</td>
</tr>
<tr>
<td>15:15</td>
<td>2615</td>
<td>WOLFENSBERGER TJ–Lausanne</td>
<td>Surgical management of vitreoretinal interface disorders</td>
</tr>
<tr>
<td>15:30</td>
<td>2616</td>
<td>POURNARAS JA–Lausanne</td>
<td>Case study</td>
</tr>
</tbody>
</table>

#### SIS New angles in glaucoma- neuroprotection

**Hermes**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>2621</td>
<td>CORDEIRO M–London</td>
<td>The potential of regenerative strategies in glaucoma</td>
</tr>
<tr>
<td>14:45</td>
<td>2622</td>
<td>CHAUHAN B–Halifax</td>
<td>The potential role of endothelin in glaucoma</td>
</tr>
<tr>
<td>15:15</td>
<td>2623</td>
<td>KOLKO M–Copenhagen</td>
<td>The role of low-grade inflammation in glaucoma</td>
</tr>
</tbody>
</table>

#### Course 10 An update on corneal procedures

**Rhodes 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>2631</td>
<td>GICQUEL J, DUA HS–Poitiers, Nottingham</td>
<td>Step by step limbal stem cell transplantation techniques</td>
</tr>
<tr>
<td>14:37</td>
<td>2632</td>
<td>MENCUCCI R–Florence</td>
<td>Indications and practical use of corneal crosslinking</td>
</tr>
<tr>
<td>14:59</td>
<td>2633</td>
<td>YEUNG A–Birmingham</td>
<td>Modern indications and limitations of amniotic membrane transplantation</td>
</tr>
<tr>
<td>15:21</td>
<td>2634</td>
<td>GICQUEL JJ–Poitiers</td>
<td>Bloodless and painless pterygium surgery</td>
</tr>
</tbody>
</table>
### FIRST AFTERNOON SESSION

**Thursday 14:15 - 15:45**

#### FP Free papers PO 2/2: Diagnostic tools in eyelid and orbital pathology

**PO Steffen HEEGAARD, Edoardo MIDENA**

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>2644</td>
<td>Unique morphology of the human orbit among the Hominioidea</td>
<td>DENION E, HITIER M, GUYADER V, DUGUE AE, MOURIAUX F – Caen</td>
<td>Rhodes 2</td>
</tr>
<tr>
<td>14:51</td>
<td>2645</td>
<td>Strabismus and diplopia revealing rhabdomyosarcoma in a 7-year-old girl</td>
<td>AZIZ A, MATONTI F, FAHKOURY O, DENIS D – Marseille</td>
<td>Rhodes 2</td>
</tr>
<tr>
<td>14:57</td>
<td>2646</td>
<td>Non graves orbital inflammations: Rationale for a diagnostic approach</td>
<td>FISCH AL, GAVARD PERRET A, LAGIER J, ROBERT PY – Nice, Limoges</td>
<td>Rhodes 2</td>
</tr>
<tr>
<td>15:09</td>
<td>2647</td>
<td>Repair of orbital implants exposures using muller muscle flaps</td>
<td>ROBERT PY, DELMAS J, ADENIS J – Limoges</td>
<td>Rhodes 2</td>
</tr>
</tbody>
</table>

#### FP Free papers IM 1/2: Ocular infections “pole to pole”: new perspectives

**IM Piergiorgio NERI, Andrew DICK**

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>2651</td>
<td>Inhibition of the DNA damage response blocks herpes simplex virus infection in corneal epithelium</td>
<td>ALEKSEEV O, AZIZKHAN-CLIFFORD J – Philadelphia, PA</td>
<td>Rhodes 3</td>
</tr>
<tr>
<td>14:27</td>
<td>2652</td>
<td>Small molecule design strategy to overcome antibiotic resistance</td>
<td>BEUERMAN R – Singapore</td>
<td>Rhodes 3</td>
</tr>
<tr>
<td>15:03</td>
<td>2655</td>
<td>Reduced Th17 type inflammation associated with enhanced Th1, Th2 and Treg responses in a model of reactivation of congenital ocular toxoplasmosis</td>
<td>SAUER A, BOURCIER T, CANDOLFI E, PFAFF AW – Strasbourg</td>
<td>Rhodes 3</td>
</tr>
</tbody>
</table>
## FIRST AFTERNOON SESSION

**14:15 - 15:45**

### THURSDAY

#### SIS

**Mitochondrial dysfunction in optic neuropathies: from disease mechanisms to therapeutic strategies**

*Rhodes 4*

**MBGE/NSPH**

Marcela VOTRUBA, Patrick YU-WAI-MAN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers and Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:33</td>
<td>2662</td>
<td>OPA1 in mitochondrial quality control and its implications for RGC degeneration</td>
<td>ALAVI M–San Francisco</td>
</tr>
<tr>
<td>14:51</td>
<td>2663</td>
<td>Mitochondrial dynamics in mitochondrial optic neuropathies</td>
<td>POUITON J, LIAO C, ASHLEY N–Oxford</td>
</tr>
<tr>
<td>15:09</td>
<td>2664</td>
<td>New concepts of treatment for LHON and other genetic mitochondrial optic neuropathies</td>
<td>SADUN A–Los Angeles</td>
</tr>
<tr>
<td>15:27</td>
<td>2665</td>
<td>Raxone (idebenone) in LHON - An update</td>
<td>MEIER T–Liestal</td>
</tr>
</tbody>
</table>

#### Joint M. EEBA symposium: storage and processing of donor tissue before transplantation

**Gallieni 1 & 2**

**COS**

Vincent BORDERIE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers and Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>2671</td>
<td>Hypothermic storage or organ culture?</td>
<td>PONZIN D–Venice</td>
</tr>
<tr>
<td>14:27</td>
<td>2672</td>
<td>Consequences of storage on the donor corneal tissue</td>
<td>ARMITAGE J–Bristol</td>
</tr>
<tr>
<td>14:39</td>
<td>2673</td>
<td>The fate of the corneal endothelium during storage: apoptosis/necrosis/survival</td>
<td>ARMITAGE J–Bristol</td>
</tr>
<tr>
<td>14:51</td>
<td>2674</td>
<td>Evaluation of the donor tissue during storage</td>
<td>BORDERIE V–Paris</td>
</tr>
<tr>
<td>15:03</td>
<td>2675</td>
<td>Preparing donor tissue for DSEK</td>
<td>DICKMAN M–Maastricht</td>
</tr>
<tr>
<td>15:15</td>
<td>2676</td>
<td>Descemet's membrane preparation in eye banks for DMEK</td>
<td>BACHMANN B, KRUSE FE–Erlangen</td>
</tr>
</tbody>
</table>
Anatomy / Cell Biology
Moderators:
Hannu UUSITALO, Debasish SINHA

T001 Comparative gene expression analysis of corneal stroma mesenchymal stem cell-like cells, limbal epithelial stem cells and bone marrow-derived mesenchymal stem cells
VEREB Z, POLISKA SZ, ALBERT R, OLSTAD OK, MOE MC, FESUS L, PETROVSKI G–Debrecen, Oslo

T002 Proteasome dysfunction in retinal pigment epithelium during aging contributes to the pathogenesis of Age-Macular related Degeneration
GIRAO H, MARQUES C, SOARES A, FERNANDES R, PEREIRA P–Coimbra

T003 Bafilomycin A1 enhances the production of IL-1b induced by the proteasome inhibitor MG-132 but not that of IL-8
PIIPPO N, NYTTI M, KINNUNEN K, SALMINEN A, KAARNIRANTA K, KAUPPINEN A–Kuopio

T004 AICAR promotes cleansing of MG-132-induced protein aggregates in ARPE-19 cells
MARCHESI N, VIIRI J, PASCALE A, AMADIO M, KAARNIRANTA K–Pavia, Kuopio

T005 Hypoxia stimulates the release of Brain Natriuretic Peptide (BNP) from RPE cells
ARJAMAA O, KINNUNEN K, KAARNIRANTA K, AALTONEN V–Turku, Kuopio

T006 PKC activation affects, via ELAVL1/HuR protein, VEGF expression in pericytic/endothelial coculture
AMADIO M, OSERA C, LUPO G, MOTTA C, DRAGO F, GOVONI S, PASCALE A–Pavia, Catania

T007 The effect of hyperglycaemia on permeability and tight junction components in human retinal and choroidal endothelial cells
STEWART EA, SAKER S, AMOAKU WM–Nottingham

T008 Glucocorticoid modulation of agonist induced microvascular endothelial permeability
SHAMS F, HUDSON N, OCKRIM Z, TUROWSKI P–London

T009 Macro and microglial retinal cells in rat organotypic cultures

T010 A new automatic method for microglial-cell quantification in whole-mount mouse retinas

T011 Characterisation of diabetic retinal neuropathy in Ins2Akita mice
ROMERO J, CHEN M, XU H–Belfast

T012 Müller cell response during degenerative retinopathy in mice

T013 Cellular senescence is increased in human retinal microaneurysms during aging

T014 The fractal properties of the retinal vascular architecture
VEKRIA P, CUBBIDGE R, HEITMAR R–Birmingham

T015 Evaluation of central retinal thickness and subfoveal choroidal thickness in normal eyes
LEE DW, KIM J, KIM CG, LEE TG–Seoul, Milwaukee

T016 Assessment of macular retinal thickness and volume in normal eyes and highly myopic eyes with spectral optical coherence tomography
CHEBIL A, BEN ACHOUR B, KORT F, CHAKER N, EL MATRI L–Tunis
POSTER SESSION 1

Electrophysiology, physiological Optics, Vision Sciences

Moderators:
Miguel CASTELO-BRANCO, Celia SANCHEZ RAMOS, Werner SPILEERS, Aldina Susana REIS

T017 The prediction error of the visual field sensitivity is large at the steep ‘border’ of glaucomatous scotoma

Aoyama Y, Murata H, Tahara M, Yanagisawa M, Hirasawa K, Mayama C, Asaoka R–Tokyo

T018 The activity of the “when” pathway during visual motion

Kengo T, Shu M–Uman, Kono-cho, Kitakatsugun, Nara

T019 Comparative analysis of hyperaemia rate between preservative-free latanoprost and preserved prostaglandin eyedrops. An adjusted indirect comparison meta-analysis

Roius S, Mathieu M, Sylvestre K, Tieche M–P abdomen, France

T020 Evaluation of direct and consensual accommodation of fellow eyes using binocular open field auto refractor/keratometer WR-5100K

Taratuta E, Tarasova N–Moscow

T021 The relationship between halo size and intraocular light scatter in normal healthy subjects


T022 Simultaneous VEP and EOG in dyslexic children


T023 Retinal vessel oxygen saturation in retinitis pigmentosa patients

Tigrkever C, Valmagia C, Orugel S, Schordert DF, Todorova MG–Basel, St. Gallen, Sion

T024 Hyperstereopsis is attenuated by the addition of secondary visual cues

Priot AE, Philippe M, Salasc CA, Neveu P, Plantier J, Roumes C–Bretigny-sur-Orge

T025 Analysis of retinal and cortical response to electrical stimulation by subretinal implant in rodent

Matonti F, Roux S, Marre O, Picault S, Chavane F–Marseille, Paris

T026 VEP evidence of significant differences in motion perception in children


T027 Effects of Quensyl on the ERG a-wave amplitude from the isolated superfused vertebrate retina

Siapich SA, Goebel A, Walter P–Aachen

T028 Keep an eye on the Pi – Using the Raspberry Pi as inexpensive, yet powerful platform for vision research

Wirth M, Weichmann F, Schaeffel F, Zrenner E, Strasser T–Augsburg, Tübingen

T029 Differential diagnosis of endogeneous visual phenomena


T030 Higher hemiretinal occult retinopathy


T031 The effect of vitreous opacities on stray light measurements

De Smet MD, Castilla M–Lausanne

Glaucoma

Moderators:
James Morgan, Aachal Kotecha, M. Francesca Cordeira

T032 The prediction error of the visual field sensitivity is large at the steep “border” of glaucomatous scotoma

Aoyama Y, Murata H, Tahara M, Yanagisawa M, Hirasawa K, Mayama C, Asaoka R–Tokyo

T033 Progression of visual field in patients with primary open-angle glaucoma (1): Preliminary results


T034 Secondary glaucoma in familial amyloid polyneuropathy


T035 Pituitary macroadenoma misdiagnosed as advanced normal tension glaucoma

Popa Cherecheanu A, Coman CI, Iancu R, Parvuescu RA, Stana D, Dascalu AM–Bucharest

T036 Effectiveness of the glaucoma screening in employees of the University Hospital St. Luc, UCL, in Brussels

Stinglhamber A, Pourjavian S–Brussels

T037 24-hour intraocular pressure rhythm in young healthy subjects evaluated with continuous monitoring using contact lens sensor


T038 Sleep apnea syndrome screening in patients with normal-tension glaucoma


T039 Comparing the use of steroid vs artificial tears following selective laser trabeculoplasty

Ali Aljassim I–Riyadh

T040 Comparative effectiveness of bimatoprost 0.03% preservative-free for the treatment of open-angle glaucoma and ocular hypertension

Breton N, Stradowicz S, Harvey B, Serrilli C, Patel V, Wong W–Sheffield, Marlow, Irvine

T041 Comparative effectiveness of bimatoprost 0.03% / timolol 0.5% preservative-free for the treatment of open-angle glaucoma and ocular hypertension

Breton N, Stradowicz S, Harvey B, Serrilli C, Wong W–Sheffield, Marlow, Irvine

T042 Comparative analysis of hyperaemia rate between preservative-free latanoprost and preserved prostaglandin eyedrops.

Roland C, Cuchet M–Lille, Paris

T043 Removal of preservative from Ganfort improves intraocular pressure (IOP) lowering in patients – A timolol dose-response phenomenon

Shen J, Bejani M, Schiffman R–Irvine

T044 SYL040012, a siRNA for the treatment of glaucoma

Pareda C–Tres Cantos, Madrid
THURSDAY

T045 
**Patient behavior when prescribed non-affordable glaucoma medication in the medical unit, National Research Center, Cairo, Egypt**

SAEED IBRAHIM A—Cairo

T046 
**Outcome of fornix-based versus limbal-based conjunctival flaps in trabeculectomy**

IBANEZ J, PEREZ GARCIA D, ASCASO PUYUELO FJ, PINILLA I, JIMENEZ DEL RIO B—Cairo, Egypt

T047 
**Ultrasonic circular cyclo coagulation in patients with primary open-angle glaucoma: A multicenter clinical trial**


T048 
**Comparison of Esnoper® implant placement in non penetrating deep sclerectomy**

IBANEZ J, PEREZ GARCIA D, ASCASO PUYUELO FJ, CRISTOBAL JA—Zaragoza

T049 
**Treatment of refractory glaucoma using UC3 procedure with HIFU (High Intensity Focused Ultrasound). Prospective series**

ROULAND J, APTEL F—Lille, Grenoble

T050 
**Argon laser trabeculoplasty (ALT) for advanced glaucoma: A 12 months follow-up study**

PELOSI L, FAYEMI A, ANSARI E—Maidstone, Kent

T051 
**Neovascular glaucomas after central retinal artery occlusions**

DEGOMOIS A, MIOCQUE S, DENION E—Caen

T052 
**Imaging of the optic nerve (opt nerve and ganglion cells analysis) in monitoring the child’s congenital glaucoma**

BOUAKAZ S, RUPIN A, LABALETTE P, ROULAND JF—Lille

T053 
**Hemifield pattern electroretinogram, frequency doubling technology and optical coherence tomography for detection of early glaucomatous optic neuropathy in ocular hypertensive patients**

CELLINI M, FINZI A, STROBBE E, CAMPOS ES—Bologna

T054 
**Backwards compatibility of HRT3 and HRT II before and after cataract surgery and intracanal lens implantation**

FALCK A, SAARELA V—Oulu

T055 
**Structure function relationship: Specific index of ganglion cell complex assessment of 2 spectral domain OCT and standard automated perimetry**


T056 
**Ganglion cell complex measurement and glaucoma diagnosis using two SD-OCT**


T057 
**Correlation between retinal ganglion cell count and morpho-functional parameters in glaucoma**


T058 
**Progression of visual field in patients with primary open-angle glaucoma (2): Level of progression**


T059 
**Ocular Pulse Amplitude is associated with ocular blood flow velocities in healthy subjects and patients with primary open angle glaucoma, but not normal tension glaucoma**

PINTO L, VANDEWALLE E, STALMANS I—Lisbon, Leuven

T060 
**Motion perception in early glaucoma**

FRANCOZ A, CARLU A, CREUZOT C, POZZO T, BRON AM—Dijon

T061 
**Cognitive function associated with larger optic nerve heads**

JONAS J, XIU L, WANG YX, LI J—Mannheim, Beijing

T062 
**Spectral analysis of ocular pulse amplitude recordings obtained using a contact lens sensor**


T063 
**Validation of Testvision, an internet-based test for the detection of visual field loss**

OLSEN AS, LA COUR M, SERUP L, ALBERTI M, DAMATO B, KOLKO M—Copenhagen, San Francisco
T068 Primary health care model for detection of ophthalmological visual disturbances in a population of employees of Universidad de Tarapaca, Chile
CHAVEZ C, VETTERLEIN V, RAMIREZ JM, DE HOZ R–Arica, Madrid

T069 Distribution of ocular biometric parameters during the eye growth
YEKTA A, HASHEMI H, OSTADIMOGHADDAM H, JAFARZADEHPOUR E, KHAZAKHOOB M, REZVAN F–Mahhad, Tehran

T070 Eye problems in deaf children: A case-control study
OSTADIMOGHADDAM H, MIRHAIJAN H, SOBHANI D, YEKTA A, HERAVIAN J, KHAZAKHOOB M–Mahhad, Tehran

T071 Profiling miRNAs in a hyperglycemic and hypoinsulinemic Ins2Akita mouse model

T072 Visual function changes in an animal model of retinitis pigmentosa
SEGURA CALVO F, LOPEZ DE LA FUENTE C, SANCHEZ-CANO A, FUENTES-BROTO L, PEREZ GARCIA D, PINILLA I–Zaragoza

T073 Influence of refractive error and axial length on retinal vessel geometric characteristics
LIM LS, CHEUNG C, LIM X, MITCHELL P, WONG TY, SAW SM–Singapore, Sydney

T074 Early dietary therapy in preventing progression of retinopathy in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency caused by the homozygous G1528C mutation
ROOMETS E, KIVELÄ T, TYNI T–Tallinn, Helsinki

T075 A cone-rod dystrophy patient with a homozygous RP1L1 mutation
KAMEYA S, KIKUCHI S, GOCHO K, KABUTO T, SUGAWARA Y, YAMAKI K, TAKAHASHI H–Inzai, Chiba, Yurihonjo, Akita, Sendagi, Tokyo

T076 Hunter Syndrome after 12 months of enzyme replacement treatment: A case report
HERRERA L, CRUZ N, CARAMELLO C, ZABADANI K, PINILLA I, ASCASO FJ, CRISTOBAL JA–Zaragoza

T077 Interleukin-8 promoter polymorphism is associated with the initial response to bevacizumab in AMD treatment

T078 Clinical findings in a Roma family with autosomal dominant cone-rod dystrophy
KOEV K, CHERNINKOVA S, KAMENAROVA K, GEORGIEV R, KANEVA R–Sofia

T079 Examination of colour vision deficiency in different types of retinitis pigmentosa
KOEV K, GEORGIEV R, CHERNINKOVA S–Sofia

T080 Retigabine-induced retinal dystrophy: First reported case

T081 Alu retrotransposon quantification in the retina and plasma: Mechanism-based risk assessment in age-related macular degeneration
FOWLER B, KERUR N, GELFAND B, BASTOS-CARVALHO A, AMBATTI J–Lexington

T082 Angiopoietin-like protein 2 contributes to pathogenesis of diabetic retinopathy
ITO Y, DIKE Y, TANIHARA H–Kumamoto

T083 Photoreceptor integrity and visual acuity in retinitis pigmentosa
EL MATRI L, CHEBIL A, LARGUECHE L, CHAKER N, CHARFI H–Tunis

T084 DNA methytransferases are differentially expressed in human eyes
BONNIN N, BLANCHON V, BELVILLE C, CHIAMBARETTA F, SAPIN V–Clermont Ferrand

T085 Analysis of mitochondrial sequences in patients with keratoconus

T086 Genotype-phenotype correlation in two patients with posterior polymorphous corneal dystrophy 3

T087 Association between endothelin receptor type A gene polymorphisms EDNRA (C+70G, C+1222T) and the endothelin-1 plasma concentration in patients with normal tension glaucoma
WROBEL-DUDZINSKA D, KOSIOR-JARECKA E, LUKASIK U, KOCKI J, ZARNOWSKI T–Lublin

T088 Intraocular foreign bodies on the Island of Sealand, a preventable serious eye disease
MELSOM H, LA COUR M–Glostrup, Copenhagen

T089 Choroidal thickness in retinitis pigmentosa using EDI OCT
AKNIN I, MELKI L–Golfe Juan, Cannes
### SIS Controversies in the pathogenesis and treatment of retinal vein occlusion

**Athena**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2711</td>
<td>Controversies in the pathogenesis of RVO – Local perspective</td>
<td>ASCASO F–Zaragoza</td>
</tr>
<tr>
<td>16:45</td>
<td>2712</td>
<td>Controversies in the pathogenesis of RVO – Systemic perspective</td>
<td>GRZYBOWSKI A–Poznan</td>
</tr>
<tr>
<td>17:00</td>
<td>2713</td>
<td>Anti-VEGF agents in the treatment of RVO</td>
<td>REHAK MATUS–Leipzig</td>
</tr>
<tr>
<td>17:15</td>
<td>2714</td>
<td>Intravitreal steroids to treat the RVO-associated macular edema</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>17:30</td>
<td>2715</td>
<td>The role of autologous plasmin enzyme in the therapy of macular edema secondary to RVO</td>
<td>UDAONDO P</td>
</tr>
<tr>
<td>17:45</td>
<td>2716</td>
<td>Controversies in the surgical treatment of RVO - Associated macular edema</td>
<td>GARCIA - ARUMI J, VELAZQUEZ VILLORIA D–Barcelona</td>
</tr>
</tbody>
</table>

### FP Free papers G 1/4: IOP measurements / Epidemiology

**Hermes**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2721</td>
<td>24 hour continuous ocular tonography Triggerfish and biorhythms of the cardiovascular system functional parameters in healthy and glaucoma populations</td>
<td>WASILEWICZ R, WASILEWICZ P, CZAPLICKA E, KOCIECKI J, BLASZCZYNSKI J, MAZUREK C, SLOWINSKI R–Poznan</td>
</tr>
<tr>
<td>16:42</td>
<td>2722</td>
<td>The therapeutic impact of office-hours diurnal pressure measurements in the management of glaucoma patients</td>
<td>LAMPE M, POURJAVAN S–Brussels</td>
</tr>
<tr>
<td>16:54</td>
<td>2723</td>
<td>Pseudoexfoliation: normative data and associations. The Central India Eye and Medical Study</td>
<td>JONAS J, NANGIA N–Mannheim, Nagpur</td>
</tr>
<tr>
<td>17:18</td>
<td>2725</td>
<td>Dependence of the origin of pain in the eyes with terminal stage of glaucoma from chemical composition of vitreous</td>
<td>ERMOLAEV A, RENDEL E, KASCHEEVA N–Moscow</td>
</tr>
<tr>
<td>17:30</td>
<td>2726</td>
<td>Cognitive function associated with larger optic nerve heads</td>
<td>JONAS J, XI L, WANG YY, LI JI–Mannheim, Beijing</td>
</tr>
</tbody>
</table>
### SECOND AFTERNOON SESSION

**THURSDAY 16:30 - 18:00**

#### SIS COS

**The quality of vision: the new frontier of modern ophthalmology**

Jean-Jacques GICQUEL, Pierre Jean PISELLA  
Rhodes 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2731</td>
<td>Why is a precise assessment of the quality of vision essential in dry eye patients?</td>
<td>PISELLA P–Tours</td>
</tr>
<tr>
<td>16:48</td>
<td>2732</td>
<td>3D or not 3D: The binocular tolerance to higher order aberrations</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>17:06</td>
<td>2733</td>
<td>Should our decision to practice cataract surgery be only based on visual acuity?</td>
<td>VAN DEN BERG TJTP–Amsterdam</td>
</tr>
<tr>
<td>17:24</td>
<td>2734</td>
<td>Spherical aberration: Friend or foe?</td>
<td>VANDERMEER G, NOCHEZ Y, PISELLA PJ–Tours</td>
</tr>
<tr>
<td>17:42</td>
<td>2735</td>
<td>The effectiveness of wavefront-guided refractive laser treatment</td>
<td>SULEMAN H, FARES U, AL-AQABA MA, OTRI AM, SAID DG, DUA HS–Nottingham</td>
</tr>
</tbody>
</table>

---

#### Course 11 Practical ophthalmic pathology - basics, updates and new insights

Rhodes 2

**PO**  
Sarah COUPLAND, Steffen HEEGAARD  
Intermediate

This aim of this course is to provide a basic overview of ophthalmic pathology, its continuing role in modern ophthalmology, and to provide practical guidelines for the evaluation of ocular specimens of varying types (e.g. diagnostic vitrectomies, conjunctival-, orbital- and chorio-retinal biopsies, enucleated eyes as well as exenteration specimens).

Furthermore, the course will cover newer technologies and methodologies in molecular diagnostics, and how these can be incorporated into the diagnostic panel in ophthalmic pathology.

This course will be based on routine examples and will be given by experienced clinicians/pathologists from a practical rather than theoretical point of view. It is aimed at ophthalmologists with an interest in pathology, as well as at pathologists and basic researchers specialising in ocular pathology.

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2741</td>
<td>Tips and tricks in grossing &amp; processing specimens</td>
<td>COUPLAND S–Liverpool</td>
</tr>
<tr>
<td>16:45</td>
<td>2742</td>
<td>Overview of conjunctival and eyelid tumours</td>
<td>VAN GINDERDEUREN R–Leuven</td>
</tr>
<tr>
<td>17:00</td>
<td>2743</td>
<td>Anterior to posterior “tour” of ocular disease processes</td>
<td>VAN GINDERDEUREN R–Leuven</td>
</tr>
<tr>
<td>17:15</td>
<td>2744</td>
<td>Overview of adult and paediatric orbital pathology</td>
<td>HEEGAARD S–Copenhagen</td>
</tr>
<tr>
<td>17:30</td>
<td>2745</td>
<td>Molecular techniques in ocular pathology</td>
<td>COUPLAND S–Liverpool</td>
</tr>
<tr>
<td>17:45</td>
<td>2746</td>
<td>Comparative ocular pathology and animal models used in eye research</td>
<td>HEEGAARD S–Copenhagen</td>
</tr>
</tbody>
</table>
## THURSDAY

### SECOND AFTERNOON SESSION

#### SIS NSPH

**Neuro-ophthalmic complications in the patient with cancer**

**Rhodes 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2751</td>
<td>Neuro-ophthalmic complications of cancer chemotherapy</td>
<td>KAWASAKI A—Lausanne</td>
</tr>
<tr>
<td>16:48</td>
<td>2752</td>
<td>Paraneoplastic syndromes</td>
<td>SZATMARY G, POLGAR TATJA—Hattiesburg</td>
</tr>
<tr>
<td>17:06</td>
<td>2753</td>
<td>Meningeal carcinomatosis</td>
<td>SZATMARY G—Hattiesburg</td>
</tr>
<tr>
<td>17:24</td>
<td>2754</td>
<td>Anterior pathway meningiomas</td>
<td>KAWASAKI A, BOSCHI A—Lausanne, Brussels</td>
</tr>
<tr>
<td>17:42</td>
<td>2755</td>
<td>Radiation optic neuropathy</td>
<td>BORRUAT F—Lausanne</td>
</tr>
</tbody>
</table>

#### FP MBGE

**Free papers MBGE 1/2: Genetics; Genotypes and Phenotypes**

**Rhodes 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2761</td>
<td>The eye screen of the German Mouse Clinic (GMC) – New genetic insights into eye development and ocular disorders</td>
<td>PUK O, FUCHS H, GAILUS-DURNER V, HRABE DE ANGELIS M, GRAW J—Neuherberg</td>
</tr>
<tr>
<td>16:42</td>
<td>2762</td>
<td>High resolution retinal image analysis of unilateral retinitis pigmentosa using adaptive optics</td>
<td>GOCHO K, KIKUCHI S, KABUTO T, AKED K, KAMEYA S, YAMAKI K, TAKAHASHI H—Inzai, Tokyo</td>
</tr>
<tr>
<td>16:54</td>
<td>2763</td>
<td>Pilot study in Polish keratoconus patients using next generation sequencing</td>
<td>GAJECKA M, KAROLAK JA, NOWAK DM, POLAKOWSKI P, SZAFLIK J—Poznan, Warsaw</td>
</tr>
<tr>
<td>17:06</td>
<td>2764</td>
<td>Role of O-GlcNAcylation of Sp1 in the pathogenesis of diabetic retinopathy</td>
<td>DONOVAN K, ALEKSEEV O, AZIZKHAN-CLIFFORD J—Philadelphia</td>
</tr>
<tr>
<td>17:18</td>
<td>2765</td>
<td>Global microarray analysis and metabolic pathway profiling of a transgenic model of conditional, selective Müller cell ablation</td>
<td>CHUNG SH, SHEN W, YANG J, JAYAWARDANA K, GILLIES MC—Sydney</td>
</tr>
<tr>
<td>17:30</td>
<td>2766</td>
<td>Genotype-phenotype correlation in two patients with posterior polymorphous corneal dystrophy 3</td>
<td>LISKOVA P, PALOS M, HARDCASTLE A, VINCENT A—Prague, London, Auckland</td>
</tr>
</tbody>
</table>

#### SIS ACB

**Mechanisms of wound healing**

**Gallieni 1 & 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>2771</td>
<td>Wound healing in health and disease</td>
<td>UUSTALO H—Tampere</td>
</tr>
<tr>
<td>16:52</td>
<td>2772</td>
<td>The role of wound healing in cornea</td>
<td>BEUERMAN R—Singapore</td>
</tr>
<tr>
<td>17:14</td>
<td>2773</td>
<td>The mouse model of glaucoma filtration surgery; from understanding the wound healing response to applications as a tool for validating anti-fibrotics</td>
<td>LI-FONG LF, WONG TT—Singapore</td>
</tr>
<tr>
<td>17:36</td>
<td>2774</td>
<td>Cell biological mechanisms of wound healing</td>
<td>JARVINEN T—Tampere</td>
</tr>
</tbody>
</table>
## INDUSTRY-SPONSORED SYMPOSIUM

**Rhodes 2**

### Ocular surface and corneal damages: new outcomes

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>2841</td>
<td>Dry eye associated with ocular surface damages</td>
<td>SCHMETTERER L–Vienna</td>
</tr>
<tr>
<td>18:30</td>
<td>2842</td>
<td>Confusing corneal ulcerations: Management of neurotrophic ulcers</td>
<td>MURALINE M–Rouen</td>
</tr>
<tr>
<td>19:00</td>
<td>2843</td>
<td>New therapy for persistent epithelial defects - report of the first cases</td>
<td>UDZIELA M–Warsaw</td>
</tr>
</tbody>
</table>

Moderators: Leopold SCHMETTERER, Marc MURALINE

---

**EVER 2013 Programme book**

EVENING SESSION

18:00 - 19:30

THURSDAY
**08:30 - 10:00 FIRST MORNING SESSION**

**SIS RV**
**Recent advances in OCT exploration of choroid in normal and diseases**

**Athena**

**RV**

**Gabriel COSCAS, Constantin POURNARAS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>3211</td>
<td>Choroidal thickness measurements and variations with age, gender in normal, myopia and high myopia</td>
<td>COSCAS G–Creteil</td>
</tr>
<tr>
<td>08:45</td>
<td>3212</td>
<td>Choroidal circulation measurements by laser Doppler flux metry</td>
<td>POURNARAS CJ–Geneve</td>
</tr>
<tr>
<td>09:00</td>
<td>3213</td>
<td>Changes in choroidal thickness in adult onset foveomacular vitelliform dystrophy versus exudative AMD</td>
<td>COSCAS F, PUCHE N, SOUIED E, COSCAS G–Creteil</td>
</tr>
<tr>
<td>09:15</td>
<td>3214</td>
<td>Evaluation of posterior limits of choroid</td>
<td>UZZAN J–Rouen</td>
</tr>
<tr>
<td>09:30</td>
<td>3215</td>
<td>Comparison of choroidal thickness between central serous choroidopathy and polypoidal choroidal vasculopathy</td>
<td>PUCHE N, COSCAS F–Paris</td>
</tr>
<tr>
<td>09:45</td>
<td>3216</td>
<td>Variations of choroidal thickness in exudative AMD before and after treatment</td>
<td>MAUGET-FAYSSE M, COSCAS G–Paris</td>
</tr>
</tbody>
</table>

**SIS G**
**Intelligent follow-up for glaucoma**

**Hermes**

**G**

**David F GARWAY-HEATH, Balwantray CHAUHAN**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>3221</td>
<td>Using 'big data' to examine visual field follow up in glaucoma</td>
<td>CRABB D–London</td>
</tr>
<tr>
<td>08:48</td>
<td>3222</td>
<td>Visual field testing in clinical practice - The role of age, stage and follow-up duration</td>
<td>JANSONIUS NM–Groningen</td>
</tr>
<tr>
<td>09:06</td>
<td>3223</td>
<td>Is there any place for non-standard automated perimetry in glaucoma monitoring?</td>
<td>CHAUHAN B–Halifax</td>
</tr>
<tr>
<td>09:24</td>
<td>3224</td>
<td>How imaging can be used for clinical decision-making?</td>
<td>GARWAY-HEATH D–London</td>
</tr>
<tr>
<td>09:42</td>
<td>3225</td>
<td>Clinically sensible follow-up for glaucoma</td>
<td>LEMI H–Rotterdam</td>
</tr>
</tbody>
</table>

**FP COS**
**Free papers COS 2/5: Eye banking and corneal bioengineering**

**Rhodes 1**

**COS**

**Gilles THURET, Christopher LIU**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
</table>
### FIRST MORNING SESSION 08:30 - 10:00

#### Rhodes 2

- **Friday**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
</table>
| 08:30 | 3241    | Congenital hypertrophy of the retinal pigment epithelium (RPE)  
ZOGRAFOS L–Lausanne |
| 08:42 | 3242    | Isolated and combined hamartomas of the RPE  
SCHALENBOURG A–Lausanne |
| 08:54 | 3243    | Congenital hypertrophy of the RPE related to familial adenomatous polyposis  
DESJARDINS L–Paris |
| 09:06 | 3244    | Irido-ciliary tumours of the pigmented and non-pigmented ciliary epithelium  
DAMATO B–Liverpool |
| 09:18 | 3245    | Controversies in the surgical treatment of combined hamartomas of the retina and retinal pigment epithelium  
GARCIA-ARUMI J, VELAZQUEZ VILLORIA D–Barcelona |
| 09:30 | 3246    | Debate: Challenging cases of retinal pigment epithelium lesions: How to diagnose? How to manage?  
GARCIA-ARUMI J, DAMATO B, DESJARDINS L, SCHALENBOURG A, ZOGRAFOS L–Barcelona |

#### Rhodes 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
</table>
| 08:30 | 3251    | The role of in vitro studies in eye research  
UUSITALO H–Tampere |
| 08:50 | 3252    | How to study heterophagy in RPE cells  
SINHA D–Baltimore |
| 09:10 | 3253    | Techniques to demonstrate immunoproteasome in retinal functions  
FERRINGTON D–Minneapolis |
| 09:30 | 3254    | Techniques for studying mechanisms of autophagy in RPE cells  
KAARNIRANTA K–Kuopio |

### Course 12 Cell biological techniques for eye research

- **Rhodes 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
</table>
| 08:30 | 3271    | Conjunctival provocation test in ophthalmology daily practice  
FAUQUERT J–Clermont-Ferrand |
| 09:00 | 3272    | Allergy and vernal keratoconjunctivitis: Results of a 251 children cohort  
CHIAMBARETTA F–Clermont Ferrand |
| 09:30 | 3273    | What’s new in atopic keratoconjunctivitis  
BREMOND-GIGNAC D–Amiens |

---

**EVER 2013 Programme book**
10:10 - 10:55
FRIDAY

10:10  Introduction by Aki Kawasaki

10:20  3321  Why is the optic nerve the canary in the coal mine of mitochondrial diseases?
        SADUN A–Los Angeles

10:50  Award of the EVER certificate of honour
## SECOND MORNING SESSION

**11:00 - 12:30**

**FRIDAY**

### SIS Retinal vein occlusions: new concepts for clinical management  
**Athena**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>3411</td>
<td>RVO: A complex disease</td>
<td>PAQUES M–Paris</td>
</tr>
<tr>
<td>11:18</td>
<td>3412</td>
<td>Is there a need for a general workup of RVO patients?</td>
<td>HERON E–Paris</td>
</tr>
<tr>
<td>11:36</td>
<td>3413</td>
<td>The issue of chronic macular edema</td>
<td>GIRMENS JF–Paris</td>
</tr>
<tr>
<td>11:54</td>
<td>3414</td>
<td>Toward a new classification of RVOs?</td>
<td>PAQUES M–Paris</td>
</tr>
<tr>
<td>12:12</td>
<td>3415</td>
<td>Discussion of clinical cases in real-life practice</td>
<td>MAUGET-FAYSSE M–Paris</td>
</tr>
</tbody>
</table>

### SIS Patient Perceptions in Glaucoma - what the doctor (thinks he) knows, and what the patient can tell us  
**Hermes**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>3421</td>
<td>What research tells us about the impact of glaucoma on the patient</td>
<td>RAMULU P–Baltimore</td>
</tr>
<tr>
<td>11:22</td>
<td>3422</td>
<td>Methods used to measure patient perceptions</td>
<td>RUBIN GS–London</td>
</tr>
<tr>
<td>11:44</td>
<td>3423</td>
<td>The art of healthcare: the importance and impact of effective Patient and Public Involvement (PPI)</td>
<td>PORTEOUS C–London</td>
</tr>
<tr>
<td>12:06</td>
<td>3424</td>
<td>What glaucoma means to me: The patient’s perspective</td>
<td>KOTECHA A–London</td>
</tr>
</tbody>
</table>

### FP Free papers COS 3/5: Keratoconus and corneal diseases  
**Rhodes 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>3431</td>
<td>Fitting tips and tricks of challenging cases of keratoconus</td>
<td>ABOU SAMRA W–Mansoura</td>
</tr>
<tr>
<td>11:12</td>
<td>3432</td>
<td>Current phenotype of keratoconus patients at King Khaled Eye Specialist Hospital</td>
<td>AL-SWAILEM S, YIU S, AL ASSIRI A, ASGHAR N, AL QASSIMI A–Riyadh, Baltimore</td>
</tr>
<tr>
<td>11:24</td>
<td>3433</td>
<td>Corneal refractive power after anterior lamellar versus penetrating keratoplasty</td>
<td>BORDERIE VM, SANDALI O, GEORGEON C, BORDERIE M, TOUZEAU O, BOUHERAOUA N, LAROCHE L–Paris</td>
</tr>
<tr>
<td>11:48</td>
<td>3435</td>
<td>Very low risk of light-induced retinal damage during Boston Keratoprosthesis surgery</td>
<td>SALVADOR CULLA B, BEHLAU I, SAYEGH RR, STACY RC, DOHLMAN CH, DELORI F–Boston</td>
</tr>
<tr>
<td>12:00</td>
<td>3436</td>
<td>Influence of growth factors on keratocyte phenotype in serum free media</td>
<td>LYNCH A, O’SULLIVAN F, AHEARNE M–Dublin</td>
</tr>
</tbody>
</table>
Course 13
Don’t panic: Hitchhiker’s guide to statistics
PO
Tero KIVELÄ, Bertil DAMATO

This course will widen your comfort zone in statistics. It highlights pearls not to be missed and pitfalls to be circumvented in using and interpreting the most common statistical methods and tests. Good science and evidence-based practice depends on accurate communication of research results and their correct interpretation by the readership. Because some authors do not seek statistical advice when planning and analysing their study and most journals do not submit their manuscripts to statistical review, the scientific reviewer is often responsible for spotting at least elementary deviations from good statistical practice. For many, this means stepping out of their comfort zone. The experience of the instructors as senior writers, reviewers and editorial board members is used to guide the participants into being more agile in the exciting field of statistical analysis whether they produce or peruse research. The items discussed are based on live examples from recent published literature.

11:00 3441 Introduction to study design
   DAMATO B–Gayton - Wirral
11:20 3442 Matching analysis with your study design
   KIVELÄ T–Helsinki
11:40 3443 Communicating your research and presenting your data
   DAMATO B–Liverpool
12:00 3444 Pearls and pitfalls
   KIVELÄ T–Helsinki
12:20 Discussion

FP Free papers IM 2/2: Hot topics in ocular immuno-infectiology
IM
Francois WILLERMAIN, Heping XU

11:00 3451 Retinal pigment epithelial (RPE) cells convert bone marrow derived macrophages into myeloid suppressor cells with novel phenotype
   XU H, ZHAO J, LUO C, CHEN M–Belfast
11:12 3452 Ocular Syphilis: Beware of the great imitator!
   VELDMAN E, MEENKEN C, HALABY T, KOOTSTRA G–Enschede, Amsterdam
11:24 3453 Intraocular rubella virus detection as a diagnostic tool for atypical forms of Fuchs cyclitis
11:36 3454 Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis: A retrospective monocentric study
   PENAUD B–Paris
11:48 3455 Tocilizumab for uveitic macular edema
   MESQUIDA M, LLORENÇ V, ADAN A–Barcelona
12:00 3456 3 months results of intravitreal dexamethasone implant in non infectious uveitis
   DARUGAR A, CHAMPION E, TOUTOU V, FARDEAU C, LE HOANG P, BODAGHI B–Paris
<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>3461</td>
<td>Three-dimensional analysis of HSV colour space to distinguish small retinal haemorrhages, hard exudates and photocoagulation marks from dust artefacts. SUZUKI N, YAMANE K–Higashi-Hiroshima, Hiroshima</td>
</tr>
<tr>
<td>12:00</td>
<td>3466</td>
<td>Autofluorescence patterns and visual acuity in macular telangiectasia type 2. BALASKAS K, LEUNG I, SALLO FB, CLEMSON TE, BIRD AC, FETO T–London, Rockville, Maryland</td>
</tr>
<tr>
<td>12:12</td>
<td>3468</td>
<td>The effect of posterior subtenon injection of triamcinolone acetonide for diabetic macular edema refractory to intravitreal bevacizumab injection. SOO GEUN JOE, MOON HAEIN, CHAE JB–Seoul, Cheongju</td>
</tr>
</tbody>
</table>

**Course 14 Visual fields: back to basics**

**NSPH** Aki KAWASAKI, François-Xavier BORRUAT

This course focuses on basic understanding and interpretation of visual fields. Basic anatomy and relevance to visual field patterns are reviewed. Principles and usage of automated and kinetic perimetry are discussed. Case illustrations and unknowns are presented to facilitate open interaction.

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>3471</td>
<td>Anatomy of afferent visual pathway. KAWASAKI A–Lausanne</td>
</tr>
<tr>
<td>11:22</td>
<td>3472</td>
<td>Principles of automated perimetry. SZATMARY G–Hattiesburg</td>
</tr>
<tr>
<td>11:44</td>
<td>3473</td>
<td>How to perform confrontational visual fields, tangent screen and manual kinetic perimetry. KAWASAKI A, BORRUAT FX–Lausanne</td>
</tr>
<tr>
<td>12:06</td>
<td>3474</td>
<td>Cases and visual field examples and discussion. KAWASAKI A, BORRUAT FX, SZATMARY G–Lausanne, Hattiesburg</td>
</tr>
</tbody>
</table>
12:35 - 13:35   LUNCHTIME SESSION

**INDUSTRY-SPONSORED SYMPOSIUM**

**Hermes**

**CROMA**

**Enhanced Oxidative Stress and ocular surface**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35</td>
<td>3521</td>
<td>Reduction of oxidative stress: Importance for age-related diseases</td>
<td>GARHOFER G–Vienna</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>3522</td>
<td>Clinical results on the anti-oxidative effect of oral vitamin and mineral supplementation (on impaired retinal vascular reactivity)</td>
<td>GARHOFER G–Vienna</td>
<td></td>
</tr>
<tr>
<td>13:10</td>
<td></td>
<td>New therapy options for dry eye. First cases and perspectives - TBD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### FIRST AFTERNOON SESSION

**SIS Fluid accumulation in the retina**  
Athena  
**GV**  
Gisèle SOUBRANE, Anat LOEWENSTEIN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3611</td>
<td>Mechanism of fluid accumulation</td>
<td>WOLFENSBERGER TJ–Lausanne</td>
</tr>
<tr>
<td>13:58</td>
<td>3612</td>
<td>Fluid of choroidal origin</td>
<td>SOUBRANE G–Paris</td>
</tr>
<tr>
<td>14:16</td>
<td>3613</td>
<td>Fluid from the retinal origin</td>
<td>WOLF-SCHNURRBUSCH U</td>
</tr>
<tr>
<td>14:34</td>
<td>3614</td>
<td>Anti VEGF: When, which effect?</td>
<td>LOEWENSTEIN A, FLEISSIG E–Tel Aviv</td>
</tr>
<tr>
<td>14:52</td>
<td>3615</td>
<td>Steroids: How does it work?</td>
<td>BEHAR-COHEN F–Paris</td>
</tr>
</tbody>
</table>

### Retinal ganglion cell degeneration and dysfunction in glaucoma

**G**  
James Edwards MORGAN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3621</td>
<td>Retinal ganglion cell degeneration: events in the human retina</td>
<td>THANOS S–Munster</td>
</tr>
<tr>
<td>14:02</td>
<td>3622</td>
<td>Retinal ganglion cell degeneration and dysfunction in glaucoma</td>
<td>LEUNG C–Kowloon City</td>
</tr>
<tr>
<td>14:24</td>
<td>3623</td>
<td>Psychophysical effects of RGC damage: What tests could we use clinically?</td>
<td>REDMOND T–Cardiff</td>
</tr>
<tr>
<td>14:46</td>
<td>3624</td>
<td>RGC degenerations. A neural substrate for reversing glaucomatous damage?</td>
<td>MORGAN J–Cardiff</td>
</tr>
</tbody>
</table>

### Course 15 Corneal Dystrophies – from molecular basis to therapeutic approach

**COS**  
Edward WYLEGALA, Anna NOWINSKA

Corneal dystrophies are the group of hereditary disorders affecting all corneal layers. Since 2008 when IC3D classification was published there are new advances in diagnosis and treatment. During this course we would like to present the current methods of diagnosis including genetic testing and different treatment options.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3631</td>
<td>Introduction, Surgical treatment options for corneal dystrophies</td>
<td>WYLEGALA E–Katowice</td>
</tr>
<tr>
<td>13:55</td>
<td>3632</td>
<td>Genetics of the stromal corneal dystrophies</td>
<td>NOWINSKA A–Katowice</td>
</tr>
<tr>
<td>14:10</td>
<td>3633</td>
<td>Classification of corneal dystrophies (IC3D)</td>
<td>NIELSEN K–Aarhus C</td>
</tr>
<tr>
<td>14:25</td>
<td>3634</td>
<td>Imaging methods of the corneal dystrophies</td>
<td>JANISZEWSKA D–Katowice</td>
</tr>
<tr>
<td>14:40</td>
<td>3635</td>
<td>Genetics of the posterior corneal dystrophies</td>
<td>DOBROWOLSKI D–Katowice</td>
</tr>
<tr>
<td>14:55</td>
<td>3636</td>
<td>Meesmann dystrophy in Denmark</td>
<td>NIELSEN K–Aarhus C</td>
</tr>
</tbody>
</table>
### 13:40 - 15:10 FIRST AFTERNOON SESSION

#### FRIDAY

#### FP Free papers NSPH 1/2: Pediatric ophthalmology Rhodes 3

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:52</td>
<td>3652</td>
<td>Retinal ganglion cell impairment in Leber Optic Neuropathy carriers triggers cortical compensatory plasticity in extrastriate cortex</td>
<td>CASTELO-BRANCO M, MATEUS C, D’ALMEIDA O, REIS A, SILVA E–Coimbra</td>
</tr>
<tr>
<td>14:04</td>
<td>3653</td>
<td>incidence of Diabetic Macular Edema in type 1 Diabetes</td>
<td>LUJAIN I–Jeddah</td>
</tr>
<tr>
<td>14:16</td>
<td>3654</td>
<td>Telemedicine screening for diagnosis of retinopathy of prematurity in clinical practice</td>
<td>LUX AL, LASTENNET F, DENION E–Caen, Le Havre</td>
</tr>
<tr>
<td>14:28</td>
<td>3655</td>
<td>Refractive error after intravitreal bevazicumab for threshold disease in retinopathy of prematurity: Two-years follow-up</td>
<td>JONAS J, HARDER B, SCHLICHTEN BREDE F, VON BALTZ S–Mannheim</td>
</tr>
<tr>
<td>14:46</td>
<td>3658</td>
<td>Quality of life among children with severe and chronic ophthalmic conditions</td>
<td>AZIZ A, MATONTI F, FAKHOURY O, DENIS D–Marseille</td>
</tr>
</tbody>
</table>

#### SIS PO FNAB for the diagnosis and management of intraocular tumours Rhodes 2

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3641</td>
<td>Diagnosis FNAB for orbital and intraocular tumours from a cytologist point of view</td>
<td>KLIJANENKO J</td>
</tr>
<tr>
<td>13:58</td>
<td>3642</td>
<td>Long term result of transcleral FNAB for genetic analysis of uveal melanoma</td>
<td>MIDENEA E–Padova</td>
</tr>
<tr>
<td>14:16</td>
<td>3643</td>
<td>Curie experience with transvitreal and transcleral FNAB</td>
<td>CASSOUX N–Paris</td>
</tr>
<tr>
<td>14:34</td>
<td>3644</td>
<td>Incisional trans-scleral biopsy of choroidal melanoma</td>
<td>DAMATO B–Liverpool</td>
</tr>
<tr>
<td>14:52</td>
<td>3645</td>
<td>How to handle ophthalmic biopsy specimen to optimize the results</td>
<td>COUPLAND S–Liverpool</td>
</tr>
</tbody>
</table>
### FIRST AFTERNOON SESSION
13:40 - 15:10

**SIS LC**

**Functional indicators for cataract surgery**

Rafael I. BARRAQUER, Ralph MICHAEL

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3661</td>
<td>Experience with straylight in the cataract clinic</td>
<td>COCHENER B–Brest</td>
</tr>
<tr>
<td>13:58</td>
<td>3662</td>
<td>Objectivity and reliability of the C-Quant in a clinical setting</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>14:16</td>
<td>3663</td>
<td>Multiparameter cataract indication approach</td>
<td>REUS NJ–Rotterdam</td>
</tr>
<tr>
<td>14:34</td>
<td>3664</td>
<td>Inclusion effects if straylight is added to the indication for cataract surgery</td>
<td>VAN DEN BERG TTP–Amsterdam</td>
</tr>
</tbody>
</table>

**FP COS**

**Free papers COS 4/5: Infected and ocular inflammatory surface**

Philippe KESTELYN, Marc MURAIIE

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>3671</td>
<td>A unilateral chronic conjunctivitis as onset of a systemic sarcoidosis</td>
<td>TARIGHT N, SMAIL A, SEVESTRE H, MILAZZO S, BREMOND-GIGNAC D–Amiens</td>
</tr>
<tr>
<td>13:52</td>
<td>3672</td>
<td>Lithium increases p63 levels in cultured human limbal epithelial stem cells</td>
<td>MOE MC, JOHNSEN E, NESS CH, SHAHDADFA A, NICOLASSEN B, NOER A–Oslo</td>
</tr>
<tr>
<td>14:04</td>
<td>3673</td>
<td>Simple novel surgical device to facilitate preparation of endothelial grafts for DMEK</td>
<td>MURAIIE M, GUEUDRY J, TOUBEAU D, LEFEVRE S, AFFRIAT M–Rouen, Reims</td>
</tr>
<tr>
<td>14:16</td>
<td>3674</td>
<td>Allergic conjunctivitis related to cat and dog dander</td>
<td>ALMALIOTIS D, MICHALIPOULOS P, GIOULEKA P, GIOULEKAS D, NAKOS E, XANTHOPOULOU E, KARAMPATAKIS V–Thessaloniki</td>
</tr>
<tr>
<td>14:40</td>
<td>3676</td>
<td>Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging</td>
<td>WOJCIECH, WYLEZAL E, SMEDOWSKI A–Katowice</td>
</tr>
</tbody>
</table>
Physiology / Biochemistry / Pharmacology

Moderators:
Gerhard GARHOFER, Neville OSBORNE

F001 Inflammatory cytokines decrease viability and alter ganglioside profile in retinal pigment epithelium cells
MASSON EA, DOSSARPS D, BERDEAUX O, BRON A, CREUZOT C, BRETILLON L–Dijon

F002 Blue light toxic action spectrum on A2E-loaded RPE cells in sunlight normalized conditions

F003 Chicken peptidylarginine deiminase type I and III are constitutively expressed in the retinal neuron
SHIMIZU A, HONDA T, KOJIMA T, KOHSAKA T, TAKAHARA H–Tokyo, Ibaraki, Shizuoka

F004 Does cycloexdrin affect penetration of diclofenac sodium through amniotic membrane?
RESCH M, MARSOVSZKY L, BUDAISZUCS M, SOOS J, BERKO SZ, SIPOS P, NEMETH J, SZABO-REVESZ P, CSANYI E–Budapest; Szeged

F005 Assessment of polyesteramide of PEA Microparticles for in vivo intraocular injections

F006 A drug-induced central retinal vein occlusion
BAUDOT A, TRECHOT F, BATT A, ANGIOI K–Nancy

F007 Aquaporin expression in the human retinal pigmented epithelial cell line ARPE-19
SAUL D, MOTULSKY E, HERET I, DELPORTE C, WILMER F–Brussels

F008 Serum concentrations of infliximab in patients with Behçet’s disease
TAGUCHI C, INOUE R, YAMAKAWA R–Kurume

F009 Suppression of TRPV 1 channels activity is a possible way in treatment of ophthalmic diseases
MIRONOVA E, GRISHIN E, PCHELINTSEVA O, KOROLKOVA U–Moscow

F010 Effect of systemic hyperoxia on retinal oxygen saturation

F011 Reproducibility of retobular blood flow velocity measurements using two different colour Doppler imaging devices

F012 Angiogenic role of glycerol in laser-induced choroidal neovascularization

F013 IL18 does not reduce choroidal neovascularization and causes retinal dysfunction in mice

F014 Circulating blood glutathione levels influence retinal microvascular function in healthy individuals
SESHADRI S, QIN L, MROCZKOWSKA S, PATEL S, GHERGHEL D–Birmingham

F015 RESVEGA, by the presence of Resveratrol, inhibits retinal endothelial tube formation
OLMIERE C, CLERC A, LECONTE L–Clermont-Ferrand, Paris

F016 Correlation between SD-OCT, immunocytochemistry and functional findings in an animal model of retinal degeneration

F017 Fundus autofluorescence, OCT thickness evaluation, angiography and immunohistochemistry correlation in albin P23H rats

F018 Ocular and systemic distribution of MRZ-99030 in pigmented mouse, rat, rabbit and non-human primate by quantitative tissue analysis
STRUBLE C, PRESCOTT E, KLEIN K, WEGENER N–Madison, Wisconsin, Frankfurt

F019 Proteomic analysis of the retina in mice deficient in glial fibrillary acid protein and vimentin
MANDAL N, HONORE B, VORUM H, PEREZ MT–Lund, Aarhus, Aalborg
RETINA / VITREOUS

Moderators:
Constantin POURNARAS, Anita LEYS,
Tina XIROU

F020 The frequency of idiopathic retinal detachment has seasonal variation and correlated with climate – A survey in Japan
TAKETANI Y, INAMOCHI K, MAYAMA C,ASAOKA R, MURATA H, NOMOTO Y–Asahi, Chiba, Tokyo

F021 Outcomes of vitrectomy for vitreous haemorrhage (VH) in patients with presumed choroidal neovascularization (CNV)
KOH I, LAUDE A–Singapore

F022 Simultaneous SD-OCT and fundus autofluorescence imaging of the macula after successful repair of rhegmatogenous retinal detachment
CHAKER N, MGHAIETH F, BOURAOUI R, GHRIBI H, EL MATRI L–Tunis

F023 Cytologic analysis in vitreo-retinal surgery
BENISTY D, HAYATE F, BOULAGNON C, DUCASSE A, ARNDT C–Reims

F024 Long-term results and prognostic factors for visual acuity after diabetic vitrectomy: A 10-year follow-up study
OSTRI C–Copenhagen

F025 Idiopathic macular hole closure toward the optic disc after internal limiting membrane peeling
OHTA K, SATO A, FUKUI E–Shiojiri

F026 Intravitreal drug dispersion and needle gauge
PEREZ-MARTIN S, MONTERO J, MERINO A–Valladolid

F027 Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction without macular hole from the MIVI-TRUST clinical program
KOSHY Z, LABOURDETTE A, DUCHATEAU L, LESCRAUWAET B–Ayr, Toulouse, Ghent, Leuven

F028 Late results of sclera reconstructive surgery aimed at preventing the progression of myopic macular dystrophies
MARKOSSIAN G, TARUTTA E, IOMDINA E, KRUZHKOVA G–Moscow

F029 Live retinal image mosaicking during fundus examination with a computer-assisted slit-lamp prototype

F030 Phacoemulcification with intravitreal bevacizumab injection in patients with cataract and diabetic clinically significant macular edema
CHEBIL A, CHAKER N, KORT F, JEDIDI L, LARGUECHE L, EL MATRI L–Tunis

F031 Evaluation of choroidal thickness depending on the stage of diabetic retinopathy by SD-OCT
CHAKER N, MGHAIETH F, DALLELI F, CHEBIL A, BOURAOUI R, MRABET A, EL MATRI L–Tunis

F032 Association of OCT parameters with HbA1c level and diabetes duration in early stage of diabetic retinopathy
OSHITARI T, NOMOMURA S, ARAI M, YAMAMOTO S–Chiba

F033 Purscher-like retinopathy associated with acute pancreatitis at Vilnius University Hospital Santariskiu Klinikos
PAULAVICIENE R, STRELKAUSKAITE E, ASOKLIS R, STRUPAITE R–Vilnius

F034 Branch retinal vein occlusion and vitreovascular traction: An SD-OCT case-control study
ASCASO FJ, PADGET E, VILLEN L, HUERVA V, ZABADANI K, DEL BUEY MA, CRISTOBAL JA–Zaragoza, Lleida

F035 Intravitreal ranibizumab following bevacizumab for macular edema due to retinal vein occlusion
DUREUX P, LABALETTE P–Lille

F036 Spectral-domain optical coherence tomography (SD-OCT) patterns in macular edema associated with retinal vein occlusion
CHEOUR M, BROUR J, HACHICA E, LAJMI H, MEHANAOUI D, SAFRA I, MAZLOUT H, KRAIEM A–Montpellier

F037 Hypertensive retinopathy complicated with bilateral retinal neovascularization: PRP versus intravitreal anti-VEGF treatment
XIROU T, BATSOS G, GEORGIAIDIS O, XIROU V, FERETIS E, KABANAROU SA–Athens

F038 Intravitreal aflibercept (IVT-AFL) for macular edema secondary to CRVO: Results of COPERNICUS and GALILEO studies
CREUZOT C–Dijon

F039 Wide field imaging in Coats’ disease
ARNDT C, BENISTY D, MASSE S, VARDI K, DUCASSE A, ZAMBROWSKI O–Reims

F040 Optic disc changes in retinal vein occlusion and correlated factors
SOF GEUN JOE, SUNG KR, LEE KS, LEE JR, CHAE JB–Seoul

F041 Autofluorescence patterns and visual acuity in macular telangiectasia type 2
BALASKAS K, LEUNG I, SALLO FB, CLEMONS TE, BIRD AC, PETO T–London, Rockville, Maryland

F042 Response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory ranibizumab
OGATA N, HASEGAWA T, YAMASHITA M, OKAMOTO M–Kashiwara, Nara

F043 AMD Drusenoid deposits characterization: Interest of OCT, OCT en FACE
GONZALEZ C–Toulouse

F044 Neovascular AMD with high recurrences and atrophic areas - Potential relationship between neovascular complication and atrophy
GONZALEZ C–Toulouse

F045 Clinical manifestation of retinal pigment epithelial tear after age-related macular degeneration treatment
CHAE JB, JOE SG–Cheongju, Seoul

F046 Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD)
CALCAGNI A, STYLES IB, PALMER AD, SHEN Y, BARTLETT H, EPERJESI F, GIBSON JM, CLARIDGE E–Birmingham

F047 Choroidal thickness in dry age-related macular degeneration
ZABADANI K, ASCASO FJ, HERRERA L, PADGET E, NURÉZ E, CRISTOBAL JA–Zaragoza

F048 Retinal tubulations in geographic atrophy associated with age-related macular degeneration
RUZ MORENO JM, LUGO FL, RUIZ-MEDRANO J, MONTERO JA, DONATE J–Albacete, Alicante, Madrid, Valladolid
**F049** Intercellular trafficking of Alu RNAs causes geographic atrophy expansion in AMD

BASTOS CARVALHO A, KERUR N, KIM Y, FOWLER B, GELFAND B, AMBATI J–Lexington, KY

**F050** New diagnostic and therapeutic strategies in acute and chronic central serous chorioretinopathy


**F051** Central serous chorioretinopathy in pregnancy: A report of two cases

CARAMELLO C, HERRERA L, CRUZ N, ZABADANI K, PINILLA I, ASCASO J, CRISTOBAL JA–Zaragoza

**F052** Leopard-spot pattern of yellow-orange subretinal deposits in central serous chorioretinopathy

DE ZAEYTJUJD I, SCHELFHOUT V, LEROY BP–Ghent, Wetteren

**F053** Effect of intravitreal bevacizumab for chronic, recurrent, or atypical central serous chorioretinopathy

SONG JH, CHUNG YR, KIM MH, LEW HM–Suwon

**F054** Choroidal thickness in eyes with idiopathic epiretinal membrane

ZABADANI K, ASCASO FJ, PADGETT E, HERRERA L, MATEO J, CRISTOBAL JA–Zaragoza

**F055** Topographic distribution of vascular and neurodegenerative signs in type 2 idiopathic macular telangiectasia

SALLO F, LEUNG I, BALASKAS K, PAULEIKHOFF D, BIRD AC, PETO T–London, Muenster

**F056** Choroidal thickness changes determined by SS OCT following intravitreal bevacizumab

RUIZ MORENO JM, MONTERO JA, RUIZ-MEDRANO J, FLORES-MORENO I, LUGO F–Albacete, Valladolid, Madrid, Alicante

**F057** Evaluation of ultra-widefield fundus autofluorescence in non-infectious posterior uveitis

KERN T, REZNICEK L, THURAU S, KAMPIK A–Munich

**F058** Swept source optical coherence tomographic findings in a case of bilateral macular coloboma

CHENG C, CHAN JH, CHEUNG G–Singapore

**F059** Retinal arteriolar diameter response to flicker light provocation - A useful marker for risk stratification in cardiovascular disease?

HEITMAR R, BLANN A, SUMMERS AJ–Birmingham

**F060** Variation of online Amsler grid from mobile apps, YouTube and Google

LUK S, CHEN K, DAVIES N–London

**F061** HMGB1 is a potent inducer of choroidal angiogenesis through a MyD88-dependent manner

KIM Y, KERUR N, LI S, AMBATI J–Lexington

**F062** Refractive error after intravitreal bevacizumab for threshold disease in retinopathy of prematurity: Two-years follow-up

JONAS J, HARDER B, SCHLICHTENBREDE E, VON BALZS S–Mannheim

**F063** Wide field imaging in patients treated with vigabatrin


**F064** Utility of systematic ophthalmological screening in congenital toxoplasmosis: Epidemiological study of a French cohort between 1990 and 2011

SAUER A, CANDOLFI E, ESCANDE B, SPEEG-SCHATZ C, SUBILIA-GUIGNIER A–Strasbourg, Colmar

**F065** Quality of life among children with severe and chronic ophthalmic conditions

AZIZ A, MATONTI F, FAKHOURY O, DENIS D–Marseille

**F066** Ocular morpho-functional analysis: Comparison between prematurely-born and born at term children

SPALLONE L, LOMBARDO S, RUBERTO G, BIANCHI PE, TINELLI C, GIULIANO R–Pavia

**F067** Choroidal thickness measurement in children using optical coherence tomography

BIODART GARNIER M, SCHWARTZ C, PUYRAVEAU M, MONTARD M, DELBOSC B, SALEH M–Besancon

**F068** Definition of a normative basis for peripapillary nerve fibers thickness in childhood with sd-oct

FACON G, DEFOORT-DIHELMELES S, LABALETTE P, ROULAND JF–Lille

**F069** Functional vision of young adults with type i diabetes since childhood

SIISKONEN M, JARVINEN K, HAUTALA N, FALCK A–Oulu

**F070** The socio-economic status of young adults with type 1 diabetes since childhood

HANNULA V, HAUTALA N, FALCK A–Lahti, Oulu

**F071** Differential diagnostic of eye morphometric parameters in patients with refractive and axial myopia

BUSHUYEVA NN, MALIIVA EV–Moscow

**F072** Changes in protein composition of tear fluid in schoolchildren with high progressing myopia

IOMDINA E, TARUTTA E, KURKLEVA I, AKSENOVA Y, SURIINA E, BOGACHUK A–Moscow

**F074** Epidemiology of patients undergoing strabismus surgery at adult age: Retrospective study of 221 patients

PROMELLE V, BREMOND-GIGNAC D, MILAZZO S–Amiens

**F075** Prevalence of binocular anomalies among preschool children in Mashhad, Iran


---

**POSTER SESSION 2 15:10 - 16:00**

- Neuro-ophthalmology / Strabismology / Pediatric / History
- Moderators: François-Xavier BORRUAT, Valerio CARELLI

**F062** Refractive error after intravitreal bevacizumab for threshold disease in retinopathy of prematurity: Two-years follow-up

JONAS J, HARDER B, SCHLICHTENBREDE E, VON BALZS S–Mannheim

**F063** Wide field imaging in patients treated with vigabatrin


**F064** Utility of systematic ophthalmological screening in congenital toxoplasmosis: Epidemiological study of a French cohort between 1990 and 2011

SAUER A, CANDOLFI E, ESCANDE B, SPEEG-SCHATZ C, SUBILIA-GUIGNIER A–Strasbourg, Colmar

**F065** Quality of life among children with severe and chronic ophthalmic conditions

AZIZ A, MATONTI F, FAKHOURY O, DENIS D–Marseille

**F066** Ocular morpho-functional analysis: Comparison between prematurely-born and born at term children

SPALLONE L, LOMBARDO S, RUBERTO G, BIANCHI PE, TINELLI C, GIULIANO R–Pavia

**F067** Choroidal thickness measurement in children using optical coherence tomography

BIODART GARNIER M, SCHWARTZ C, PUYRAVEAU M, MONTARD M, DELBOSC B, SALEH M–Besancon

**F068** Definition of a normative basis for peripapillary nerve fibers thickness in childhood with sd-oct

FACON G, DEFOORT-DIHELMELES S, LABALETTE P, ROULAND JF–Lille

**F069** Functional vision of young adults with type i diabetes since childhood

SIISKONEN M, JARVINEN K, HAUTALA N, FALCK A–Oulu

**F070** The socio-economic status of young adults with type 1 diabetes since childhood

HANNULA V, HAUTALA N, FALCK A–Lahti, Oulu

**F071** Differential diagnostic of eye morphometric parameters in patients with refractive and axial myopia

BUSHUYEVA NN, MALIIVA EV–Moscow

**F072** Changes in protein composition of tear fluid in schoolchildren with high progressing myopia

IOMDINA E, TARUTTA E, KURKLEVA I, AKSENOVA Y, SURIINA E, BOGACHUK A–Moscow

**F073** Epidemiology of patients undergoing strabismus surgery at adult age: Retrospective study of 221 patients

PROMELLE V, BREMOND-GIGNAC D, MILAZZO S–Amiens

**F074** Screening of visual disorders among high school students without expressed complaint

KOVARSKI C, CARLU C, PORTALIER S, FAUCHER C, DUFIER JL, ROCHE O, ORSSAUD C–Lyon, Paris, Quebec

**F075** Prevalence of binocular anomalies among preschool children in Mashhad, Iran

F076 Change in the antioxidative capacity of extraocular muscles in patients with exotropia
JUNG S–Seoul

F077 Incidence of associated other oculomotor disturbances with internuclear ophthalmoplegia
VILA J, BORRUAT FX–Lausanne

F078 Optical coherence tomography as a progression marker in mild cognitive impairment and Alzheimer’s disease

F079 Evaluation of optical features of the macula in multiple sclerosis
VARGA BE, TATRAI E, LAURIK L, OLEVDY V, SIMO M, NEMETH J, SOMFAI GM, DEBUC D–Budapest, Miami, FL

F080 Visual evoked potentials, short wave-length automated perimetry, standard automated perimetry, contrast sensitivity and stereoacuity testing in visually asymptomatic eyes of patients with multiple sclerosis
HERAVIAN J, NAJJARAN M, FOROUGHIPUR M, AZIMI A, SABER MOGHADDAM A, OSTADIMOGHADDAM H, YEKTA A, KHOSHIMA J–Mashhad

F081 Neuromyelitis optica (devic’s disease): The use of the spectral domain optical coherence tomography (OCT) in the follow up of the disease
XIROU T, PORTALIOU D, BOURANTANI S, PANOUSOPOULOU A, KOURENTIS C, KABANAROU SA–Athens

F082 Retinal nerve fibre layer thickness as a neurological dysfunction marker in fibromyalgia patients

F083 Optical coherence tomography and electrophysiology to evaluate Parkinson disease severity

F084 Relevance of contrast sensitivity for the diagnosis and monitoring of early stages of Alzheimer’s disease
GARCÍA MARTIN E, ROJAS B, GIL P, YUBERO R, RAMIREZ JM–Madrid

F085 Retinal layer segmentation: Non-invasive technique demonstrating hyperplasia of nerve fibers and ganglion cells in the Ataxia of Charlevoix-Saguenay

F086 Optic disc drusen and peripapillary subretinal neovascular membranes in children
BENNAI D, BENZERROUG M, BENHAMANA A, BREMOND-GIGNAC D, MILAZZO S–Amiens

F087 Accuracy of fluorescein angiography (FA) based diagnosis for retinopathy of prematurity: Expert versus non expert graders evaluation

F088 A case of cortical blindness due to cerebral isquemia during OPCAB surgery and later recovery
GUTIRREZ BONET R, QUIJADA ANGELI S, SANTOS VICENTE E–Madrid

F089 Adult-onset aqueductal stenosis: A case report
BARTA B, TRECHOT F, CLOCHE V, MAALOUF T, ANGIOLI K–Nancy

F090 Presumed eosinophilic granuloma of the orbital roof in an adult man
BLASETTI F, MAIORE I, BRUNUDE P, PINNA A–Sassari

F091 Eye and optic tract function in patients with cavernous sinus meningioma undergoing CyberKnife robotic radiosurgery
ORSKI M, TARNAWSKA D, WYLEGA J–Katowice

F092 Glaucomatic optic neuropathy in congenital glaucoma
KATARGINA L, MAZANOVA E, TARASENKOVA A–Moscow

F093 First outcomes of silicon rod frontalis suspension prospective follow-up in congenital blepharoptosis
GRIVET D, NEZAR H, CAMPOGLI N, REYMOND M, THURET G, GAIN P–Saint-Etienne, Clermont-Ferrand

F094 The Leonardo Da Vinci Program in the ophthalmological formation of residents
JANUSCHOWSKI K, ZARZO-VARGAS MONICA M, SOLE GONZALEZ L, MIRANDA JOSE–Tubingen, Santa Cruz
**BUSINESS MEETINGS**

**FRIDAY**

16:00 - 16:40

---

### Business meetings of the scientific sections

- ACB - Anatomy / Cell Biology .......................................................... Gallieni 1 & 2
- COS - Cornea / Ocular Surface ....................................................... Rhodes 1
- EOVS - Electrophysiology, Physiological Optics, Vision Sciences ........... Hermes
- G - Glaucoma ................................................................................ Hermes
- IM - Immunology / Microbiology .................................................. Rhodes 1
- LC - Lens and Cataract ................................................................. Rhodes 4
- MBGE - Molecular Biology / Genetics / Epidemiology ...................... Gallieni 5
- NSPH - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History .... Rhodes 3
- PO - Pathology / Oncology ............................................................ Rhodes 2
- PBP - Physiology / Biochemistry / Pharmacology ............................. Athena
- RV - Retina / Vitreous .................................................................... Athena

### Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year’s meeting:
   - nomination of the 2014 section programme secretary (different from the section chair)
   - proposals of 2014 Special Interest Symposia (SIS)
   - proposals of 2014 Courses
   - proposals for 2015 Keynote speakers
4. Comment on the EVER activities
5. Other business

In addition to the agenda, the sections ACB, EOVS and MBGE will nominate at least 2 candidates for section chair.
### FRIDAY

#### SIS RV/ACB

**The myofibroblast: a key player of tissue repair**  
Marie-Luce BOCHATON-PIALLAT, Constantin POURNARAS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>Athena</td>
<td>Myofibroblast biology and interactions with the environment</td>
<td>DESMOULIERE A–Limoges</td>
</tr>
<tr>
<td>17:07</td>
<td></td>
<td>Fibrotic alterations in glaucoma</td>
<td>WALLACE D</td>
</tr>
<tr>
<td>17:29</td>
<td></td>
<td>Regeneration of lymphatic vessels after lymphatic-specific photodynamic therapy is not dependent on lymphangiogenesis and tissue remodeling by myofibroblast</td>
<td>KILARSKI W–Lausanne</td>
</tr>
<tr>
<td>17:51</td>
<td></td>
<td>Role of myofibroblasts in epiretinal membrane development</td>
<td>BOCHATON-PIALLAT ML–Geneva</td>
</tr>
</tbody>
</table>

#### FP G

**Free papers G 2/4: Glaucoma surgery part 1**  
Joaquin BARRAQUER, K. Sheng LIM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>Hermes</td>
<td>Glaucoma surgery</td>
<td>BARRAQUER J, CANUT M–Barcelona</td>
</tr>
<tr>
<td>16:57</td>
<td></td>
<td>Reducing high intraocular pressure with hypertonic saline before eye surgery</td>
<td>TORVÍNEN PIA–Helsinki</td>
</tr>
<tr>
<td>17:21</td>
<td></td>
<td>Trabeculectomy revision surgery with Ologen biodegradable collagen matrix implant</td>
<td>PELOSINI L, ANSARI E–Maidstone, Kent</td>
</tr>
<tr>
<td>17:33</td>
<td></td>
<td>Efficacy and safety of combined trans-scleral cyclophotocoagulation (TSCPC) and phacoemulsification surgery</td>
<td>ANSARI E, HAWKES E–Maidstone</td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Argon laser trabeculoplasty (ALT) for advanced glaucoma: A 12 months follow-up study</td>
<td>PELOSINI L, FAYEMI A, ANSARI E–Maidstone, Kent</td>
</tr>
<tr>
<td>17:51</td>
<td></td>
<td>Motion perception in early glaucoma</td>
<td>FRANCOZ A, CARLINI A, CREUZOT C, POZZO T, BRON AM–Dijon</td>
</tr>
</tbody>
</table>

**Second Afternoon Session**

16:45 - 18:15
### Course 16  Stem cells for treatment of eye diseases

**Rhodes 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>3731</td>
<td>The limbal stem cell niche</td>
<td>SHORTT AJ–London</td>
</tr>
<tr>
<td>17:00</td>
<td>3732</td>
<td>Assessment of the limbal condition</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>17:15</td>
<td>3733</td>
<td>Transplantation of cultured limbal epithelial cells</td>
<td>BORDERIE V–Paris</td>
</tr>
<tr>
<td>17:30</td>
<td>3734</td>
<td>Transplantation of cultured oral mucosal epithelium</td>
<td>BURILLON C–Lyon</td>
</tr>
<tr>
<td>17:45</td>
<td>3735</td>
<td>Bioengineering and stem cells for corneal endothelial cell therapy</td>
<td>THURET G, HE Z, SUFFEE N, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, CROUZET E, PISELLI S, HA THI BM, FOREST F, DUMOLLARD JM, PEOC’H M, GAIN P–Saint Etienne</td>
</tr>
<tr>
<td>18:00</td>
<td>3736</td>
<td>Pluripotent stem cells (ES &amp; iPS) for treatment of retinal dystrophies</td>
<td>GOUREAU O–Paris</td>
</tr>
</tbody>
</table>

### SIS Cell migration and xenografting in ocular melanoma

**Rhodes 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>3741</td>
<td>Animal models for ocular melanoma</td>
<td>CAO J, JAGER M–Leiden</td>
</tr>
<tr>
<td>17:00</td>
<td>3742</td>
<td>Use of xenografts for preclinical drug testing</td>
<td>DE LANGE MI, NEMATI F, VERSLUIS M, JAGER MJ, LUYTEN GPM, DECAUDIN D, VAN DER VELDEN PA–Leiden, Paris</td>
</tr>
<tr>
<td>17:30</td>
<td>3744</td>
<td>Orthotopic xenografts in ocular tumours</td>
<td>CASSOUX N–Paris</td>
</tr>
<tr>
<td>17:45</td>
<td>3745</td>
<td>Stem cells in conjunctival melanoma xenografts</td>
<td>KSANDER B–Boston</td>
</tr>
<tr>
<td>18:00</td>
<td>3746</td>
<td>miRNA and conjunctival melanoma migration</td>
<td>MOULIN A, NICOLAS M–Lausanne</td>
</tr>
</tbody>
</table>

### Joint M. ARVO @ EVER: Molecular Imaging of the Retina

**Rhodes 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>3751</td>
<td>Molecular Imaging of Protein and RNA Biomarkers in Retinal Vascular Disease</td>
<td>JAYAGOPAL A–Nashville</td>
</tr>
<tr>
<td>17:05</td>
<td>3752</td>
<td>In Vivo Bioimaging of RPE cell death</td>
<td>AMBATI J, KLEINMAN ME–Lexington</td>
</tr>
<tr>
<td>17:25</td>
<td>3753</td>
<td>Retinal Oximetry – Metabolic Imaging of the Retina</td>
<td>STEFANSSON E, HARDARSON SK, GEIRSDOTTIR A, KRISTIANSDOTTIR JV, SCHEVING T, OLAFSDOTTIR OB–Reykjavik</td>
</tr>
<tr>
<td>17:45</td>
<td>3754</td>
<td>DARC, Sick and Dying Cells</td>
<td>CORDEIRO M–London</td>
</tr>
</tbody>
</table>
FRIDAY

**SECOND AFTERNOON SESSION**

**16:45 - 18:15**

**SIS LC**

**Oxidative stress and cataract**

**Rhodes 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>3761</td>
<td>Glutathione and Ascorbate: The balance between oxidant and carbonyl stress in the aging human lens</td>
<td>MONNIER VM, FAN XI–Cleveland, Cleveland</td>
</tr>
<tr>
<td>17:03</td>
<td>3762</td>
<td>Antioxidant delivery to the lens nucleus: A strategy to delay age related nuclear cataract</td>
<td>DONALDSON PI, VAGHEFI E, GREY AC, LIM JC–Auckland</td>
</tr>
<tr>
<td>17:21</td>
<td>3763</td>
<td>In vivo quantitative measurement of antioxidant effects in the lens</td>
<td>SÖDERBERG P, KRONSCHLÄGER M, TALEBIZADEH N, YU Z, WANG J, XIAO Y–Uppsala</td>
</tr>
<tr>
<td>17:39</td>
<td>3764</td>
<td>Antioxidative properties of glutaredoxin 2 in the lens</td>
<td>LOU MF, WU HL–Lincoln, NE</td>
</tr>
<tr>
<td>17:57</td>
<td>3765</td>
<td>Age-related human nuclear cataract. Blindness due to inexorable protein deterioration</td>
<td>TRUSCOTT R–Wollongong</td>
</tr>
</tbody>
</table>

**FP NSPH**

**Free papers NSPH 2/2: Neuro-ophthalmology**

**Gallieni 1 & 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>3771</td>
<td>Macular nerve-fiber-layer measurement in early stage Alzheimer’s disease using optical coherence tomography</td>
<td>GARCIA MARTIN E, DE HOZ R, ROJAS B, GIL P, YUBERO R, RAMIREZ JM–Madrid</td>
</tr>
<tr>
<td>16:57</td>
<td>3772</td>
<td>Age macular degeneration-alzheimer disease in-between correlations: One year screening, follow-up and outcome</td>
<td>GONZALEZ C–Toulouse</td>
</tr>
<tr>
<td>17:09</td>
<td>3773</td>
<td>MR imaging in posterior ischemic optic neuropathy</td>
<td>DEMAEREL P, VAN DEN EYNDEN K, CASSIMAN C–Leuven</td>
</tr>
<tr>
<td>17:33</td>
<td>3775</td>
<td>Idiopathic optic-chiasmatic arachnoiditis (OCA) — enigmatic or non existent disorder?</td>
<td>GRZYBOWSKI A, LESSELL S–Poznan, Boston</td>
</tr>
</tbody>
</table>
EVENING SESSION

FRIDAY

18:15 - 19:15

INDUSTRY-SPONSORED SYMPOSIUM

Non-infectious uveitis.
A short look back and a long look forward

Hermes
Pseudophakic Retinal Detachments have some unique characteristics, because they affect mostly older people. Affected eyes may have age-related ocular changes. Vitreous body may be more syneretic. Posterior capsular opacification makes difficult visualization of retinal breaks that can be smaller and more peripheral. Intraocular lens in the presence of posterior capsular break can give intra-operative and post-operative problems. A carefully planned surgical approach is necessary for the management of the Pseudophakic Retinal Detachments. The available options to achieve our goal, a successful retinal reattachment, will be discussed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>4211</td>
<td>Vitrectomy for R.D. in eyes with different/unusual IOLs</td>
<td>GEORGALAS I–Athens</td>
</tr>
<tr>
<td>08:45</td>
<td>4212</td>
<td>Problems in vitrectomy and gas for the treatment of Ps RDs</td>
<td>THEOCHARIS IP–Athens</td>
</tr>
<tr>
<td>09:00</td>
<td>4213</td>
<td>Pars Plana Vitrectomy alone vs Vitrectomy with scleral buckling for PRDs</td>
<td>ASTERIADIS S–Thessaloniki</td>
</tr>
<tr>
<td>09:15</td>
<td>4214</td>
<td>Scleral buckle vs primary vitrectomy in PRDs</td>
<td>PARIAKIS EA–Athens</td>
</tr>
<tr>
<td>09:30</td>
<td>4215</td>
<td>360 degrees prophylactic laser retinopexy during the surgery for the treatment of pseudophakic retinal detachment</td>
<td>KOURENTIS C, XIROU T–Athens</td>
</tr>
<tr>
<td>09:45</td>
<td>4216</td>
<td>Macular problems in PsRD</td>
<td>PAPPAS G–Heraklion</td>
</tr>
</tbody>
</table>

**FP Free papers G 3/4: Medical treatment**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>4221</td>
<td>Comparative study of the IOP-lowering effect of Xalatan vs generic latanoprost in normal subjects</td>
<td>YUWEI (VINCENT) Q, POURJAVAN S–Woluwe Saint Lambert, Brussels</td>
</tr>
<tr>
<td>08:42</td>
<td>4222</td>
<td>Efficacy of a preservative-free fixed combination of bimatoprost and timolol in treatment-naïve versus previously treated patients</td>
<td>CORDEIRO MF, GOLDBERG I, SCHIFFMAN R, BERNSTEIN P, LIU C, BEJANIAN M–London, Sydney, Irvine, CA</td>
</tr>
<tr>
<td>08:54</td>
<td>4223</td>
<td>Does generic latanoprost measure up to the branded, well-known Xalatan?</td>
<td>MARINASCU C, POURJAVAN S–Brussels</td>
</tr>
<tr>
<td>09:06</td>
<td>4224</td>
<td>24h IOP control by subchronic AMA0076 administration in Dutch Belted rabbits</td>
<td>VAN DE VELE S, VAN BERGEN T, HOLLANDERS K, SUNAVE D, VANDEVALLE E, MOONS L, STALMANS I–Leuven</td>
</tr>
<tr>
<td>09:18</td>
<td>4225 rf</td>
<td>Patient behavior when prescribed non-affordable glaucoma medication in the medical unit, National Research Center, Cairo, Egypt</td>
<td>SAEED IBRAHIM A–Cairo</td>
</tr>
<tr>
<td>09:24</td>
<td>4226 rf</td>
<td>Removal of preservative from Ganfort improves intraocular pressure (IOP) lowering in patients – A timolol dose-response phenomenon</td>
<td>SHEN J, BEJANIAN M, SCHIFFMAN R–Irvine</td>
</tr>
<tr>
<td>09:30</td>
<td>4227 rf</td>
<td>SYL040012, a siRNA for the treatment of glaucoma</td>
<td>PAIREDA C–Tres Cantos, Madrid</td>
</tr>
<tr>
<td>09:36</td>
<td>4228 rf</td>
<td>Validation of Testvision, an internet-based test for the detection of visual field loss</td>
<td>OLSEN AS, LA COUR M, SERUP L, ALBERTI M, DAMATO B, KOLKO M–Copenhagen, San Francisco</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Presenters</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>08:30</td>
<td>SIS/RV</td>
<td>Therapeutics in the pipeline for unmet needs in ophthalmology</td>
<td>Rhodes 1</td>
</tr>
<tr>
<td>08:30</td>
<td>4231</td>
<td>Biomaterials for ophthalmic implants - all for one and one for all?</td>
<td>Thomas FUCHSLUGER, Einar STEFANSSON</td>
</tr>
<tr>
<td>09:06</td>
<td>4233</td>
<td>Nanoparticles for drug delivery to the retina</td>
<td>ELLIS S–Oxford</td>
</tr>
<tr>
<td>09:24</td>
<td>4234</td>
<td>Nanoparticles for delivery of therapeutical nucleic acids to corneal endothelium</td>
<td>STEFANSSON E–Reykjavik</td>
</tr>
<tr>
<td>09:42</td>
<td>4235</td>
<td>Nanoparticles incorporated collagen hydrogels for sustained release of EGF</td>
<td>RAFAT M, MONDAL D, ISLAM M, LIEBERG B, GRIFFITH M–Linköping</td>
</tr>
<tr>
<td>08:30</td>
<td>PO</td>
<td>Advances in the treatment of retinoblastoma</td>
<td>Rhodes 2</td>
</tr>
<tr>
<td>08:30</td>
<td>4241</td>
<td>The treatment of retinoblastoma with intravenous chemotherapy + local treatment</td>
<td>Laurence DESJARDINS, Francis MUNIER</td>
</tr>
<tr>
<td>08:48</td>
<td>4242</td>
<td>Intravitreal chemotherapy: Indications and results</td>
<td>DESJARDINS L, LUMBROSOLOEROUIC L, LEVY C, CASSOUX N, AERTS I, SAVIGNONI A, DENDALE R, SASTRE X–Paris</td>
</tr>
<tr>
<td>09:06</td>
<td>4243</td>
<td>Intraarterial chemotherapy: Indications and results</td>
<td>MUNIER F, GAILLARD MC, BALMER A, BECK-POPOVIC M–Lausanne</td>
</tr>
<tr>
<td>09:24</td>
<td>4244</td>
<td>Management of locally advanced retinoblastoma</td>
<td>HADJISTILIANOU T–Sienna</td>
</tr>
<tr>
<td>09:42</td>
<td>4245</td>
<td>Case reports</td>
<td>DESJARDINS L, MUNIER F, HADJISTILIANOU T, LUMBROSO L–Paris</td>
</tr>
</tbody>
</table>
### FIRST MORNING SESSION

#### SATURDAY

#### Rhodes 3

**SIS**  
**Optical and functional correlation of forward and backward scattering in the lens**  
**LC**  
Alfred WEGENER, Ralph MICHAEL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>4251</td>
<td>Basics of forward and backward scatter in the human eye lens</td>
<td>VAN DEN BERG TJTP–Amsterdam</td>
</tr>
<tr>
<td>08:52</td>
<td>4252</td>
<td>Lens slitlamp image grading and nuclear hardness</td>
<td>BARRAQER R–Barcelona</td>
</tr>
<tr>
<td>09:14</td>
<td>4253</td>
<td>Pentacam HR and C-Quant – forward versus back-ward light scattering, what is the correlation?</td>
<td>WEGENER A–Bonn</td>
</tr>
<tr>
<td>09:36</td>
<td>4254</td>
<td>Pentacam measurements and IOL scattering</td>
<td>BAUMEISTER M–Frankfurt</td>
</tr>
</tbody>
</table>

#### Rhodes 4

**SIS**  
**Controversies in history of ophthalmology**  
**NSPH**  
Andrzej GRZYBOWSKI, Francisco ASCASO

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>4261</td>
<td>Cataract surgery up to the age of Daviel</td>
<td>DE LAEY JJ–Ghent</td>
</tr>
<tr>
<td>08:48</td>
<td>4262</td>
<td>Who really introduced pneumatic retinopexy for retinal detachment outpatient management?</td>
<td>ASCASO F–Zaragoza</td>
</tr>
<tr>
<td>09:06</td>
<td>4263</td>
<td>Controversies in the history of glaucoma</td>
<td>GRZYBOWSKI A–Poznan</td>
</tr>
<tr>
<td>09:24</td>
<td>4264</td>
<td>Trichromasy versus colour opponency: The controversy in 19th and 20th century’s colour science and its solution</td>
<td>KRASTEL H, UDODOV E, GRüTZNER P–Mannheim, Nesvizh, Darmstadt</td>
</tr>
<tr>
<td>09:42</td>
<td>4265</td>
<td>Description of retinoblastoma by Pieter Pauw of Leiden in early 1600’s</td>
<td>KIVELÄ T–Helsinki</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Introduction by Leopold Schmetterer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 10:25  | Molecular sensors for the decoding of homeostasis disruptions in the retinal pigment epithelium: towards the understanding of retinal degenerative diseases
BAZAN N–New Orleans |
| 10:50  | Award of the EVER certificate of honour                              |
### SIS Benche to bedside to registration - the intricate world of drug development

**Athena**

**RV**

Marc D DE SMET, Mark VEZINA

11:00 4411 *Introduction - The challenges to drug approval: Going from an idea, early data onto registration*

DE SMET MD–Lausanne

11:18 4412 Pre-clinical testing: Good laboratory practice and the requirements imposed by the agencies

VEZINA M–Senneville

11:36 4413 Designing clinical trials - How best to optimize ideas, resources and patients

LEHMACHER W–Köln

11:54 4414 Running clinical trials - The challenges of international research

ANGLADE E–Jersey City, NJ

12:12 4415 Facing the regulators - Partnership or opponent

GRANZER U–München

---

### Free papers G 4/4: Glaucoma surgery part 2

**Hermes**

Ejaz ANSARI

11:00 4421 Glaucoma surgery outcome in Rwanda

DE SMEDT S, FONTEYNE Y–Muhanga

11:12 4422 Intracameral bevacizumab as an adjunct to trabeculectomy: A one year prospective, randomized study

VANDEWALLE E, PINTO L, VAN BERGEN T, SPIELBERG L, SPILEERS W, ZEYEN T, STALMANS I–Leuven, Lisbon, Rotterdam

11:24 4423 Bevacizumab together with MMC may have complementary effects in the improvement of surgical outcome after glaucoma filtration surgery

VAN BERGEN T, HOLLANDERS K, SUNAVE D, VAN DE VELDE S, VANDEWALLE E, MOONS L, STALMANS I–Leuven

11:36 4424 What is the most optimal administration route of bevacizumab after glaucoma filtration surgery in mice?

HOLLANDERS K, VAN BERGEN T, SUNAVE D, VAN DE VELDE S, VANDEWALLE E, STALMANS I–Leuven

11:48 4425 Refractive and axial length changes after trabeculectomy for open angle glaucoma

POPA CHERECHEANU A, CORBU C, COMAN C, IANCU R–Bucharest

12:00 4426 Risk factors for the development of glaucoma after vitreoretinal surgery

DE VRIES MM, MüSKENS RPHM, RENARDEL DE LAVALETTE VW, HOOYMANS JMM, JANSONIUS NM–Groningen

---

### Cornea & Ocular surface: update

**Rhodes 1**

Thomas FUCHSLUGER, Sanjay PATEL, Haydee BAZAN

11:00 4431 Rigid gas-permeable contact lens correction of infant aphakia following congenital cataract surgery

GRUENERT A, KLUERPEL M, HAUSser J, REINHARD T, SUNDMACHER R, GUTHOFF T, FUCHSLUGER T, GEERLING G–Duesseldorf, Moers, Freiburg

11:15 4432 Stem cells in the central cornea: To be or not to be?

MAJO F–Lausanne

11:30 4433 The latest developments in the genetics of Fuchs corneal dystrophy

BARATZ K–Rochester

11:45 4434 "No-touch" DMEK: Learning curve and outcomes

DROUTSAS K–Marburg

12:00 4435 Silica-collagen hybrid artificial cornea

PATEL SV, DIVITO MD, RUDISILL SG, STEIN A, MCLAREN JW, HUBEL A–Rochester, MN, Minneapolis, MN

12:15 4436 Modulators of corneal nerve regeneration

BAZAN H–New Orleans
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Rhodes 2</td>
<td>C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions</td>
<td>PARROZZANI R, BLANDAMURA S, ALESSANDRINI L, PERRINI P, FRIZZIERO L, MIDENA E–Roma, Padova</td>
</tr>
<tr>
<td>11:24</td>
<td>Rhodes 2</td>
<td>Uveal melanoma among Finnish octogenarians</td>
<td>ALJAMAL R, KIVELÄ T–Helsinki</td>
</tr>
<tr>
<td>11:36</td>
<td>Rhodes 2</td>
<td>Family relationships of recent familial uveal melanomas in Finland</td>
<td>KIVELÄ T, TALL M, RAIVIO V, TUOMINEN J, LEHESJOKI AE–Helsinki, Jyväskylä</td>
</tr>
<tr>
<td>11:48</td>
<td>Rhodes 2</td>
<td>Quantitative proteomic analysis of uveal melanoma reveals potential therapeutic targets</td>
<td>ANGI M, KALIRAI H, DAMATO BE, COUPLAND SE–Liverpool</td>
</tr>
<tr>
<td>12:00</td>
<td>Rhodes 2</td>
<td>Uveal metastases from carcinoid tumours: Clinical and therapeutic assessment</td>
<td>MIDENA E, PILOTTO E, FRIZZIERO L, PARROZZANI R–Padova, Roma</td>
</tr>
<tr>
<td>12:12</td>
<td>Rhodes 2</td>
<td>Use of dexamethasone 0.7mg intravitreal implant in radiation macular edema</td>
<td>BAILLIF S, MASCHI C, STAHL P, CAUJOLLE JP–Nice</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Rhodes 3</td>
<td>Comparison of the biometric measurements obtained using IOL Master and ALADDIN systems</td>
<td>MILKA M, WYLEGALA E, NOWINSKA A, JANISZEWSKA D, WEGLARZ B–Katowice</td>
</tr>
<tr>
<td>11:12</td>
<td>Rhodes 3</td>
<td>Harmlessness of 1 mg cefuroxime intracameral injection at the end of cataract surgery</td>
<td>BARREA G, BOURMAULT L, DOST L, ADENIS JR, ROBERT PY–Limoges</td>
</tr>
<tr>
<td>11:24</td>
<td>Rhodes 3</td>
<td>Intravitreal corticosteroids as first-line adjunctive treatment in acute post cataract surgery endophthalmitis</td>
<td>KOEHRER P, BRON AM, CREUZOT C–Dijon</td>
</tr>
<tr>
<td>11:36</td>
<td>Rhodes 3</td>
<td>Optimizing number of postoperative visits after cataract surgery – a safety perspective</td>
<td>WESTBORG INGER, MÖNESTAM EVA–Umeå</td>
</tr>
<tr>
<td>11:54</td>
<td>Rhodes 3</td>
<td>Cataract surgery and retinal vein occlusion: Is there an association?</td>
<td>TING DS, HEGGE V–Carlisle</td>
</tr>
<tr>
<td>12:00</td>
<td>Rhodes 3</td>
<td>Morphological and proliferative studies on ex vivo cultured human anterior capsule lens epithelial cells</td>
<td>ANDJELIC S, DRASLAR K, HAWLINA M, PETROVSKI G–Ljubljana, Szeged</td>
</tr>
<tr>
<td>FP</td>
<td>Free papers RV 3/4: Retina imaging 2</td>
<td>Rhodes 4</td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pedro GUIMARAES, Rui BERNARDES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>4461</td>
<td>Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial</td>
<td></td>
</tr>
<tr>
<td>11:12</td>
<td>4462</td>
<td>Fast fully-automated multimodal image co-registration (optical coherence tomography, colour fundus photography, red-free, fluorescein angiography)</td>
<td></td>
</tr>
<tr>
<td>11:24</td>
<td>4463</td>
<td>Non-invasive discrimination between perfused and occluded vessels by optical coherence tomography</td>
<td></td>
</tr>
<tr>
<td>11:36</td>
<td>4464</td>
<td>Enhanced 3D retinal vascular network reconstruction from high-definition SD-OCT</td>
<td></td>
</tr>
<tr>
<td>11:48</td>
<td>4465</td>
<td>En face 3D-SDOCT images and the saltmarshes sign</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>4466</td>
<td>Visualization of 3D retinal microcapillary network using OCT</td>
<td></td>
</tr>
<tr>
<td>12:12</td>
<td>4467</td>
<td>Swept source optical coherence tomographic findings in a case of bilateral macular coloboma</td>
<td></td>
</tr>
<tr>
<td>12:18</td>
<td>4468</td>
<td>Wide field imaging in Coat’s disease</td>
<td></td>
</tr>
</tbody>
</table>

**Joint M. Improved monitoring and treatment of endogenous uveitis is modifying disease management/outcomes II**

<table>
<thead>
<tr>
<th>IM</th>
<th>Piergiorgio NERI, Carl P HERBORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>4471</td>
</tr>
<tr>
<td>11:15</td>
<td>4472</td>
</tr>
<tr>
<td>11:30</td>
<td>4473</td>
</tr>
<tr>
<td>11:45</td>
<td>4474</td>
</tr>
<tr>
<td>12:00</td>
<td>4475</td>
</tr>
<tr>
<td>12:15</td>
<td>4476</td>
</tr>
</tbody>
</table>
LUNCHTIME SESSION
12:35 - 13:35
SATURDAY

INDUSTRY-SPONSORED SYMPOSIUM
Rhodes 2

**Aflibercept: an innovation in health care for a chronic condition**

**Moderator:** Paolo LANZETTA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35</td>
<td>4541</td>
<td>Welcome and introduction</td>
<td>LANZETTA P–Udine</td>
</tr>
<tr>
<td>12:40</td>
<td>4542</td>
<td>Aflibercept: innovation for wet AMD</td>
<td>TADAYONI R–Paris</td>
</tr>
<tr>
<td>12:50</td>
<td>4543</td>
<td>Optimising anti-VEGF therapy for wet AMD</td>
<td>LANZETTA P–Udine</td>
</tr>
<tr>
<td>13:10</td>
<td></td>
<td>Long-term treatment experience: beyond aflibercept initiation - TBD</td>
<td></td>
</tr>
<tr>
<td>13:25</td>
<td></td>
<td>Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>
Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.

Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org
## Joint M. OOG: Retinoblastoma and others

**Laurence DESJARDINS, Theodora HADJISTILIANOU**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:16</td>
<td>Rhodes 2</td>
<td>The treatment of bilaterally advanced retinoblastoma: The Institut Curie experience</td>
<td>DESJARDINS L, LUMBROSOLEROUC L, LEVY C, CASSOUX N, AERTS I, SASTRE X, SAVIGNONI A–Paris</td>
</tr>
<tr>
<td>14:28</td>
<td>Rhodes 2</td>
<td>Molecular profiling of ocular surface squamous neoplasia identifies multiple DNA copy number alterations including recurring 8p11.22 amplicons</td>
<td>ALKATAN H, EBERHART C–Riyadh, Baltimore</td>
</tr>
<tr>
<td>14:40</td>
<td>Rhodes 2</td>
<td>IgG4-Positive orbitopathy</td>
<td>HEEGAARD S–Copenhagen</td>
</tr>
<tr>
<td>14:52</td>
<td>Rhodes 2</td>
<td>Pigmented basal cell carcinoma of the eyelid</td>
<td>ROSNER M, PRIEL A, BEN SIMON1 G, ROSEN N–Tel Hashomer</td>
</tr>
</tbody>
</table>

---

## SIS Controversies in Cataract Surgery

**Alfred WEGENER, Andrzej GRZYBOWSKI**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td>Rhodes 3</td>
<td>Do we have any effective measure to minimize PCO?</td>
<td>TASSIGNON MJ, NI DHBGHAILL S–Antwerp</td>
</tr>
<tr>
<td>13:58</td>
<td>Rhodes 3</td>
<td>Is there any place for relaxing incisions in cataract surgery?</td>
<td>COCHENER B–Brest</td>
</tr>
<tr>
<td>14:16</td>
<td>Rhodes 3</td>
<td>What is important in present and future IOL materials &amp; design?</td>
<td>BARRAQUER R–Barcelona</td>
</tr>
<tr>
<td>14:34</td>
<td>Rhodes 3</td>
<td>Pentacam nuclear staging versus LOCS III grading for cataract classification</td>
<td>WEGENER A–Bonn</td>
</tr>
<tr>
<td>14:52</td>
<td>Rhodes 3</td>
<td>Is preoperative antibiotic use justified by evidence based medicine?</td>
<td>GRZYBOWSKI A–Poznan</td>
</tr>
</tbody>
</table>
### FIRST AFTERNOON SESSION 13:40 - 15:10  
SATURDAY

#### FP Free papers ACB 2/2: Cell biology of AMD and DR  
Deborah A FERRINGTON, Heli SKOTTMAN  
Rhodes 4

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:04</td>
<td>4663</td>
<td>Pro-inflammatory cytokines induce apoptosis of human retinal capillary endothelial cells through downregulation of Hsp27</td>
<td>NAGARAJ R, NAHOMI R–Cleveland</td>
</tr>
<tr>
<td>14:40</td>
<td>4666</td>
<td>The effect of hyperglycaemia on permeability and tight junction components in human retinal and choroidal endothelial cells</td>
<td>STEWART EA, SAKER S, AMOAKU WM–Nottingham</td>
</tr>
<tr>
<td>14:46</td>
<td>4667</td>
<td>Proteasome dysfunction in retinal pigment epithelium during aging contributes to the pathogenesis of Age-Macular related Degeneration</td>
<td>GIRAO H, MARQUES C, SOARES A, FERNANDES R, PEREIRA P–Coimbra</td>
</tr>
</tbody>
</table>

#### FP Free papers MBGE 2/2: Genetics and epidemiology  
Bart LEROY, Marzena GAJECKA  
Gallieni 1 & 2

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:28</td>
<td>4675</td>
<td>Functional characterization of retinitis pigmentosa causing RPRG mutations</td>
<td>SHU X, PATNAIK S, CRAFT J, MCCULLOCH D–Glasgow</td>
</tr>
<tr>
<td>14:40</td>
<td>4676</td>
<td>Influence of refractive error and axial length on retinal vessel geometric characteristics</td>
<td>LIM LS, CHEUNG C, LIM X, MITCHELL P, WONG TY, SAW SM–Singapore, Sydney</td>
</tr>
<tr>
<td>14:46</td>
<td>4677</td>
<td>Early dietary therapy in preventing progression of retinopathy in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency caused by the homozygous G152BC mutation</td>
<td>ROOMETS E, KIVELÄ T, TYNI T–Tallinn, Helsinki</td>
</tr>
</tbody>
</table>
S001 Mesenchymal stem cells as an alternative source of stem cells for ocular surface regeneration
HOLAN V, JAVORKOVA E, TROSA P, KRULOVA M, ZAJICOVA A--Prague

S002 Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing
ALLEN C, CLARE G, STEWART E, BRANCH M, MCINTOSH O, VERMA M, DUA HS, HOPKINSON A--Nottingham

S003 High doses of fatty acids for treating severe dry eye disease
GEORGIOU T, NICOLAOU D, NEKLEDOUS A, MICHAEL S, IKONOMOU C--Nicosia

S004 Tear secretion impairment as a function of severity of herpetic keratitis

S005 Corneal nerve structure and function in patients with non-Sjögren dry eye
LABBE A, LIANG Q, XU L, BAUDOUIN C, SUN X--Paris, Beijing

S006 The usefulness of corneal confocal microscopy to assessing and monitoring changes associated with hematopoietic diseases
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S007 Effects of cyclosporine in an experimental rat model of dry eye
CIMBOLINI N, ANTONELLI S, FERAILLE L, MARGARON P, ELENA PP--La Gaude

S008 Ocular tolerability of preservative-free prostaglandin eye drops
PELLINEN P, ESAKI Y, SHIMAZAKI A--Tampere, Nara

S009 Optimisation of a standardised chemical burn animal model for use in corneal wound healing
MCINTOSH OD, ALLEN CL, HOPKINSON A, DUA HS--Nottingham

S010 Treatment of Meibomian gland disease with the Lipiflow® system: A prospective study
MICHEE S, RABUT G, BAUDOUIN C, LABBE A--Paris

S011 Impact of two different prostaglandin preparations on human corneal epithelial cells (HCE-2) in vitro conditions
SMEdowski A, SEPPiNEEN A, KAARNIrANTA K, WylegalA E--Katowice, Kuopio

S012 Tear levels of lopetrednol etabonate following instillation of a novel gel formulation
SIo-MerMET R, ONG T, LOWE E--Montpellier, Madison, NJ, Rochester

S013 In vivo confocal microscopy of cystic lesions in corneal disorders
ORSKI M, WylegalA E, TARiNAWSKA D, SMEADOWski A--Katowice

S014 Full-field optical coherence tomography of human donor and diseased corneas
GHOualI W, GriEe K, BElleFQH S, LArcHO L, PAQUES M, BORDERIE V--Paris

S015 Aquaporin expression in pterygium
VIEL A, MOTULSKY E, PERRET J, GREGOIRE F, CASPERS L, DE SAINT AUBAIN N, DELPORTE C, WILLErmain F--Bruxelles

S016 Expression of Huntingtons disease markers in the cornea of minipig transgenic for the human mutated huntingtin
ARDAN T, JUHAS S, MOTLIK J--Liberev

S017 Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S018 Ocular surface dysfunction and tear osmolarity after cataract surgery
KUZMIENI E--Kuwait

S019 Ultrastructure features of dhub lizard (Uromastyx aegyptia) cornea
AkhTAR S, ALKHALAF M, KHAN A, ALMUBRAD T--Riyadh

S020 Variability of oxidative stress-related genes in keratoconus and Fuchs endothelial corneal dystrophy
SzaflKi Jp, SynoWiweC E, WOJCiK K, SzaflKi J, BlasiAK j--Warszawa, Lodz

S021 Galilei Dual Scheimpflug Analyzer: Corneal thickness and anterior chamber characteristics in healthy human eyes
Segura Calvo F, Sanchez-Cano A, Lopez de la Fuente C, Fuente-BrotLo L, OrdunA Hospital E, Pinilla I--Zaragoza

S022 Pragmatic approach in a case of unknown bilateral corneal opacity and staphyloma in a child in Timor Leste
Graeff E, Meyer P--Basel

S023 Semiology of patient derivated to pterygium surgery at Fuan Noe c. Hospital in Arica city, Chile
Chavez C, VetTerlein V, Fontecilia C, Ramirez Jm, De HOz r--Arica, Barcelona, Madrid

S024 Evaluation of transplanted oral epithelium by confocal microscopy correlates with success rate in aniridia patients
WOWra B, DobроволSKi D, WrobleWSka-CZauKA E, Grolik M, WylegalA E--Katowice

S025 Effects of acute in vivo exposure of rabbit cornea and conjunctiva to artificial sunlight

S026 Prevalence of allergic conjunctivitis in allergic population in northern Greece
ALMaliotis D, MichalopouLos P, Goulekas D, Gouleka P, Papakostas D, SiemPs T, KaramPatakis V--Thessaloniki

S027 Management of HSV-1 necrotizing keratitis with amniotic membrane transplantation combined with antiviral and steroid therapy
Gueudry J, Duncome B, Maringe e, Muraine M--Rouen

S028 Diagnosis of infectious keratitis by mass spectrometry
HoFFart L, Dranceourt M, Dornadin A--Marseille

S029 Chitosan-based biocompatible materials in ophthalmology
WOWra B, Grolik M, SzcZubialka K, NowakowskiK S, DobроволSKi D, Orzechowska-Wylegala B, Wylegala e--Katowice, Cracov

S030 The use of tear osmolarity as a diagnostic tool for detection of dry eye prior to cataract surgery
BAumann An, Cochener B--Lormaria-Plouzane, Brest

S031 Topical treatment with a new matrix therapy agent (RGTA) in the treatment of herpetic keratitis
KoCm Tezr, Membeam H, Dehoz r--Arica, Barcelona, Madrid

S032 Various epithelial manifestations of herpetic keratitis in corneal confocal microscopy imaging
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S033 Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S034 Corneal thickness and anterior chamber characteristics in healthy human eyes
Segura Calvo F, Sanchez-Cano A, Lopez de la Fuente C, Fuente-BrotLo L, OrdunA Hospital E, Pinilla I--Zaragoza

S035 Evaluation of transplanted oral epithelium by confocal microscopy correlates with success rate in aniridia patients
WOWra B, DobроволSKi D, WrobleWSka-CZauKA E, Grolik M, WylegalA E--Katowice

S036 Effects of acute in vivo exposure of rabbit cornea and conjunctiva to artificial sunlight

S037 Management of HSV-1 necrotizing keratitis with amniotic membrane transplantation combined with antiviral and steroid therapy
Gueudry J, Duncome B, Maringe e, Muraine M--Rouen

S038 Diagnosis of infectious keratitis by mass spectrometry
HoFFart L, Dranceourt M, Dornadin A--Marseille

S039 Chitosan-based biocompatible materials in ophthalmology

S040 The use of tear osmolarity as a diagnostic tool for detection of dry eye prior to cataract surgery
BAumann An, Cochener B--Lormaria-Plouzane, Brest

S041 Topical treatment with a new matrix therapy agent (RGTA) in the treatment of herpetic keratitis
KoCm Tezr, Membeam H, Dehoz r--Arica, Barcelona, Madrid

S042 Various epithelial manifestations of herpetic keratitis in corneal confocal microscopy imaging
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S043 Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging
WOJCiK L, WYLEGALa E, SMEADOWski A--Katowice

S044 Corneal thickness and anterior chamber characteristics in healthy human eyes
Segura Calvo F, Sanchez-Cano A, Lopez de la Fuente C, Fuente-BrotLo L, OrdunA Hospital E, Pinilla I--Zaragoza

S045 Evaluation of transplanted oral epithelium by confocal microscopy correlates with success rate in aniridia patients
WOWra B, DobроволSKi D, WrobleWSka-CZauKA E, Grolik M, WylegalA E--Katowice

S046 Effects of acute in vivo exposure of rabbit cornea and conjunctiva to artificial sunlight

S047 Management of HSV-1 necrotizing keratitis with amniotic membrane transplantation combined with antiviral and steroid therapy
Gueudry J, Duncome B, Maringe e, Muraine M--Rouen

S048 Diagnosis of infectious keratitis by mass spectrometry
HoFFart L, Dranceourt M, Dornadin A--Marseille

S049 Chitosan-based biocompatible materials in ophthalmology

S050 The use of tear osmolarity as a diagnostic tool for detection of dry eye prior to cataract surgery
BAumann An, Cochener B--Lormaria-Plouzane, Brest

S051 Topical treatment with a new matrix therapy agent (RGTA) in the treatment of herpetic keratitis
KoCm Tezr, Membeam H, Dehoz r--Arica, Barcelona, Madrid
**S032** Simulation of DSAEK in a new corneal bioreactor  

**S033** Risk factors for contact lens-related microbial keratitis: A case-control multicenter study  

**S034** Visual acuity outcomes after Descemet’s stripping automated endothelial keratoplasty compared to penetrating keratoplasty  

**S035** Uniformity of the thickness of LASIK corneal flaps made by IntraLase FS 60 laser femtosecond (IntraLase, AMO USA) measured by OCT spectral domain (Heidelberg, Germany)  
ABRIEU LACAILLE M, RAMBAUD C, CREPY P, FROUSSART F, RIGAL-SASTOURNE JC–Clamart

**S036** Reproducibility of the thickness of Lasik corneal flaps made by IntraLase FS 60 laser femtosecond (IntraLase, AMO USA) measured by OCT spectral domain (Heidelberg, Germany)  
ABRIEU LACAILLE M, RAMBAUD C, CREPY P, FROUSSART F, RIGAL-SASTOURNE JC–Clamart

**S037** Extracellular matrix derived hydrogel for corneal tissue engineering  
AHEARNE M, LYNCH A–Dublin

**S038** Age-related changes in central corneal thickness and corneal endothelial characteristics  
GALGAUSKAS S, NORVYDAITE D, STECH S, ASOKLIS R–Vilnius

**S039** Differences in corneal epithelium in patients with diagnosed macular and granular corneal dystrophy  
SMEDOWSKI A, WYLEGALA E, WOJCIC K–Katowice

**S040** Outcome of phacoemulsification after Descemet membrane endothelial keratoplasty (DMEK)  
YEH R, MUSA F, CABRERIZO J, QUILENDRINO R, DAPENA I, HAM L, MELLES GG–Liege, Rotterdam, Manilla

**S041** New Image Plugin for rapid and reproducible measurement of viable corneal endothelial cell density  

**S042** Analysis of fungal contamination in contact lens storage cases between 2000 and 2012  

**S043** Expression levels of purinergic receptors in the endothelium of human and murine cornea  
CZUGALA M, FUCHSLUGER T, FUJIKAI T, CHAUHAN S, DANA R–Essen, Boston, MA

**S044** Worldwide Eye Banking (WEB) project: International survey of demand and supply  
JULIENNE R, CAMPOLMI N, ALDOSSARY M, THURET G, GAIN P–Saint-Etienne

**S045** Improvement of delivery of molecules into corneal endothelium using nanoparticles activated by femtosecond laser pulses  

**S046** Biomechanical consequences of keratoconus treatments  
HUGNY LARROQUE C, COCHENER B–Brest

**S047** Microbial keratitis after penetrating keratoplasty  
EL MATRI L, KIMAIE M, CHEBIL A, KORT F, MGHAIETH F–Tunis

**S048** Viable endothelial cell density by triple HEC staining of a failed Descemet stripping automated endothelial keratoplasty  

**S049** Corneal graft imaging by anterior segment OCT during storage in eye banks  

**S050** Femtosecond laser cutting of multiple ultrathin corneal stromal lamellae for endothelial graft bioengineering  
BERNARD A, HE Z, CAMPOLMI N, PISSELLI S, FOREST F, PEOC'H M, DUMOLLARD JM, THURET G, GAIN P–Saint-Etienne

**S051** Long-term outcomes of penetrating keratoplasty in children  
DOBROWSKIS D, WYLEGALA E, WROBLESKOS–CZAJKA E, WOWRA B–Katowice

**S052** Intrastromal corneal rings and corneal collagen crosslinking for progressive keratoconus: Comparison of 2 sequences  
SAIB N, BONNIE M, ABRIEU M, RIGAL-SASTOURNE JC–Clamart

**S053** Ferrara ring’s effects on corneal asphericity in keratoconus treatment  
BONNIE M, LUISATO F, FENOLLAND Jr, SAIB N, RABAUD C, ABRIEU M, FROUSSART F, RIGAL-SASTOURNE JC–Clamart

**S054** Intracorneal foreign body in the confocal microscopy in vivo images  
WOJCIC K, WYLEGALA E, SMEDOWSKI A–Katowice
S055 Kyrieleis plaques in herpes zoster virus associated acute retinal necrosis
KONIDARIS V, BRENT A, VARDARINOS A, DEANE J, EMPESLIDIS T—Leicester

S056 Cytomegalovirus retinitis (CMVR)-related retinal detachment (RD) surgery in AIDS patients in an Asian population
WONG J, WONG E, TEOH S—Singapore

S057 High doses of fatty acids for reducing cystoid macular oedema secondary to inflammation or branch retinal vein occlusion
GEORGIOU T, PHOTIOU DMF, NICOLAOU D, NEOKLEOUS A, MICHAEL S, IKONOMOU C—Nicosia

S058 The regulatory effects of 1, α, 25-dihydroxyvitamin D3 on the expression of inflammatory cytokines in diabetic retinopathy
TOHARI A, CRAFT J, SHU X—Glasgow

S059 Detection of antibodies against homologous Mycobacterium avium subspecies paratuberculosis and beta-cell antigen zinc transporter 8 epitopes in Sardinian type 1 diabetic patients with proliferative diabetic retinopathy
PINNA A, MASALA S, BLASETTI F, MAIORE I, BRUNDU E, COSSU D, PACCAGNINI D, SECHI LA—Sassari

S060 Uveitis and Lyme disease: About two case reports
NGUYEN KIM P, TOUITOU V, LEHOANG P, BODAGHI B—Paris

S061 Can we consider syphilitic uveitis as neurosyphilis? A retrospective analysis of lumbar puncture results in a cohort of syphilitic uveitis patients
LHOIR S, WILLERMAIN F, JANSSEN J, LIBOIS A, VAN CALSTER J, CASPERS L, SECHI LA—Glasgow

S062 Persistent macular edema with secondary neovascular membrane following a panuveitis in woman with Behçet’s disease resolved by a switching to aflibercept injections
Toro M, Reibaldi M, Stella S, Amato R, Longo A, Gagliano C—Catania

S063 Clinical characteristics of acute retinal pigment epitheliitis: Case series
Han J, Yang J—Uijeongbu, Gyeonggi

S064 Adaptive optics imaging of retinal vasculitis
ERRERA MH, PAQUES M—Paris

S065 Hyporeflective dots detected in the retina using spectral domain optical coherence tomography
KUOLENE K, STECH S, CIMBALAS A, ASOKLIS R—Vilnius

S066 Swept source-optical coherence tomography analysis of choroidal involvement in patients with uveitis
DIWO E, RAZAVI S, LEHOANG P, BODAGHI B—Paris, Tours

Immunology / Microbiology
Moderators: Heping XU, Bahram BODAGHI, Nadia BOUCHENAKI

Lens and Cataract
Moderators: Alfred WEGENER, Stefan LÖFGREN, Thomas JTP VAN DEN BERG

S067 Mydriasert pupillary dilation for cataract surgery: A clinical and economic study
SHAH A, JOHAL S, LEE N—Uxbridge, Luton

S068 Cataract surgery and retinal vein occlusion: Is there an association?
TING DSJ, HEGDE V—Carlisle

S069 Risk factors for intraoperative floppy iris syndrome: One year prospective study
CHATZIRALLI I, PARIKAKIS E, PEPONIS V, MANIATEA A, MITROPOLLOUS P—Athens

S070 Cataract and uveitis: Comparison of two different anti inflammatory protocols for the prevention of post-operative complications
BUTEL N, FARGEAU M, LE HOANG P, BODAGHI B—Boulogne Billancourt, Paris

S071 Cataractogenesis and surgical outcome in patients with uveitis
REMOND A, LE HOANG P, BODAGHI B—Paris

S072 Femtosecond laser capsulotomy versus manual technique: A clinicomorphological study of the resected capsules
MEYER P, PRUENTE C—Basel, Binningen bei Basel

S073 Transporters of glycine, cystine, glutamate and glutamine in canine lens epithelial cells
ANDJELIC S, DRASLAR K, HAWLINA M, PETROVSKI G—Sagamihara

S074 Morphological and proliferative studies on ex vivo cultured human anterior capsule lens epithelial cells
ANDEJELIC S, DRASLARI K, HAWLINA M, PETROVSKI G—Szeged

S075 Active caspase-3 expression in healthy lens epithelium
TALEBI ZADEH N, YU Z, KRONSHLAGER M, SÖDERBERG P—Uppsala

S076 In vivo analysis of protein quality control in response to aging using transgenic mice
MARQUES C, MATAFOME P, SANTOS A, LOBO C, SHANG F, PEREIRA P, GIRAO H—Coimbra, Boston

S077 The effects of actomyosin inhibitors on cytoskeletal distributions in the lens
WON G, CHOH V—Waterloo

S078 Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer’s disease

S079 Absence of amyloid beta in human lens opacities: A confocal Raman study

S080 Elastic properties of human lens zonules as a function of age in presbyopes
MIKLEWICZ M, MICHAEL R, MONTENEGRO G, PINILLA L, BARRERU R—Barcelona

15:15-16:10 POSTER SESSION 3
Immunology / Microbiology
Moderators: Heping XU, Bahram BODAGHI, Nadia BOUCHENAKI

Lens and Cataract
Moderators: Alfred WEGENER, Stefan LÖFGREN, Thomas JTP VAN DEN BERG
POSTER SESSION 3

15:15 - 16:10

S081 Comparison of different techniques to evaluate the biomechanics of the accommodative apparatus in human eyes
PINILLA L, BURD HJ, MONTENEGRO GA, MIKIELEWICZ M, BARRAQUER RI, MICHAEL R--Barcelona, Oxford

S082 Retinal straylight and the yellow Bag in the Lens IOL
JONGENELEN S, ROZEMA JJ, TASSIGNON MJ--Edegem

S083 Halo size after implantation of a multifocal intraocular lens
PEREZ CARRASCO MJ, ÁLVAREZ-REMENTERIA L, HURTADO-CÉNÁ, HEREDIA-TEJADO L, DORADO-PALACIOS FI, PUELL MC--Madrid

S084 Do multifocal intraocular lens implants allow spectacle independence?
G’GALLAGHER MK, CHAKRABARTI M, FRAZER DG--Belfast

S085 Quality of vision with traditional monovision versus modified monovision
VANDERMEER G, LEGRAS R, GICQUEL JJ, PISELLA PJ--Tours, Orsay, Poitiers

S086 A novel imaging approach to periorcular basal cell carcinoma: In vivo optical coherence tomography and histological correlates
PELOSINI L, SMITH HB, SCHOFIELD J, DHITAL A, KHANWALA M--Maidstone, Kent

S087 Strabismus and diplopia revealing rhabdomyosarcoma in a 7-year-old girl
AZIZ A, MATONTI F, FAKHOURY O, DENIS D--Marseille

S088 Unique morphology of the human orbit among the Hominoidea
DENION E, HITIER M, GUAYDER V, DUCUE AE, MOURIAUX F--Caen

S089 Orbital melanocytosis and OTA naevus
DE KEIZER RLV, LAUWERS N, DE GROOT V--Antwerp

S090 Different assessments of immunohistochemically stained Ki-67 ocular malignancies
PAULAVICIENE R, PETROSKA D, ASOKLIS R--Vilnius

S091 Rare iridociliary pediatric tumours and pseudotumours: Cases report and literature review
HADJISTILIANOU T, TSYGANKOV A, DE LUCA MC, DEFRANCESCO SONIA, MICHELI L, BORRI M, MENICACCI F--Siena, Moscow

S092 Expression of stem cell markers in human uveal melanoma
STEIBER Z, HALMOS G, CSERHATI Z, TRESZL A--Debrecen

S093 Metastases inhibition and cellular damage in melanoma cells irradiated with proton beam

S094 Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy
KONSTANTINIDIS L, DAMATO B--Liverpool

S095 Photodynamic therapy for juxtapapillary retinal capillary hemangioma: A case report
CHATZIRALLI I, PARIKAKIS E, PEPSIS V, TSIOTRA V, MITROPoulos P--Athens

S096 Cases of choroidal metastasis revealing lung cancer
BARCATALI M, MIOCQUE S, HADDAD M, MOURIAUX F--Caen

S097 Synchronous malignant transformation of bilateral symmetrical retinocytoma
DE FRANCESCO S, DE LUCA M, GALIMBERTI D, CAINI M, HADJISTILIANOU T--Siena

S098 Case of primary neuroendocrine carcinoma in lacrimal gland
DAISUKE Y, TOSHIYUKI O, SHUICHI Y--Chibacity

S099 Mucormycosis is a rare etiology of ophthalmoplegia: How to diagnose and to manage it, about one exceptional case
LAGENAITE C--Lyon

S100 A time-line model of developmental events within the human fovea based on imaging and histology data
SJÖSTRAND J, POPOVIC Z--Göteborg
### SECOND AFTERNOON SESSION

**Free papers RV 4/4: Medical retina**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Presenter(s)</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>4711</td>
<td>Catherine CREUZOT, Tassos GEORGIOU</td>
<td>Macular choroidal thickness profile in healthy population measured by swept-source optical coherence tomography</td>
<td>Ruiz Moreno JM, Ruiz-Medrano J, Flores-Moreno I, Peña-García P, Montero JA–Albacete, Madrid, Alicante, Valladolid</td>
</tr>
<tr>
<td>16:27</td>
<td>4712</td>
<td></td>
<td>Combination of ranibizumab and navigated retinal photocoagulation in diabetic macular edema, compared to ranibizumab mono-therapy: Twelve month results</td>
<td>Kernt M–Munich</td>
</tr>
<tr>
<td>16:51</td>
<td>4714</td>
<td></td>
<td>Intravitreal aflibercept (IVT-AFL) for macular edema secondary to CRVO: Results of COPERNICUS and GALILEO studies</td>
<td>Creuzot C–Dijon</td>
</tr>
</tbody>
</table>

### SIS G Modern glaucoma surgery: efficacy and safety

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Presenter(s)</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>4721</td>
<td>Andrew MCNAUGHT, Alain BRON</td>
<td>Modern Trabeculectomy: Technique, and results from a UK muticentre study</td>
<td>Kirwan JF, Lockwood A, Mcnaught A, Macleod A, Shah P, King AJ, Broadaway DC, Agrawal P–Portsmouth</td>
</tr>
<tr>
<td>16:37</td>
<td>4722</td>
<td></td>
<td>Viscocanalostomy and canaloplasty: Technique and results</td>
<td>Sunarie Megevand G–Geneva</td>
</tr>
<tr>
<td>16:59</td>
<td>4723</td>
<td></td>
<td>Novel glaucoma surgery techniques</td>
<td>Zeyen T–Leuven</td>
</tr>
</tbody>
</table>

### Joint M. COS Keratoprosthesis 2 - Tissue and bioengineering approaches

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Presenter(s)</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>4732</td>
<td></td>
<td>Biomaterials in ophthalmic applications - IOL’s and keratoprosthesis</td>
<td>Storsberg J, Schmidt C, Duncker G, Schrage N, Sel S–Potsdam, Halle, Cologne, Heidelberg</td>
</tr>
<tr>
<td>16:45</td>
<td>4733</td>
<td></td>
<td>In vivo integrity of intra-corneal bioengineered discs in rabbit models</td>
<td>Rafat M, Lagali N, Koulikovska M, Griffith M, Fagerholm P–Linköping</td>
</tr>
<tr>
<td>17:00</td>
<td>4734</td>
<td></td>
<td>Nanofibrous scaffolds for corneal tissue engineering</td>
<td>Fuchsluger T, Bahniers T, Czugala M, Gutmann J, Salehi S–Düsseldorf, Krefeld</td>
</tr>
<tr>
<td>17:15</td>
<td>4735</td>
<td></td>
<td>Ocular surface reconstruction</td>
<td>Shortt AJ–London</td>
</tr>
</tbody>
</table>
Joint M. OOG: Business meeting

PO

1. Minutes of previous Business Meeting (Lapland, February 2013)
2. Financial report
3. OOG Website update
4. OOG YIN update
5. Nominations for membership to OOG
6. Update on current collaborative studies/new proposals
7. Details of next OOG Meetings
8. Any Other Business (AOB)
9. Closure of Business Meeting

Course 18  Femtosecond laser cataract surgery

LC  Rafael I. BARRAQUER, Zoltan NAGY

The course will review the basic aspects of femtosecond laser cataract surgery, the special features of the different available platforms for this procedure, the different aspects of the surgical techniques relative to the standard cataract (phaco) procedure, the published and emerging evidence on the advantages of this technology, as well as the complications and a discussion of special cases.

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>4751</td>
<td>The basics of femtosecond laser cataract surgery</td>
<td>NAGY Z–Budapest</td>
</tr>
<tr>
<td>16:33</td>
<td>4752</td>
<td>Current available platforms for femtosecond laser cataract surgery</td>
<td>ALVAREZ DE TOLEDO J, BARRAQUER RI, NAGY Z–Barcelona, Budapest</td>
</tr>
<tr>
<td>16:51</td>
<td>4753</td>
<td>Femtosecond cataract surgery: The basic procedure and surgical details</td>
<td>BARRAQUER R, NAGY Z, ALVAREZ DE TOLEDO J–Barcelona, Budapest</td>
</tr>
<tr>
<td>17:09</td>
<td>4754</td>
<td>Proven advantages of femtosecond laser cataract surgery</td>
<td>NAGY Z–Budapest</td>
</tr>
<tr>
<td>17:27</td>
<td>4755</td>
<td>Complications &amp; special cases of femtosecond laser cataract surgery</td>
<td>BARRAQUER R, NAGY Z, ALVAREZ DE TOLEDO J–Barcelona, Budapest</td>
</tr>
</tbody>
</table>
## FP COS Free papers COS 5/5: Corneal miscellaneous

### Rhodes 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>4761</td>
<td>Endothelial graft precutting from the epithelial and endothelial side with the femtosecond laser, on cornea stored in a new corneal bioreactor</td>
<td>BERNARD A, MAUCLAIR C, BAUBEAU E, GRANIER J, EGAUD G, HE Z, CAMPOLMI N, PISELLI S, FOREST F, PEOC’H M, DUMOLLARD JM, THURET G, GAIN F</td>
<td>Saint-Etienne</td>
</tr>
<tr>
<td>16:27</td>
<td>4762</td>
<td>Ultrastructural 3D imaging of collagen fibrils and proteoglycans of macular dystrophy cornea</td>
<td>AKHTAR S, KHAN A, KIRAT Q, ALKATAN H, ALMUBRAD T</td>
<td>Riyadh</td>
</tr>
<tr>
<td>16:39</td>
<td>4763</td>
<td>Integrin alphavbeta5 identifies human corneal epithelial stem cells</td>
<td>DI GIROLAMO N, ORDONEZ P, CHOW S</td>
<td>Sydney</td>
</tr>
<tr>
<td>16:51</td>
<td>4764</td>
<td>Predictive value of optical coherence tomography in graft attachment after Descemet membrane endothelial keratoplasty</td>
<td>YEH RY, QUILENDRINO R, MUSA F, LIAKAKOS V, DAPENA I, MELLES GJ</td>
<td>Ans, Manilla, Rotterdam</td>
</tr>
<tr>
<td>17:03</td>
<td>4765</td>
<td>Filamentary keratitis epidemiology</td>
<td>PRONKIN I, MAYCHUK D, VASILIEVA O</td>
<td>Moscow</td>
</tr>
<tr>
<td>17:27</td>
<td>4767</td>
<td>Adeno-associated viral vector serotypes for gene transfer to corneal endothelial cells</td>
<td>FUCHSLUGER T, MUELLER C, DANA R</td>
<td>Düsseldorf, Boston MA</td>
</tr>
</tbody>
</table>

## FP PBP Free papers PBP 2/2: Retina toxicity and RPE

### Gallieni 1 & 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>4771</td>
<td>Iron antagonism of DICER1 promotes NLRP3 inflammasome priming due to enhanced Alu RNA stability</td>
<td>GELFAND B, KIM Y, YASUMA T, U S, FOWLER B, KLEINMAN M, AMABTI J</td>
<td>Lexington</td>
</tr>
<tr>
<td>16:27</td>
<td>4772</td>
<td>Quercetin counteracts the cellular damage caused by HNE and inhibits inflammation in ARPE-19 cells</td>
<td>HYTTI M, PIIPPO N, SALMINEN A, KAARNIRANTA K, KAUPPINEN A</td>
<td>Kuopio</td>
</tr>
<tr>
<td>16:51</td>
<td>4774</td>
<td>Retinal pigment epithelium cell-derived microparticles mediate oxidative stress-induced retinal cells dysfunction</td>
<td>TAHIRI H, YANG C, DUHAMEL F, CHEMTOB S, HARDY P</td>
<td>Montreal</td>
</tr>
<tr>
<td>17:03</td>
<td>4775</td>
<td>Hepatocyte growth factor in neovascular age related macular degeneration: In vitro study of its effects on choroidal endothelial cells</td>
<td>STEWART EA, SAMARANAYAKE GJ, AMOAKU WM</td>
<td>Nottingham</td>
</tr>
<tr>
<td>17:15</td>
<td>4776</td>
<td>Plasma gangliosides and age-related macular degeneration</td>
<td>DOSSARPS D, MASSON EA, BERDEAUX O, BRON A, CREUZOT C, BRETILLON L</td>
<td>Dijon</td>
</tr>
</tbody>
</table>
EVER General assembly and prize giving

Agenda

1. President’s address, Philippe Kestelyn
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Jean-Jacques Gicquel
   - approval of the accounts 2012
   - discharge to the directors
   - approval budget for 2013
6. Results of the elections
7. Presentation of the board 2014
8. President Elect, Vice President Elect (2)
9. Presentation and report of the Business Meetings of the Scientific Sections meetings
10. Future congresses
11. Prize giving
12. Miscellanea
13. Acknowledgments
14. Handover of chain of office

19:30-21:00

EVER FAREWELL COCKTAIL

Mykonos area
EUPO 2014
RETINA
Sept 30 - Oct 1
NICE, France
In conjunction with EVER 2014

EUPO Office • Kapucijnenvoer 33 • 3000 Leuven • Belgium • www.eupo.eu • office@eupo.eu

Awardees of the EVERf Research Fellowships 2013
Dr. Reka ALBERT, Hungary
Dr. Minika JASIELSKA, Poland

European Association for Vision and Eye Research Foundation
Acta Ophthalmologica
Edited by: Einar Stefánsson

Why should you be reading?

• Impact – our impact factor now stands at 2.345*, placing us amongst the most highly-cited ophthalmology journals.

• Coverage that’s relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye.

• Official publication of EVER and all five Nordic Ophthalmological Societies.

Visit www.actaophthalmologica.com for more information

Members of EVER receive FREE online access to Acta Ophthalmologica as part of their membership.

*2012 JCR, Thomson Reuters

ARVO 2014
MAY 4 – 8 | ORLANDO, FLORIDA
LEADING EYE AND VISION RESEARCH

ARVO 2014 Key Dates

■ Hotel reservations
  Now open at arvo.org/hotels

■ Early meeting registration
  Opens September 16, 2013

■ Abstract submission
  Opens October 15 – December 6, 2013

■ Abstract acceptance notification
  February 18, 2014

■ ARVO Imaging Conference/ARVO Education Courses
  May 3, 2014 — Orlando, Fla.

■ ARVO Annual Meeting
  May 4 – 8, 2014 — Orlando, Fla.

Travel grants are available. Apply when submitting your abstract.
+1.240.221.2900; arvo@arvo.org

arvo.org/am
PRESENTING FIRST AUTHORS

KEYNOTE LECTURES

SCHMETTERER L > Wednesday, 17:15
GRZYBOWSKI A > Wednesday, 17:50
KIVELÄ T > Wednesday, 18:25
CHAUHAN B > Thursday, 10:15
OSBORNE N > Thursday, 13:40
SADUN A > Friday, 10:10
BAZAN N > Saturday, 10:15

Four digit numbers refer to oral presentations
One letter and three digit numbers refer to posters

Day   | Timeslot | Hall | Order in session
---    | ---      | ---  | ---
W 17:15 |         |      |      
W 17:50 |         |      |      
W 18:25 |         |      |      
T 10:15 |         |      |      
T 13:40 |         |      |      
F 10:10 |         |      |      
S 10:15 |         |      |      

X  X  X  X
Day | Order in the postsession

ABOU SAMRA W: 3431
ABRIEU LACAILLE M: S035, S036
ABU EL ASRAR A: 1753, 2254, 2256
ACAR N: 1613
AGARD E: T038
AHEARNE M: S037
AKHTAR S: S019, 4762
AKNIN I: T089
ALAVI M: 2662
ALBERT R: 4766
ALEKSEEV O: 2651
AL-ALJASIM L: T039
ALJAMAL R: 4443
ALKATAN H: 4645
ALLEN C: S002
ALMALIOTIS D: S025, S026, 3674
AL-SWAILEM S: 3432
ALVAREZ DE TOLEDO J: 4752
AMADIO M: T006, 4662
AMBATI J: 2231, 3752
AMBROSIOS AF: 1742
ANDJELIC S: 1742
ANDROUDI S: 1452
ANGI M: 4445
ANGLADE E: 4414
ANSARI E: 2223, 2224, 3725
AOYAMA Y: T032
APTEL F: T033, T047
ARDAN T: S016
ARJAMAA O: T005
ARMITAGE J: 2672, 2673
ARNDT C: F039, F063, 3656, 4468
ASCASO F: F034, T080, 2711, 4262
ASLAM T: 2541
ASNAGHI L: 1772
ASPINALL P: 3665
ASTERIA AISIS: S019, 4762
AU L: 1731
AVADHANAM V: 4633, 4634
AZIZ A: F065, 5087, 2645, 3658
BACHMANN B: 2676
BAILLIF S: 4447
BALASKAS K: F041, 3466
BARATZ K: 4433
BARCATAI M: 5096
BARRAQUER J: 3721
BARRAQUER R: 4252, 4653, 4755
BARREAU G: 4452
BASTOS CARVALHO A: F049
BATH C: 2434
BATTI B: F089
BAUDOT A: F006
BAUMANN A: S030
BAUMEISTER M: 4254
BAZAN H: 4436
BAZAN N: 4321
BEHAR-COHEN F: 3615
BENISTY D: F023
BENNAI D: F086
BERENDSCHOT T: 1443
BERNARD A: S041, 5050, 4761
BERNADES R: 4463
BERROD JP: 1712, 2413
BEUERMANN R: 2652, 2772
BIDAUT GARNIER M: F067, 3462
BIGOT K: F002
BLASSETI F: F090
BOCHATON-PIALLAT ML: 3714
BOCK F: 2431
BODAGHI B: 1655, 1755, 2451, 4473
BOLTZ A: 1746
BONNEAU D: 2264
BONNIN N: T084
BORDERIE V: 2674, 3433, 3733
BERRUA F: 2755
BOUKAZ S: T052
BOUCHENAKI N: 2252
BOUHRAOUL A: S042
BOUILLAT A: 3453
BRANCH M: 1625
BREMONT-GIGNAC D: 1421, 1723, 3273
BRERETON N: T040, T041
BRON A: 1431, 1541, 2222, 2724
BRONKHORST IIG: 1771
BULOCK J: 2653, 4731
BURILLON C: 3734
BUSHUVEYA NN: F071
BUTEL N: S070
CACCAGNI A: F046
CAMPOIMI M: S048, S087, 3323
CAO J: 3741
CARAMELLO C: F051, F082
CARELLI V: 2265
CASSOUX N: 3643, 3744
CASTELANO-M: 3652
CAJAUOLLE J: 2441
CELLINI M: T053
CHAE JB: F045
CHAKER N: F022, F031
CHATZIRALLI I: S069, S095
CHAUHAN B: 2321, 2622, 3223
CHAVEZ C: S023, T068
CHEBIL A: F030, T016
CHENG C: F058, 4467
PRESENTING FIRST AUTHORS

 CHEOUR M: F036
 CHIAMBARETTA F: 1422, 3272
 CHIOQUET C: 2656
 CHUNG SH: 2765
 CIMBOLINI N: S007
 COCHENER B: 3661, 4652
 CORDEIRO M: 2621, 3754, 4222
 COSCAS F: 3213
 COSCAS G: 3211
 COUPLAND S: 2244, 2741, 2745, 3645
 CRABB D: 3221
 CREUZOT C: F038, 1615, 1711, 2214, 2542, 2714, 3465, 4714
 CROWSTON JG: 2262
 CZUGALA M: S043, 4234
 DAEN V: 4672
 DAIEN V: 4672
 DAMATO B: 2445, 3244, 3441, 3443, 3644
 DARUGAR A: 3456
 DEBELLEMANIERE G: 3464
 DE FRANCESCO S: S097, 4642
 DE HOZ R: F005, T010
 DE LA CRUZ J: 4632
 DE LAEY JJ: 4261
 DE LA PAZ M: 3434
 DELBARRE M: T057
 DELCOURT C: 1611
 DELMAS D: 2543
 DEMAREL P: 3773
 DENION E: S088, 2644
 DESJARDINS L: 2444, 3243, 4241, 4245, 4644
 DE SMEDT S: 4421
 DE SMET MD: T031, 1714, 4411
 DESMOULIERE A: 3711
 DEV BORMAN A: 1776
 DE VRIES MM: 4426
 DE ZAEYTIJD J: F052
 DICK A: 1451, 1456, 1751
 DICKMAN M: 2675
 DI GIROLAMO N: 4763
 DIWO E: S066
 DOBROWOLSKI D: S051, 3635
 DONALDSON PJ: 3762
 DONOVAN K: 2764
 DOSSARPS D: 4776
 DROUTAS K: 4434
 DURIEUX P: F035
 EL CHEHAB H: T055
 ELLIS S: 4232
 EL MATRI L: S047, T083
 ERMOLAEE A: 2725
 ESPINASSE M: 2641
 FACON G: F068
 FALCK A: T054
 FAUQUERT J: 3271
 FEL A: 3651
 FERRINGTON D: 2273, 3253
 FISCH AL: 2646
 FLORES M: 3463
 FOWLER B: T081
 FRANCOZ A: T066, 3727
 FRANCOZ M: T056
 FRIMPOONG-ANSAH K: 1413
 FRUSCHELLI M: F050
 FUCHSFLUGER T: 4734, 4767
 GAJECKA M: 2763
 GALGAUSKAS S: S038
 GALLEGO B: T009, 1741
 GANDORFER A: 2415
 GARCIA-ARUMI J: 2716, 3245, 3246
 GARCIA MARTIN E: F083, F084, F085, 3771
 GARHOFER G: 1641, 3521, 3522
 GARWAY-HEATH D: 3224
 GAUTHIER A: 3234
 GAVARD PERRET A: 2241
 GELFAND B: 3471
 GEORGALAS I: 1415, 4211
 GEORGIU T: S003, S057, 4713
 GHOUALI W: S014
 GICQUEL J: 1424, 1621, 1622, 1721, 1724, 2631, 2634, 2732, 3662, 3732
 GILBERT A: T058
 GIOCATI-AUREGAN A: T071
 GIRAO H: T002, 4667
 GIRAUD JM: T064
 GIRMENS JF: 3413
 GOCHO K: 2762
 DONI F: 1542
 GONZALES C: F043, F044, 3772
 GOTZARDIS S: 1414
 GOURIEU O: 3736
 GRAEFF E: S022
 GRIEB K: 4415
 GRAW J: 4673
 GRIEVET D: T093, 2642
 GRUENERT A: 4431
 GRUS F: 2452
 GRZYBOWSKI A: 2712, 3775, 4263, 4655
 GUAGLIANO R: F087
 GUEUDRY J: S027
 GUILLAUME C: F029
 GUIMARAES P: 4462
 GUTIÉRREZ BONET R: F088
 HADJISTILIANOU T: S091, 4243, 4643
 HAN J: S063
 HANNUALA V: F070
 HARDARSON S: 1442
 HAUTAMÄKI A: 4674
 HEEGAARD S: 2744, 2746, 4646
 HEITMAR R: F059
 HERAVIAN J: F080, T022
 HERBERT C: 1455, 1654, 2251, 2255, 4475
 HERON E: 3412
 HERRERA L: F078, T076
 HIRN C: T062, 2727
 HOFFART L: S028, 1664
 HOLAN V: S001
 HOLDER G: 1464, 1762, 1764
 HOLLANDERS K: 1471, 4424
 HOMMER A: 1432
 HONDEGHEM K: 2421
 HOPKINSON A: 1623, 2432
 HUGNAY LARROQUE C: S046, 1632
 HYTTI M: 4772
 IBANIEZ J: T046, T048
 IMMONE N: T077
 IOMDINA E: F072
 ITO Y: T082
 JANISZEWSKA D: 3634
 JANSZONIUS NM: 3222
PRESENTING FIRST AUTHORS

JANUSCHOWSKI K: F094
JÄRVINEN T: 2774
JAYAGOPAL A: 3751
JOHNSTON R: 4724
JONAS J: F062, T061, 1433, 2211, 2723, 2726, 3655, 4622
JONGENELEN S: S082
JULIENNE R: S044
JUMELLE C: S045
JUNG S: F076
KAARNIRANTA K: 2272, 3254
KAUPPINEN A: 4661
KAWASAKI A: 1463, 2751, 2754, 3471, 3473, 3474
KERO M: T019
KERNT M: F057, 3467, 4712
KHAIRALLAH M: 1653, 4476
KILARSKI W: 3713
KIM Y: F061
KIRWAN JF: 4721
KLAVER A: T029, T030, 4264
LABOUCHE P: 2623
KAHRneh A: 4661
KOH L: F021
KOHMO M: 2623
KONIDARIS V: S055
KONSTANTINIDIS L: S094
KOSTH Z: F027, 2414, 2416
KOTECHA A: 2424, 3424
KOURENTIS C: 4215
KOVARSKI C: F074
KRISTEL H: T029, T030, 4264
KSANDER B: 3745
KUBOVA Z: T026, 1661
KUoliene K: S065
KUZMENKO L: S018
LABELE M: 3005, 2454
LADENNAI: S004, 1722
LAMBE R: 2776
LAMBE M: 2722
LANSETTA P: 4541, 4543
LECLERC C: 3774
LEE DW: T015
LEHMACHER W: 4413
LE MEHL Y: 2614
LEMIJ H: 3225
LENAERS G: 2661
LERQ B: 1462, 1761, 1763
LEUNG C: 3622
LHOIR S: S061
LI-FONG LF: 2773
LIGHTMAN S: 2234
LIM K: 1733
LIM LS: T073, 4676
LIPSKI D: 1472
LISKOVA P: T086, 2766
LIU C: 4635
LOEWENSTEIN A: 2233, 3614
LONGSTAFF S: 1732
LOU MF: 3764
LUIJN X: 3653
LUX S: T060
LUMBRUSO L: 2444
LUX AL: 3654
LYNCH A: 3436
MAO: 4432
MANDAL N: F019
MANU MD: T017, T018
MARCHESI N: T004
MARINESCU C: 4223
MARINGE E: S031
MARKKOSSAN G: F028
MARQUES C: S076
MARSOVSKY L: 1636
MARTENS T: 1473
MARTIN L: 1663
MASSIN P: 1715, 2212
MASSON EA: F001
MATAT A: 2654
MATHEI B: 4664
MATONITI F: T025
MAUGHER-FAYSSÈ M: 3216, 3415
MCINTOSH O: S009
MEIER T: 2665
MELSON M: T088
MENCUCCI R: 2632
MENDES-JORGE L: T012, T013, 2475
MESQUIDA M: 3455
MEYER P: S072
MICHAEL R: S079
MICHIE S: S010
MICHIOI L: 4641
MIDENA E: 2213, 2443, 3642, 4446
MIKIELEWICZ M: S080
MILANO G: T063
MILKA M: 4451
MIRONOVA E: F009
MOE MC: 3672
MONNIER VM: 3761
MORGAN J: 3624
MOITTE B: T037
MOULIN A: 3746
MOUNA ALI: S034
MUNIER F: 4242
MURANE M: 2842, 3673
NAGARAJ R: 4663
NAGY Z: 4751, 4754
NAIGEON N: 3675
NAKAI K: 2253
NAVARRO J: 1743
NEMATI F: 3743
NERI P: 1453, 1754, 4472
NGUYEN KIM P: S060
NI DUBHGHAILL S: 1474
NIelsen K: 3633, 3636
NOWAK DM: T085, 2767
NOWINSKA A: 3632
OCHIHEI H: S074
O’GALLAGHER MK: S084
OGATA N: F042
OHTA K: F025
OLMIERE C: F015
OLSEN AS: T067, 4228
ORSKI M: F091, S013
OSBORNE N: 1644, 2261, 2621
OSHITARI T: F032
OSTADIMOGHADDAM H: T070
OSTRI C: F024
OVERBY D: 1734
PALKOVITS S: 1745
TRUSCOTT R: 3765
TÜRKSEVER C: T023
UDAONDO P: 2715
UDZIELA M: 2843
UUSITALO H: 2771, 3251
UZZAN J: 3214
VAINIO I: 2474
VAN BERGEN T: 1477, 4423
VAN CAUWENBERGH C: 1671
VAN DEN BERG TJTP: 2733, 3664, 4251
VAN DE PUT M: 2411
VANDERMEER G: S085, 2734
VAN DE VELDE S: 1672, 4224
VANDEWALLE E: 4422, 4621
VAN ESSEN TH: 2435
VAN GIJNDERDEUREN R: 1775, 2742, 2743
VAN HOUCKE J: 1673
VAN HOVE I: 1674
VAN LOOVEREN J: 1675
VAN PELT S: 1774
VARGA BE: F079
VEKRIA P: T014
VELDMAN E: 3452
VERBIN H: 1676
VEREB Z: T001, 2477
VERSUIS M: 1773
VERTICCHIO VERCELLIN AC: F011
VEZINA M: 4412
VIDAL-SANZ M: 2453
VIEL A: S015
VILA J: F077
VOTRUBA M: 4671
WALLACE D: 3712
WASILEWICZ R: 2721
WEGENER A: 4253, 4654
WESTBOURG INGER: 4454
WILLERMAN F: 1651, 1752
WILSON S: 1624, 2471
WIRTH M: T028
WOJCIK L: S006, S017, S054, 3676
WOLFENSBERGER TJ: 2615, 3611
WOLF-SCHNURBBUSCH U: 3613
WON G: S077
WONG J: S056
WOWRA B: S024, S029
WROBEL-DUDZINSKA D: T087
WYLEGALA E: 3631
XIYOU T: F037, F081
XU H: 3451
YASUMA R: F012
YASUMA T: F013
YEH R: S040, 4764
YEKTA A: F075, T069
YEUNG A: 1423, 2633
YU-WAI-MAN P: 2263
YU (VINCENT) Q: 4221
ZABADANI K: F047, F054
ZAKARIA N: 1677, 2433
ZEYEN T: 1434, 2221, 4723
ZIELICKA Z: 4715
ZOGRAFOS L: 3241
Attending hundreds of scientific sessions led by internationally renowned experts.

Participating in cutting-edge continuing education opportunities.

Learning about over 100 exhibiting companies.

Connecting with more than 10,000 attendees from over 120 countries.

Discovering Tokyo during the beautiful cherry blossom season.

WOC2014: Delivering world-class education, insight, and inspiration to a global ophthalmology community for improving quality eye care and preventing visual loss.

Register Today at woc2014.org for Early Bird Rates
<table>
<thead>
<tr>
<th>Country</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>4</td>
</tr>
<tr>
<td>Austria</td>
<td>7</td>
</tr>
<tr>
<td>Belgium</td>
<td>29</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>4</td>
</tr>
<tr>
<td>Chile</td>
<td>1</td>
</tr>
<tr>
<td>Cyprus</td>
<td>1</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>4</td>
</tr>
<tr>
<td>Denmark</td>
<td>7</td>
</tr>
<tr>
<td>Egypt</td>
<td>2</td>
</tr>
<tr>
<td>Estonia</td>
<td>2</td>
</tr>
<tr>
<td>Finland</td>
<td>18</td>
</tr>
<tr>
<td>France</td>
<td>138</td>
</tr>
<tr>
<td>Germany</td>
<td>22</td>
</tr>
<tr>
<td>Greece</td>
<td>12</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>1</td>
</tr>
<tr>
<td>Hungary</td>
<td>9</td>
</tr>
<tr>
<td>Iceland</td>
<td>2</td>
</tr>
<tr>
<td>India</td>
<td>1</td>
</tr>
<tr>
<td>Iran</td>
<td>3</td>
</tr>
<tr>
<td>Ireland</td>
<td>3</td>
</tr>
<tr>
<td>Israel</td>
<td>2</td>
</tr>
<tr>
<td>Italy</td>
<td>23</td>
</tr>
<tr>
<td>Japan</td>
<td>15</td>
</tr>
<tr>
<td>Lithuania</td>
<td>4</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td>15</td>
</tr>
<tr>
<td>New Zealand</td>
<td>2</td>
</tr>
<tr>
<td>Norway</td>
<td>1</td>
</tr>
<tr>
<td>Poland</td>
<td>19</td>
</tr>
<tr>
<td>Portugal</td>
<td>11</td>
</tr>
<tr>
<td>Romania</td>
<td>2</td>
</tr>
<tr>
<td>Russia</td>
<td>7</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>6</td>
</tr>
<tr>
<td>Singapore</td>
<td>6</td>
</tr>
<tr>
<td>Slovenia</td>
<td>1</td>
</tr>
<tr>
<td>South Korea</td>
<td>6</td>
</tr>
<tr>
<td>Spain</td>
<td>31</td>
</tr>
<tr>
<td>Sweden</td>
<td>7</td>
</tr>
<tr>
<td>Switzerland</td>
<td>26</td>
</tr>
<tr>
<td>Tunisia</td>
<td>5</td>
</tr>
<tr>
<td>Ukraine</td>
<td>1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>64</td>
</tr>
<tr>
<td>United States</td>
<td>30</td>
</tr>
</tbody>
</table>
EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2013. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

MAIN SPONSORS

- **ALLERGAN**
- **NOVARTIS**

MAJOR SPONSOR

- **BAYER**

CIS SPONSORS

- **ABBVIE**
- **ALLERGAN**
- **BAYER**
- **CROMA**
- **Théa**

SIS SPONSORS

- **Aeon Astron**
- **ALLERGAN**
- **BAUSCH+LOMB**
- **Horus**
- **NOVARTIS**
- **Santen**
- **Santhera Pharmaceuticals**
- **Théa**

SPONSORS IN EXHIBITION

- **ALIMERA SCIENCES**
- **ALLERGAN**
- **Charles River**
- **EyeTechCare**
- **Horus**
- **iris Pharma**
- **NOVARTIS**
- **Ocuscience**
- **OPHTA BIOTECH**
- **Toxikon**
- **Ursapharm**
- **WisePress**

NON PROFIT SPONSORS

- **ARVO**
- **WOC 2014**